

**Clinical trial results:****A Two-Year, Randomized, Double-Masked, Multicenter, Two-Arm Study Comparing the Efficacy and Safety of RTH258 6mg Versus Aflibercept in Subjects with Neovascular Age-Related Macular Degeneration****Summary**

EudraCT number	2014-004886-26
Trial protocol	SK PT FI AT NO IE ES EE LT SE DE HU CZ NL GB LV DK BE PL
Global end of trial date	GR HR IT 17 March 2018

Results information

Result version number	v2 (current)
This version publication date	24 October 2019
First version publication date	16 March 2019

Version creation reason

Trial information**Trial identification**

Sponsor protocol code	RTH258-C002
-----------------------	-------------

Additional study identifiers

ISRCTN number	-
ClinicalTrials.gov id (NCT number)	NCT02434328
WHO universal trial number (UTN)	-

Notes:

Sponsors

Sponsor organisation name	Alcon Research, Ltd.
Sponsor organisation address	6201 S. Freeway, Fort Worth, TX, United States, 76134
Public contact	EMA Regulatory Affairs, Alcon Eye Care UK Ltd, eurmea.ra@alcon.com
Scientific contact	EMA Regulatory Affairs, Alcon Eye Care UK Ltd, eurmea.ra@alcon.com

Notes:

Paediatric regulatory details

Is trial part of an agreed paediatric investigation plan (PIP)	No
Does article 45 of REGULATION (EC) No 1901/2006 apply to this trial?	No
Does article 46 of REGULATION (EC) No 1901/2006 apply to this trial?	No

Notes:

Results analysis stage

Analysis stage	Final
Date of interim/final analysis	07 March 2018
Is this the analysis of the primary completion data?	No
Global end of trial reached?	Yes
Global end of trial date	07 March 2018
Was the trial ended prematurely?	No

Notes:

General information about the trial

Main objective of the trial:

The purpose of this study was to compare brolucizumab (RTH258) ophthalmic solution for intravitreal (IVT) injection (6 mg) to aflibercept ophthalmic solution for IVT injection (2 mg) in subjects with untreated active choroidal neovascularization (CNV) secondary to age-related macular degeneration (AMD) in the study eye. Subjects were randomized to brolucizumab 6 mg and aflibercept 2 mg in a 1:1 ratio. Subjects in both treatment arms received 3 monthly loading doses (Day 0, Week 4 and Week 8), followed by a maintenance regimen, until the end of the study. All subjects attended pre-specified visits every 4 weeks.

Protection of trial subjects:

Prior to the start of the study, the study protocol, the informed consent and assent documents, patient instruction sheets, the Investigator's Brochure, as well as any advertising materials used to recruit patients were submitted to institutional review boards (IRBs) and independent ethics committees (IECs). The IRB/IECs reviewed all documents and approved required documents; copies of the approval letters were provided to Alcon. Consistent with both the IRB/IEC's requirements and all applicable regulations, the Investigators periodically provided study updates to the IRB/IEC. This study was conducted in accordance with Good Clinical Practices (GCP) and the ethical principles that have their origins in the Declaration of Helsinki.

Background therapy: -

Evidence for comparator: -

Actual start date of recruitment	27 July 2015
Long term follow-up planned	No
Independent data monitoring committee (IDMC) involvement?	Yes

Notes:

Population of trial subjects

Subjects enrolled per country

Country: Number of subjects enrolled	Netherlands: 9
Country: Number of subjects enrolled	Norway: 5
Country: Number of subjects enrolled	Poland: 60
Country: Number of subjects enrolled	Portugal: 15
Country: Number of subjects enrolled	Slovakia: 46
Country: Number of subjects enrolled	Spain: 114
Country: Number of subjects enrolled	United Kingdom: 35
Country: Number of subjects enrolled	Croatia: 7
Country: Number of subjects enrolled	Austria: 15
Country: Number of subjects enrolled	Belgium: 2
Country: Number of subjects enrolled	Czech Republic: 38
Country: Number of subjects enrolled	Denmark: 5
Country: Number of subjects enrolled	Estonia: 12

Country: Number of subjects enrolled	Finland: 1
Country: Number of subjects enrolled	France: 83
Country: Number of subjects enrolled	Germany: 31
Country: Number of subjects enrolled	Greece: 15
Country: Number of subjects enrolled	Hungary: 84
Country: Number of subjects enrolled	Ireland: 5
Country: Number of subjects enrolled	Italy: 42
Country: Number of subjects enrolled	Latvia: 12
Country: Number of subjects enrolled	Lithuania: 11
Country: Number of subjects enrolled	Switzerland: 17
Country: Number of subjects enrolled	Taiwan: 5
Country: Number of subjects enrolled	Turkey: 21
Country: Number of subjects enrolled	Vietnam: 9
Country: Number of subjects enrolled	Singapore: 4
Country: Number of subjects enrolled	Russian Federation: 8
Country: Number of subjects enrolled	Korea, Republic of: 28
Worldwide total number of subjects	739
EEA total number of subjects	647

Notes:

Subjects enrolled per age group

In utero	0
Preterm newborn - gestational age < 37 wk	0
Newborns (0-27 days)	0
Infants and toddlers (28 days-23 months)	0
Children (2-11 years)	0
Adolescents (12-17 years)	0
Adults (18-64 years)	72
From 65 to 84 years	567
85 years and over	100

Subject disposition

Recruitment

Recruitment details:

Subjects were recruited from investigative sites located in Austria, Belgium, Croatia, Czech Republic, Denmark, Estonia, Finland, France, Germany, Greece, Hungary, Ireland, Italy, South Korea, Latvia, Lithuania, Netherlands, Norway, Poland, Portugal, Russia, Singapore, Slovakia, Spain, Switzerland, Taiwan, Turkey, UK, and Vietnam.

Pre-assignment

Screening details:

This reporting group includes all randomized and treated subjects (739).

Period 1

Period 1 title	Overall (overall period)
Is this the baseline period?	Yes
Allocation method	Randomised - controlled
Blinding used	Double blind
Roles blinded	Subject, Investigator

Arms

Are arms mutually exclusive?	Yes
Arm title	Brolucizumab 6 mg

Arm description:

Single intravitreal (IVT) injection of brolucizumab ophthalmic solution at Day 0, Week 4, and Week 8, followed by q8w/q12w maintenance regimen until study exit

Arm type	Experimental
Investigational medicinal product name	Brolucizumab ophthalmic solution
Investigational medicinal product code	
Other name	RTH258
Pharmaceutical forms	Solution for injection
Routes of administration	Intravitreal use, Ophthalmic use

Dosage and administration details:

Brolucizumab ophthalmic solution, 6 mg/50 µL dose, administered as a single IVT injection at Day 0, Week 4, and Week 8, followed by 1 injection every 8 weeks/1 injection every 12 weeks (q8w/q12w) maintenance regimen until study exit.

Arm title	Aflibercept 2 mg
------------------	------------------

Arm description:

Single IVT injection of aflibercept ophthalmic solution at Day 0, Week 4, and Week 8, followed by q8w maintenance regimen until study exit

Arm type	Active comparator
Investigational medicinal product name	Aflibercept
Investigational medicinal product code	
Other name	EYLEA®
Pharmaceutical forms	Solution for injection
Routes of administration	Intravitreal use, Ophthalmic use

Dosage and administration details:

Aflibercept ophthalmic solution, 2 mg/50 µL dose, administered as a single IVT injection at Day 0, Week 4, and Week 8, followed by q8w maintenance regimen until study exit.

Number of subjects in period 1	Brolucizumab 6 mg	Aflibercept 2 mg
Started	370	369
Completed	342	329
Not completed	28	40
Adverse event, serious fatal	4	7
Consent withdrawn by subject	12	21
Physician decision	-	1
Adverse event, non-fatal	8	3
Lost to follow-up	1	6
Other - not specified	3	-
Lack of efficacy	-	2

Baseline characteristics

Reporting groups

Reporting group title	Brolucizumab 6 mg
-----------------------	-------------------

Reporting group description:

Single intravitreal (IVT) injection of brolucizumab ophthalmic solution at Day 0, Week 4, and Week 8, followed by q8w/q12w maintenance regimen until study exit

Reporting group title	Aflibercept 2 mg
-----------------------	------------------

Reporting group description:

Single IVT injection of aflibercept ophthalmic solution at Day 0, Week 4, and Week 8, followed by q8w maintenance regimen until study exit

Reporting group values	Brolucizumab 6 mg	Aflibercept 2 mg	Total
Number of subjects	370	369	739
Age categorical Units: Subjects			
Age continuous Units: years arithmetic mean standard deviation	74.8 ± 8.58	75.5 ± 7.87	-
Gender categorical Units: Subjects			
Female	210	212	422
Male	160	157	317

End points

End points reporting groups

Reporting group title	Brolucizumab 6 mg
Reporting group description: Single intravitreal (IVT) injection of brolucizumab ophthalmic solution at Day 0, Week 4, and Week 8, followed by q8w/q12w maintenance regimen until study exit	
Reporting group title	Aflibercept 2 mg
Reporting group description: Single IVT injection of aflibercept ophthalmic solution at Day 0, Week 4, and Week 8, followed by q8w maintenance regimen until study exit	

Primary: Change from Baseline in Best Corrected Visual Acuity (BCVA) (letters read) at Week 48 - Study Eye

End point title	Change from Baseline in Best Corrected Visual Acuity (BCVA) (letters read) at Week 48 - Study Eye
End point description: BCVA (with spectacles or other visual corrective devices) was assessed using Early Treatment Diabetic Retinopathy Study (ETDRS) testing at 4 meters and reported in letters read correctly. Baseline was defined as the last measurement prior to first treatment. An increase (gain) in letters read from the baseline assessment indicates improvement. One eye (study eye) contributed to the analysis.	
End point type	Primary
End point timeframe: Baseline, Week 48	

End point values	Brolucizumab 6 mg	Aflibercept 2 mg		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	370	369		
Units: letters				
arithmetic mean (standard deviation)	6.9 (± 11.47)	7.6 (± 12.47)		

Statistical analyses

Statistical analysis title	Change from Baseline in BCVA at Week 48
Comparison groups	Brolucizumab 6 mg v Aflibercept 2 mg
Number of subjects included in analysis	739
Analysis specification	Pre-specified
Analysis type	
P-value	< 0.0001 ^[1]
Method	ANOVA
Parameter estimate	Least Squares Mean Difference
Point estimate	-0.7

Confidence interval	
level	95 %
sides	2-sided
lower limit	-2.4
upper limit	1
Variability estimate	Standard error of the mean
Dispersion value	0.86

Notes:

[1] - 1-sided p-value reported. Hypothesis tested according to the pre-specified hierarchical testing that ensures the global type I error rate at 0.05.

Secondary: Average Change from Baseline in BCVA (letters read) over the Period Week 36 through Week 48 - Study Eye

End point title	Average Change from Baseline in BCVA (letters read) over the Period Week 36 through Week 48 - Study Eye
-----------------	---

End point description:

BCVA (with spectacles or other visual corrective devices) was assessed using ETDRS testing at 4 meters and reported in letters read correctly. For each subject, this endpoint was defined as the average of the changes from baseline to Weeks 36, 40, 44, and 48. Baseline was defined as the last measurement prior to first treatment. An increase (gain) in letters read from the baseline assessment indicates improvement. One eye (study eye) contributed to the analysis.

End point type	Secondary
----------------	-----------

End point timeframe:

Baseline, Weeks 36, 40, 44, 48

End point values	Brolucizumab 6 mg	Aflibercept 2 mg		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	370	369		
Units: letters				
arithmetic mean (standard deviation)	6.6 (± 11.10)	7.7 (± 11.81)		

Statistical analyses

Statistical analysis title	Av Chg from BL in BCVA Wk 36-48 - Study Eye
Comparison groups	Brolucizumab 6 mg v Aflibercept 2 mg
Number of subjects included in analysis	739
Analysis specification	Pre-specified
Analysis type	
P-value	= 0.0003 ^[2]
Method	ANOVA
Parameter estimate	Least Squares Mean Difference
Point estimate	-1.2
Confidence interval	
level	95 %
sides	2-sided
lower limit	-2.8
upper limit	0.5

Variability estimate	Standard error of the mean
Dispersion value	0.82

Notes:

[2] - 1-sided p-value reported. Hypothesis tested according to the pre-specified hierarchical testing that ensures the global type I error rate at 0.05.

Secondary: Proportion of subjects with positive q12 (every 12 weeks) treatment status at Week 48

End point title	Proportion of subjects with positive q12 (every 12 weeks) treatment status at Week 48 ^[3]
-----------------	--

End point description:

Positive q12 treatment status was defined as IVT injections per planned dosing regimen (one injection every 12 weeks "q12w", after the initial three loading injections every 4 weeks "q4w"). A disease activity assessment (DAA) was performed at pre-specified visits (Weeks 16, 20, 28, 32, 40, 44) to identify q8w (one injection every 8 weeks) need. The estimate for the proportion of subjects with a positive q12w status at Week 48 were derived from Kaplan-Meier time to event analyses for the event of first q8w need, applying event allocations (in case of lack of efficacy and/or lack of safety=efficacy/safety approach) and censoring as described in the SAP. Censored subjects were considered to be not anymore under risk for a q8 need identification at later visits. Corresponding 95% Confidence Intervals (CIs) were derived from the LOGLOG transformation. This outcome measure was pre-specified for brolucizumab 6 mg arm only. Hypothesis testing not pre-specified.

End point type	Secondary
----------------	-----------

End point timeframe:

Weeks 16, 20, 28, 32, 40, 44, 48

Notes:

[3] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period. Justification: This outcome measure was pre-specified for brolucizumab 6 mg arm only.

End point values	Brolucizumab 6 mg			
Subject group type	Reporting group			
Number of subjects analysed	370			
Units: proportion of subjects				
number (confidence interval 95%)	0.5101 (0.4567 to 0.5610)			

Statistical analyses

No statistical analyses for this end point

Secondary: Proportion of subjects with positive q12 treatment status at Week 48 within the subjects with no q8 (every 8 weeks) treatment need during the initial q12w cycle (Week 16, Week 20)

End point title	Proportion of subjects with positive q12 treatment status at Week 48 within the subjects with no q8 (every 8 weeks) treatment need during the initial q12w cycle (Week 16, Week 20) ^[4]
-----------------	--

End point description:

Positive q12 treatment status was defined as IVT injections per planned dosing regimen (one injection every 12 weeks "q12w", after the initial three loading injections every 4 weeks "q4w"). A disease activity assessment (DAA) was performed at pre-specified visits (Weeks 16, 20, 28, 32, 40, 44) to identify q8w need. The estimate for the proportion of subjects with a positive q12w status at Week 48 were derived from Kaplan-Meier time to event analyses for the event of first q8w need, applying event allocations (in case of lack of efficacy and/or lack of safety=efficacy/safety approach) and censoring as described in the SAP. Censored subjects were considered to be not anymore under risk for a q8 need

identification at later visits. Corresponding 95% Confidence Intervals (CIs) were derived from the LOGLOG transformation. This outcome measure was pre-specified for brolucizumab 6 mg arm only. Hypothesis testing not pre-specified.

End point type	Secondary
End point timeframe:	
Weeks 16, 20, 28, 32, 40, 44, 48	

Notes:

[4] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period. Justification: This outcome measure was pre-specified for brolucizumab 6 mg arm only.

End point values	Brolucizumab 6 mg			
Subject group type	Reporting group			
Number of subjects analysed	220			
Units: proportion of subjects				
number (confidence interval 95%)	0.8170 (0.7582 to 0.8629)			

Statistical analyses

No statistical analyses for this end point

Secondary: Proportion of subjects with positive q12 treatment status up to Week 96

End point title	Proportion of subjects with positive q12 treatment status up to Week 96 ^[5]
-----------------	--

End point description:

Positive q12 treatment status was defined as IVT injections per planned dosing regimen (one injection every 12 weeks "q12w", after the initial three loading injections every 4 weeks "q4w"). A disease activity assessment (DAA) was performed at pre-specified visits (Weeks 16, 20, 28, 32, 40, 44, 52, 56, 64, 68, 76, 80, 88, 92) to identify q8w need. The estimate for the proportion of subjects with a positive q12w status at Week 48 were derived from Kaplan-Meier time to event analyses for the event of first q8w need, applying event allocations (in case of lack of efficacy and/or lack of safety=efficacy/safety approach) and censoring as described in the SAP. Censored subjects were considered to be not anymore under risk for a q8 need identification at later visits. Corresponding 95% Confidence Intervals (CIs) were derived from the LOGLOG transformation. This outcome measure was pre-specified for brolucizumab 6 mg arm only. Hypothesis testing not pre-specified.

End point type	Secondary
End point timeframe:	
Weeks 16, 20, 28, 32, 40, 44, 52, 56, 64, 68, 76, 80, 88, 92, 96	

Notes:

[5] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period. Justification: This outcome measure was pre-specified for brolucizumab 6 mg arm only.

End point values	Brolucizumab 6 mg			
Subject group type	Reporting group			
Number of subjects analysed	370			
Units: proportion of subjects				
number (confidence interval 95%)	0.3856 (0.3336 to 0.4372)			

Statistical analyses

No statistical analyses for this end point

Secondary: Proportion of subjects with positive q12 treatment status at Week 96 within the subjects with no q8 treatment need during the initial q12w cycle (Week 16, Week 20)

End point title	Proportion of subjects with positive q12 treatment status at Week 96 within the subjects with no q8 treatment need during the initial q12w cycle (Week 16, Week 20) ^[6]
-----------------	--

End point description:

Positive q12 treatment status was defined as IVT injections per planned dosing regimen (one injection every 12 weeks "q12w", after the initial three loading injections every 4 weeks "q4w"). A disease activity assessment (DAA) was performed at pre-specified visits (Weeks 16, 20, 28, 32, 40, 44, 52, 56, 64, 68, 76, 80, 88, 92) to identify q8w need. The estimate for the proportion of subjects with a positive q12w status at Week 48 were derived from Kaplan-Meier time to event analyses for the event of first q8w need, applying event allocations (in case of lack of efficacy and/or lack of safety=efficacy/safety approach) and censoring as described in the SAP. Censored subjects were considered to be not anymore under risk for a q8 need identification at later visits. Corresponding 95% Confidence Intervals (CIs) were derived from the LOGLOG transformation. This outcome measure was pre-specified for brolucizumab 6 mg arm only. Hypothesis testing not pre-specified.

End point type	Secondary
----------------	-----------

End point timeframe:

Weeks 16, 20, 28, 32, 40, 44, 52, 56, 64, 68, 76, 80, 88, 92, 96

Notes:

[6] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period. Justification: This outcome measure was pre-specified for brolucizumab 6 mg arm only.

End point values	Brolucizumab 6 mg			
Subject group type	Reporting group			
Number of subjects analysed	221			
Units: proportion of subjects				
number (confidence interval 95%)	0.6170 (0.5465 to 0.6799)			

Statistical analyses

No statistical analyses for this end point

Secondary: Change from Baseline in BCVA (letters read) at each post-baseline Visit - Study Eye

End point title	Change from Baseline in BCVA (letters read) at each post-baseline Visit - Study Eye
-----------------	---

End point description:

BCVA (with spectacles or other visual corrective devices) was assessed using ETDRS testing at 4 meters

and reported in letters read correctly. Baseline was defined as the last measurement prior to first treatment. An increase (gain) in letters read from the baseline assessment indicates improvement. One eye (study eye) contributed to the analysis.

End point type	Secondary
End point timeframe:	
Baseline, Weeks 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44, 48, 52, 56, 60, 64, 68, 72, 76, 80, 84, 88, 92, 96	

End point values	Brolucizumab 6 mg	Aflibercept 2 mg		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	370	369		
Units: letters				
arithmetic mean (standard deviation)				
Change from baseline at Week 4	3.7 (± 7.03)	4.7 (± 7.62)		
Change from baseline at Week 8	5.0 (± 8.16)	6.0 (± 9.32)		
Change from baseline at Week 12	5.4 (± 9.35)	6.4 (± 10.14)		
Change from baseline at Week 16	5.4 (± 9.65)	6.3 (± 10.46)		
Change from baseline at Week 20	5.4 (± 10.42)	6.9 (± 10.66)		
Change from baseline at Week 24	5.8 (± 10.76)	6.7 (± 11.17)		
Change from baseline at Week 28	6.3 (± 10.97)	7.4 (± 11.86)		
Change from baseline at Week 32	6.5 (± 10.92)	7.3 (± 11.44)		
Change from baseline at Week 36	6.4 (± 11.32)	7.6 (± 11.99)		
Change from baseline at Week 40	6.4 (± 11.66)	7.6 (± 11.85)		
Change from baseline at Week 44	6.5 (± 11.51)	8.0 (± 12.28)		
Change from baseline at Week 48	6.9 (± 11.47)	7.6 (± 12.47)		
Change from baseline at Week 52	6.8 (± 12.03)	7.4 (± 12.91)		
Change from baseline at Week 56	6.6 (± 12.43)	7.2 (± 13.04)		
Change from baseline at Week 60	6.5 (± 12.23)	7.4 (± 13.49)		
Change from baseline at Week 64	6.5 (± 12.51)	7.2 (± 13.79)		
Change from baseline at Week 68	6.5 (± 12.22)	7.1 (± 14.29)		
Change from baseline at Week 72	6.1 (± 13.32)	6.9 (± 13.74)		
Change from baseline at Week 76	6.3 (± 13.44)	6.8 (± 13.80)		
Change from baseline at Week 80	6.4 (± 13.43)	6.6 (± 13.97)		
Change from baseline at Week 84	5.8 (± 13.76)	6.7 (± 14.04)		
Change from baseline at Week 88	6.3 (± 13.40)	6.9 (± 14.02)		
Change from baseline at Week 92	6.1 (± 13.85)	6.5 (± 14.29)		
Change from baseline at Week 96	6.1 (± 14.06)	6.6 (± 14.55)		

Statistical analyses

Statistical analysis title	Chg from BL in BCVA (letters read) - Study Eye
Statistical analysis description:	
Week 4	
Comparison groups	Brolucizumab 6 mg v Aflibercept 2 mg

Number of subjects included in analysis	739
Analysis specification	Pre-specified
Analysis type	
Method	ANOVA
Parameter estimate	Least Squares Mean Difference
Point estimate	-1
Confidence interval	
level	95 %
sides	2-sided
lower limit	-2
upper limit	0
Variability estimate	Standard error of the mean
Dispersion value	0.52

Statistical analysis title	Chg from BL in BCVA (letters read) - Study Eye
Statistical analysis description:	
Week 8	
Comparison groups	Brolucizumab 6 mg v Aflibercept 2 mg
Number of subjects included in analysis	739
Analysis specification	Pre-specified
Analysis type	
Method	ANOVA
Parameter estimate	Least Squares Mean Difference
Point estimate	-1
Confidence interval	
level	95 %
sides	2-sided
lower limit	-2.2
upper limit	0.2
Variability estimate	Standard error of the mean
Dispersion value	0.63

Statistical analysis title	Chg from BL in BCVA (letters read) - Study Eye
Statistical analysis description:	
Week 12	
Comparison groups	Brolucizumab 6 mg v Aflibercept 2 mg
Number of subjects included in analysis	739
Analysis specification	Pre-specified
Analysis type	
Method	ANOVA
Parameter estimate	Least Squares Mean Difference
Point estimate	-1

Confidence interval	
level	95 %
sides	2-sided
lower limit	-2.4
upper limit	0.4
Variability estimate	Standard error of the mean
Dispersion value	0.71

Statistical analysis title	Chg from BL in BCVA (letters read) - Study Eye
Statistical analysis description:	
Week 16	
Comparison groups	Brolucizumab 6 mg v Aflibercept 2 mg
Number of subjects included in analysis	739
Analysis specification	Pre-specified
Analysis type	
Method	ANOVA
Parameter estimate	Least Squares Mean Difference
Point estimate	-0.9
Confidence interval	
level	95 %
sides	2-sided
lower limit	-2.3
upper limit	0.6
Variability estimate	Standard error of the mean
Dispersion value	0.73

Statistical analysis title	Chg from BL in BCVA (letters read) - Study Eye
Statistical analysis description:	
Week 20	
Comparison groups	Brolucizumab 6 mg v Aflibercept 2 mg
Number of subjects included in analysis	739
Analysis specification	Pre-specified
Analysis type	
Method	ANOVA
Parameter estimate	Least Squares Mean Difference
Point estimate	-1.5
Confidence interval	
level	95 %
sides	2-sided
lower limit	-3
upper limit	0
Variability estimate	Standard error of the mean
Dispersion value	0.76

Statistical analysis title	Chg from BL in BCVA (letters read) - Study Eye
Statistical analysis description:	
Week 24	
Comparison groups	Brolucizumab 6 mg v Aflibercept 2 mg
Number of subjects included in analysis	739
Analysis specification	Pre-specified
Analysis type	
Method	ANOVA
Parameter estimate	Least Squares Mean Difference
Point estimate	-0.9
Confidence interval	
level	95 %
sides	2-sided
lower limit	-2.5
upper limit	0.6
Variability estimate	Standard error of the mean
Dispersion value	0.79

Statistical analysis title	Chg from BL in BCVA (letters read) - Study Eye
Statistical analysis description:	
Week 28	
Comparison groups	Brolucizumab 6 mg v Aflibercept 2 mg
Number of subjects included in analysis	739
Analysis specification	Pre-specified
Analysis type	
Method	ANOVA
Parameter estimate	Least Squares Mean Difference
Point estimate	-1.1
Confidence interval	
level	95 %
sides	2-sided
lower limit	-2.7
upper limit	0.5
Variability estimate	Standard error of the mean
Dispersion value	0.82

Statistical analysis title	Chg from BL in BCVA (letters read) - Study Eye
Statistical analysis description:	
Week 32	
Comparison groups	Brolucizumab 6 mg v Aflibercept 2 mg

Number of subjects included in analysis	739
Analysis specification	Pre-specified
Analysis type	
Method	ANOVA
Parameter estimate	Least Squares Mean Difference
Point estimate	-0.9
Confidence interval	
level	95 %
sides	2-sided
lower limit	-2.5
upper limit	0.7
Variability estimate	Standard error of the mean
Dispersion value	0.81

Statistical analysis title	Chg from BL in BCVA (letters read) - Study Eye
Statistical analysis description:	
Week 36	
Comparison groups	Brolucizumab 6 mg v Aflibercept 2 mg
Number of subjects included in analysis	739
Analysis specification	Pre-specified
Analysis type	
Method	ANOVA
Parameter estimate	Least Squares Mean Difference
Point estimate	-1.2
Confidence interval	
level	95 %
sides	2-sided
lower limit	-2.9
upper limit	0.4
Variability estimate	Standard error of the mean
Dispersion value	0.84

Statistical analysis title	Chg from BL in BCVA (letters read) - Study Eye
Statistical analysis description:	
Week 40	
Comparison groups	Brolucizumab 6 mg v Aflibercept 2 mg
Number of subjects included in analysis	739
Analysis specification	Pre-specified
Analysis type	
Method	ANOVA
Parameter estimate	Least Squares Mean Difference
Point estimate	-1.2

Confidence interval	
level	95 %
sides	2-sided
lower limit	-2.9
upper limit	0.5
Variability estimate	Standard error of the mean
Dispersion value	0.85

Statistical analysis title	Chg from BL in BCVA (letters read) - Study Eye
Statistical analysis description:	
Week 44	
Comparison groups	Brolucizumab 6 mg v Aflibercept 2 mg
Number of subjects included in analysis	739
Analysis specification	Pre-specified
Analysis type	
Method	ANOVA
Parameter estimate	Least Squares Mean Difference
Point estimate	-1.6
Confidence interval	
level	95 %
sides	2-sided
lower limit	-3.2
upper limit	0.1
Variability estimate	Standard error of the mean
Dispersion value	0.86

Statistical analysis title	Chg from BL in BCVA (letters read) - Study Eye
Statistical analysis description:	
Week 48	
Comparison groups	Brolucizumab 6 mg v Aflibercept 2 mg
Number of subjects included in analysis	739
Analysis specification	Pre-specified
Analysis type	
Method	ANOVA
Parameter estimate	Least Squares Mean Difference
Point estimate	-0.7
Confidence interval	
level	95 %
sides	2-sided
lower limit	-2.4
upper limit	1
Variability estimate	Standard error of the mean
Dispersion value	0.86

Statistical analysis title	Chg from BL in BCVA (letters read) - Study Eye
Statistical analysis description:	
Week 52	
Comparison groups	Brolucizumab 6 mg v Aflibercept 2 mg
Number of subjects included in analysis	739
Analysis specification	Pre-specified
Analysis type	
Method	ANOVA
Parameter estimate	Least Squares Mean Difference
Point estimate	-0.7
Confidence interval	
level	95 %
sides	2-sided
lower limit	-2.5
upper limit	1.1
Variability estimate	Standard error of the mean
Dispersion value	0.9

Statistical analysis title	Chg from BL in BCVA (letters read) - Study Eye
Statistical analysis description:	
Week 56	
Comparison groups	Brolucizumab 6 mg v Aflibercept 2 mg
Number of subjects included in analysis	739
Analysis specification	Pre-specified
Analysis type	
Method	ANOVA
Parameter estimate	Least Squares Mean Difference
Point estimate	-0.7
Confidence interval	
level	95 %
sides	2-sided
lower limit	-2.5
upper limit	1.1
Variability estimate	Standard error of the mean
Dispersion value	0.92

Statistical analysis title	Chg from BL in BCVA (letters read) - Study Eye
Statistical analysis description:	
Week 60	
Comparison groups	Brolucizumab 6 mg v Aflibercept 2 mg

Number of subjects included in analysis	739
Analysis specification	Pre-specified
Analysis type	
Method	ANOVA
Parameter estimate	Least Squares Mean Difference
Point estimate	-0.8
Confidence interval	
level	95 %
sides	2-sided
lower limit	-2.7
upper limit	1
Variability estimate	Standard error of the mean
Dispersion value	0.93

Statistical analysis title	Chg from BL in BCVA (letters read) - Study Eye
Statistical analysis description:	
Week 64	
Comparison groups	Brolucizumab 6 mg v Aflibercept 2 mg
Number of subjects included in analysis	739
Analysis specification	Pre-specified
Analysis type	
Method	ANOVA
Parameter estimate	Least Squares Mean Difference
Point estimate	-0.7
Confidence interval	
level	95 %
sides	2-sided
lower limit	-2.5
upper limit	1.2
Variability estimate	Standard error of the mean
Dispersion value	0.95

Statistical analysis title	Chg from BL in BCVA (letters read) - Study Eye
Statistical analysis description:	
Week 68	
Comparison groups	Brolucizumab 6 mg v Aflibercept 2 mg
Number of subjects included in analysis	739
Analysis specification	Pre-specified
Analysis type	
Method	ANOVA
Parameter estimate	Least Squares Mean Difference
Point estimate	-0.7

Confidence interval	
level	95 %
sides	2-sided
lower limit	-2.5
upper limit	1.2
Variability estimate	Standard error of the mean
Dispersion value	0.96

Statistical analysis title	Chg from BL in BCVA (letters read) - Study Eye
Statistical analysis description:	
Week 72	
Comparison groups	Brolucizumab 6 mg v Aflibercept 2 mg
Number of subjects included in analysis	739
Analysis specification	Pre-specified
Analysis type	
Method	ANOVA
Parameter estimate	Least Squares Mean Difference
Point estimate	-0.9
Confidence interval	
level	95 %
sides	2-sided
lower limit	-2.8
upper limit	1.1
Variability estimate	Standard error of the mean
Dispersion value	0.98

Statistical analysis title	Chg from BL in BCVA (letters read) - Study Eye
Statistical analysis description:	
Week 76	
Comparison groups	Brolucizumab 6 mg v Aflibercept 2 mg
Number of subjects included in analysis	739
Analysis specification	Pre-specified
Analysis type	
Method	ANOVA
Parameter estimate	Least Squares Mean Difference
Point estimate	-0.5
Confidence interval	
level	95 %
sides	2-sided
lower limit	-2.5
upper limit	1.4
Variability estimate	Standard error of the mean
Dispersion value	0.98

Statistical analysis title	Chg from BL in BCVA (letters read) - Study Eye
Statistical analysis description:	
Week 80	
Comparison groups	Brolucizumab 6 mg v Aflibercept 2 mg
Number of subjects included in analysis	739
Analysis specification	Pre-specified
Analysis type	
Method	ANOVA
Parameter estimate	Least Squares Mean Difference
Point estimate	-0.2
Confidence interval	
level	95 %
sides	2-sided
lower limit	-2.1
upper limit	1.8
Variability estimate	Standard error of the mean
Dispersion value	0.99

Statistical analysis title	Chg from BL in BCVA (letters read) - Study Eye
Statistical analysis description:	
Week 84	
Comparison groups	Brolucizumab 6 mg v Aflibercept 2 mg
Number of subjects included in analysis	739
Analysis specification	Pre-specified
Analysis type	
Method	ANOVA
Parameter estimate	Least Squares Mean Difference
Point estimate	-0.9
Confidence interval	
level	95 %
sides	2-sided
lower limit	-2.9
upper limit	1.1
Variability estimate	Standard error of the mean
Dispersion value	1

Statistical analysis title	Chg from BL in BCVA (letters read) - Study Eye
Statistical analysis description:	
Week 88	
Comparison groups	Brolucizumab 6 mg v Aflibercept 2 mg

Number of subjects included in analysis	739
Analysis specification	Pre-specified
Analysis type	
Method	ANOVA
Parameter estimate	Least Squares Mean Difference
Point estimate	-0.6
Confidence interval	
level	95 %
sides	2-sided
lower limit	-2.6
upper limit	1.3
Variability estimate	Standard error of the mean
Dispersion value	0.99

Statistical analysis title	Chg from BL in BCVA (letters read) - Study Eye
Statistical analysis description:	
Week 92	
Comparison groups	Brolucizumab 6 mg v Aflibercept 2 mg
Number of subjects included in analysis	739
Analysis specification	Pre-specified
Analysis type	
Method	ANOVA
Parameter estimate	Least Squares Mean Difference
Point estimate	-0.4
Confidence interval	
level	95 %
sides	2-sided
lower limit	-2.4
upper limit	1.6
Variability estimate	Standard error of the mean
Dispersion value	1.02

Statistical analysis title	Chg from BL in BCVA (letters read) - Study Eye
Statistical analysis description:	
Week 96	
Comparison groups	Brolucizumab 6 mg v Aflibercept 2 mg
Number of subjects included in analysis	739
Analysis specification	Pre-specified
Analysis type	
Method	ANOVA
Parameter estimate	Least Squares Mean Difference
Point estimate	-0.4

Confidence interval	
level	95 %
sides	2-sided
lower limit	-2.5
upper limit	1.6
Variability estimate	Standard error of the mean
Dispersion value	1.04

Secondary: Average change from baseline in BCVA (letters read) over the period Week 4 to Week 48/96 - Study Eye

End point title	Average change from baseline in BCVA (letters read) over the period Week 4 to Week 48/96 - Study Eye
-----------------	--

End point description:

BCVA (with spectacles or other visual corrective devices) was assessed using ETDRS testing at 4 meters and reported in letters read correctly. Baseline was defined as the last measurement prior to first treatment. An increase (gain) in letters read from the baseline assessment indicates improvement. One eye (study eye) contributed to the analysis.

End point type	Secondary
----------------	-----------

End point timeframe:

Baseline, Weeks 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44, 48, 52, 56, 60, 64, 68, 72, 76, 80, 84, 88, 92, 96

End point values	Brolucizumab 6 mg	Aflibercept 2 mg		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	370	369		
Units: letters				
arithmetic mean (standard deviation)				
Change from baseline over the period Week 4 to 48	5.8 (± 9.11)	6.9 (± 10.11)		
Change from baseline over the period Week 4 to 96	6.1 (± 10.42)	6.9 (± 11.41)		

Statistical analyses

Statistical analysis title	Av chg from BL in BCVA Wk 4-48 - Study Eye
----------------------------	--

Statistical analysis description:

Week 4 to Week 48

Comparison groups	Brolucizumab 6 mg v Aflibercept 2 mg
Number of subjects included in analysis	739
Analysis specification	Pre-specified
Analysis type	
Method	ANOVA
Parameter estimate	Least Squares Mean Difference
Point estimate	-1.1

Confidence interval	
level	95 %
sides	2-sided
lower limit	-2.4
upper limit	0.3
Variability estimate	Standard error of the mean
Dispersion value	0.69

Statistical analysis title	Av chg from BL in BCVA Wk 4-96 - Study Eye
Statistical analysis description: Week 4 to Week 96	
Comparison groups	Brolucizumab 6 mg v Aflibercept 2 mg
Number of subjects included in analysis	739
Analysis specification	Pre-specified
Analysis type	
Method	ANOVA
Parameter estimate	Least Squares Mean Difference
Point estimate	-0.8
Confidence interval	
level	95 %
sides	2-sided
lower limit	-2.4
upper limit	0.7
Variability estimate	Standard error of the mean
Dispersion value	0.78

Secondary: Average change from baseline in BCVA (letters read) over the Period Week 12 to Week 48/96 - Study Eye

End point title	Average change from baseline in BCVA (letters read) over the Period Week 12 to Week 48/96 - Study Eye
End point description: BCVA (with spectacles or other visual corrective devices) was assessed using ETDRS testing at 4 meters and reported in letters read correctly. Baseline was defined as the last measurement prior to first treatment. An increase (gain) in letters read from the baseline assessment indicates improvement. One eye (study eye) contributed to the analysis.	
End point type	Secondary
End point timeframe: Baseline, Weeks 12, 16, 20, 24, 28, 32, 36, 40, 44, 48, 52, 56, 60, 64, 68, 72, 76, 80, 84, 88, 92, 96	

End point values	Brolucizumab 6 mg	Aflibercept 2 mg		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	370	369		
Units: letters				
arithmetic mean (standard deviation)				
Change from baseline over the period Week 12 to 48	6.1 (\pm 9.91)	7.2 (\pm 10.77)		
Change from baseline over the period Week 12 to 96	6.2 (\pm 10.97)	7.0 (\pm 11.88)		

Statistical analyses

Statistical analysis title	Av chg from BL in BCVA Wk 12-48 - Study Eye
Statistical analysis description: Week 12 to Week 48	
Comparison groups	Brolucizumab 6 mg v Aflibercept 2 mg
Number of subjects included in analysis	739
Analysis specification	Pre-specified
Analysis type	
Method	ANOVA
Parameter estimate	Least Squares Mean Difference
Point estimate	-1.1
Confidence interval	
level	95 %
sides	2-sided
lower limit	-2.5
upper limit	0.4
Variability estimate	Standard error of the mean
Dispersion value	0.74

Statistical analysis title	Av chg from BL in BCVA Wk 12-96 - Study Eye
Statistical analysis description: Week 12 to Week 96	
Comparison groups	Brolucizumab 6 mg v Aflibercept 2 mg
Number of subjects included in analysis	739
Analysis specification	Pre-specified
Analysis type	
Method	ANOVA
Parameter estimate	Least Squares Mean Difference
Point estimate	-0.8
Confidence interval	
level	95 %
sides	2-sided
lower limit	-2.4
upper limit	0.8
Variability estimate	Standard error of the mean
Dispersion value	0.82

Secondary: Average change from baseline in BCVA (letters read) over the period Week 84 to Week 96 - Study Eye

End point title	Average change from baseline in BCVA (letters read) over the period Week 84 to Week 96 - Study Eye
-----------------	--

End point description:

BCVA (with spectacles or other visual corrective devices) was assessed using ETDRS testing at 4 meters and reported in letters read correctly. Baseline was defined as the last measurement prior to first treatment. An increase (gain) in letters read from the baseline assessment indicates improvement. One eye (study eye) contributed to the analysis.

End point type	Secondary
----------------	-----------

End point timeframe:

Baseline, Weeks 84, 88, 92, 96

End point values	Brolucizumab 6 mg	Aflibercept 2 mg		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	370	369		
Units: letters				
arithmetic mean (standard deviation)	6.1 (± 13.51)	6.7 (± 13.96)		

Statistical analyses

Statistical analysis title	Av chg from BL in BCVA Wk 84-96 - Study Eye
Comparison groups	Brolucizumab 6 mg v Aflibercept 2 mg
Number of subjects included in analysis	739
Analysis specification	Pre-specified
Analysis type	
Method	ANOVA
Parameter estimate	Least Squares Mean Difference
Point estimate	-0.6
Confidence interval	
level	95 %
sides	2-sided
lower limit	-2.5
upper limit	1.4
Variability estimate	Standard error of the mean
Dispersion value	0.99

Secondary: Percentage of subjects with ≥15 letter gain from baseline in BCVA (letters read) at each post-baseline visit - Study Eye

End point title	Percentage of subjects with ≥15 letter gain from baseline in BCVA (letters read) at each post-baseline visit - Study Eye
-----------------	--

End point description:

BCVA (with spectacles or other visual corrective devices) was assessed using ETDRS testing at 4 meters and reported in letters read correctly. Baseline was defined as the last measurement prior to first treatment. An increase (gain) in letters read from the baseline assessment indicates improvement. 95% confidence interval (CI) for binomial proportions was based on Clopper-Pearson exact method. One eye (study eye) contributed to the analysis.

End point type	Secondary
----------------	-----------

End point timeframe:

Baseline, Weeks 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44, 48, 52, 56, 60, 64, 68, 72, 76, 80, 84, 88, 92, 96

End point values	Brolucizumab 6 mg	Aflibercept 2 mg		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	370	369		
Units: percentage of subjects				
number (confidence interval 95%)				
Change from baseline at Week 4	7.6 (5.1 to 10.8)	8.9 (6.2 to 12.3)		
Change from baseline at Week 8	13.8 (10.4 to 17.7)	18.2 (14.4 to 22.5)		
Change from baseline at Week 12	16.5 (12.9 to 20.7)	21.4 (17.3 to 26.0)		
Change from baseline at Week 16	20.0 (16.0 to 24.4)	22.2 (18.1 to 26.8)		
Change from baseline at Week 20	20.5 (16.5 to 25.0)	23.6 (19.3 to 28.2)		
Change from baseline at Week 24	23.8 (19.5 to 28.5)	22.8 (18.6 to 27.4)		
Change from baseline at Week 28	23.8 (19.5 to 28.5)	27.4 (22.9 to 32.2)		
Change from baseline at Week 32	25.4 (21.0 to 30.2)	28.7 (24.2 to 33.6)		
Change from baseline at Week 36	26.2 (21.8 to 31.0)	30.9 (26.2 to 35.9)		
Change from baseline at Week 40	27.0 (22.6 to 31.9)	31.4 (26.7 to 36.4)		
Change from baseline at Week 44	26.8 (22.3 to 31.6)	31.2 (26.5 to 36.2)		
Change from baseline at Week 48	29.5 (24.9 to 34.4)	29.8 (25.2 to 34.8)		
Change from baseline at Week 52	30.3 (25.6 to 35.2)	30.6 (26.0 to 35.6)		
Change from baseline at Week 56	29.7 (25.1 to 34.7)	30.6 (26.0 to 35.6)		
Change from baseline at Week 60	28.6 (24.1 to 33.5)	30.6 (26.0 to 35.6)		
Change from baseline at Week 64	29.7 (25.1 to 34.7)	30.9 (26.2 to 35.9)		
Change from baseline at Week 68	28.9 (24.3 to 33.8)	32.2 (27.5 to 37.3)		
Change from baseline at Week 72	27.6 (23.1 to 32.4)	31.4 (26.7 to 36.4)		
Change from baseline at Week 76	28.4 (23.8 to 33.3)	30.6 (26.0 to 35.6)		
Change from baseline at Week 80	28.1 (23.6 to 33.0)	30.4 (25.7 to 35.3)		

Change from baseline at Week 84	27.6 (23.1 to 32.4)	31.2 (26.5 to 36.2)		
Change from baseline at Week 88	27.6 (23.1 to 32.4)	33.1 (28.3 to 38.1)		
Change from baseline at Week 92	29.5 (24.9 to 34.4)	30.9 (26.2 to 35.9)		
Change from baseline at Week 96	29.2 (24.6 to 34.1)	31.4 (26.7 to 36.4)		

Statistical analyses

Statistical analysis title	>=15 letter gain from baseline in BCVA - Study Eye
Statistical analysis description:	
Week 4	
Comparison groups	Brolucizumab 6 mg v Aflibercept 2 mg
Number of subjects included in analysis	739
Analysis specification	Pre-specified
Analysis type	
Method	Regression, Logistic
Parameter estimate	Difference in proportions
Point estimate	-1.3
Confidence interval	
level	95 %
sides	2-sided
lower limit	-5.1
upper limit	2.9

Statistical analysis title	>=15 letter gain from baseline in BCVA - Study Eye
Statistical analysis description:	
Week 8	
Comparison groups	Brolucizumab 6 mg v Aflibercept 2 mg
Number of subjects included in analysis	739
Analysis specification	Pre-specified
Analysis type	
Method	Regression, Logistic
Parameter estimate	Difference in proportions
Point estimate	-4.3
Confidence interval	
level	95 %
sides	2-sided
lower limit	-9.5
upper limit	1

Statistical analysis title	>=15 letter gain from baseline in BCVA - Study Eye
-----------------------------------	--

Statistical analysis description:

Week 12

Comparison groups	Brolucizumab 6 mg v Aflibercept 2 mg
Number of subjects included in analysis	739
Analysis specification	Pre-specified
Analysis type	
Method	Regression, Logistic
Parameter estimate	Difference in proportions
Point estimate	-5
Confidence interval	
level	95 %
sides	2-sided
lower limit	-10.5
upper limit	0.3

Statistical analysis title

>=15 letter gain from baseline in BCVA - Study Eye

Statistical analysis description:

Week 16

Comparison groups	Brolucizumab 6 mg v Aflibercept 2 mg
Number of subjects included in analysis	739
Analysis specification	Pre-specified
Analysis type	
Method	Regression, Logistic
Parameter estimate	Difference in proportions
Point estimate	-2.3
Confidence interval	
level	95 %
sides	2-sided
lower limit	-8.4
upper limit	3.7

Statistical analysis title

>=15 letter gain from baseline in BCVA - Study Eye

Statistical analysis description:

Week 20

Comparison groups	Brolucizumab 6 mg v Aflibercept 2 mg
Number of subjects included in analysis	739
Analysis specification	Pre-specified
Analysis type	
Method	Regression, Logistic
Parameter estimate	Difference in proportions
Point estimate	-3.1
Confidence interval	
level	95 %
sides	2-sided
lower limit	-8.8
upper limit	2.8

Statistical analysis title	>=15 letter gain from baseline in BCVA - Study Eye
Statistical analysis description:	
Week 24	
Comparison groups	Brolucizumab 6 mg v Aflibercept 2 mg
Number of subjects included in analysis	739
Analysis specification	Pre-specified
Analysis type	
Method	Regression, Logistic
Parameter estimate	Difference in proportions
Point estimate	0.9
Confidence interval	
level	95 %
sides	2-sided
lower limit	-5.2
upper limit	6.7

Statistical analysis title	>=15 letter gain from baseline in BCVA - Study Eye
Statistical analysis description:	
Week 32	
Comparison groups	Brolucizumab 6 mg v Aflibercept 2 mg
Number of subjects included in analysis	739
Analysis specification	Pre-specified
Analysis type	
Method	Regression, Logistic
Parameter estimate	Difference in proportions
Point estimate	-3.6
Confidence interval	
level	95 %
sides	2-sided
lower limit	-10.5
upper limit	2.7

Statistical analysis title	>=15 letter gain from baseline in BCVA - Study Eye
Statistical analysis description:	
Week 28	
Comparison groups	Brolucizumab 6 mg v Aflibercept 2 mg
Number of subjects included in analysis	739
Analysis specification	Pre-specified
Analysis type	
Method	Regression, Logistic
Parameter estimate	Difference in proportions
Point estimate	-3.7

Confidence interval	
level	95 %
sides	2-sided
lower limit	-9.9
upper limit	2.3

Statistical analysis title	>=15 letter gain from baseline in BCVA - Study Eye
Statistical analysis description:	
Week 36	
Comparison groups	Brolucizumab 6 mg v Aflibercept 2 mg
Number of subjects included in analysis	739
Analysis specification	Pre-specified
Analysis type	
Method	Regression, Logistic
Parameter estimate	Difference in proportions
Point estimate	-4.9
Confidence interval	
level	95 %
sides	2-sided
lower limit	-11.6
upper limit	1.3

Statistical analysis title	>=15 letter gain from baseline in BCVA - Study Eye
Statistical analysis description:	
Week 40	
Comparison groups	Brolucizumab 6 mg v Aflibercept 2 mg
Number of subjects included in analysis	739
Analysis specification	Pre-specified
Analysis type	
Method	Regression, Logistic
Parameter estimate	Difference in proportions
Point estimate	-4.7
Confidence interval	
level	95 %
sides	2-sided
lower limit	-11.5
upper limit	1.9

Statistical analysis title	>=15 letter gain from baseline in BCVA - Study Eye
Statistical analysis description:	
Week 44	
Comparison groups	Brolucizumab 6 mg v Aflibercept 2 mg

Number of subjects included in analysis	739
Analysis specification	Pre-specified
Analysis type	
Method	Regression, Logistic
Parameter estimate	Difference in proportions
Point estimate	-4.6
Confidence interval	
level	95 %
sides	2-sided
lower limit	-11.3
upper limit	1.8

Statistical analysis title	>=15 letter gain from baseline in BCVA - Study Eye
Statistical analysis description:	
Week 48	
Comparison groups	Brolucizumab 6 mg v Aflibercept 2 mg
Number of subjects included in analysis	739
Analysis specification	Pre-specified
Analysis type	
Method	Regression, Logistic
Parameter estimate	Difference in proportions
Point estimate	-0.6
Confidence interval	
level	95 %
sides	2-sided
lower limit	-7.1
upper limit	5.8

Statistical analysis title	>=15 letter gain from baseline in BCVA - Study Eye
Statistical analysis description:	
Week 52	
Comparison groups	Brolucizumab 6 mg v Aflibercept 2 mg
Number of subjects included in analysis	739
Analysis specification	Pre-specified
Analysis type	
Method	Regression, Logistic
Parameter estimate	Difference in proportions
Point estimate	-0.6
Confidence interval	
level	95 %
sides	2-sided
lower limit	-7
upper limit	5.5

Statistical analysis title	>=15 letter gain from baseline in BCVA - Study Eye
Statistical analysis description:	
Week 56	
Comparison groups	Brolucizumab 6 mg v Aflibercept 2 mg
Number of subjects included in analysis	739
Analysis specification	Pre-specified
Analysis type	
Method	Regression, Logistic
Parameter estimate	Difference in proportions
Point estimate	-1.1
Confidence interval	
level	95 %
sides	2-sided
lower limit	-7.7
upper limit	5.4

Statistical analysis title	>=15 letter gain from baseline in BCVA - Study Eye
Statistical analysis description:	
Week 60	
Comparison groups	Brolucizumab 6 mg v Aflibercept 2 mg
Number of subjects included in analysis	739
Analysis specification	Pre-specified
Analysis type	
Method	Regression, Logistic
Parameter estimate	Difference in proportions
Point estimate	-2.2
Confidence interval	
level	95 %
sides	2-sided
lower limit	-8.3
upper limit	4.2

Statistical analysis title	>=15 letter gain from baseline in BCVA - Study Eye
Statistical analysis description:	
Week 64	
Comparison groups	Brolucizumab 6 mg v Aflibercept 2 mg
Number of subjects included in analysis	739
Analysis specification	Pre-specified
Analysis type	
Method	Regression, Logistic
Parameter estimate	Difference in proportions
Point estimate	-1.4

Confidence interval	
level	95 %
sides	2-sided
lower limit	-7.9
upper limit	5.4

Statistical analysis title	>=15 letter gain from baseline in BCVA - Study Eye
Statistical analysis description:	
Week 68	
Comparison groups	Brolucizumab 6 mg v Aflibercept 2 mg
Number of subjects included in analysis	739
Analysis specification	Pre-specified
Analysis type	
Method	Regression, Logistic
Parameter estimate	Difference in proportions
Point estimate	-3.5
Confidence interval	
level	95 %
sides	2-sided
lower limit	-9.9
upper limit	3.1

Statistical analysis title	>=15 letter gain from baseline in BCVA - Study Eye
Statistical analysis description:	
Week 72	
Comparison groups	Brolucizumab 6 mg v Aflibercept 2 mg
Number of subjects included in analysis	739
Analysis specification	Pre-specified
Analysis type	
Method	Regression, Logistic
Parameter estimate	Difference in proportions
Point estimate	-4.1
Confidence interval	
level	95 %
sides	2-sided
lower limit	-10.2
upper limit	2.3

Statistical analysis title	>=15 letter gain from baseline in BCVA - Study Eye
Statistical analysis description:	
Week 76	
Comparison groups	Brolucizumab 6 mg v Aflibercept 2 mg

Number of subjects included in analysis	739
Analysis specification	Pre-specified
Analysis type	
Method	Regression, Logistic
Parameter estimate	Difference in proportions
Point estimate	-2.4
Confidence interval	
level	95 %
sides	2-sided
lower limit	-8.8
upper limit	4

Statistical analysis title	>=15 letter gain from baseline in BCVA - Study Eye
Statistical analysis description:	
Week 80	
Comparison groups	Brolucizumab 6 mg v Aflibercept 2 mg
Number of subjects included in analysis	739
Analysis specification	Pre-specified
Analysis type	
Method	Regression, Logistic
Parameter estimate	Difference in proportions
Point estimate	-2.6
Confidence interval	
level	95 %
sides	2-sided
lower limit	-9
upper limit	3.5

Statistical analysis title	>=15 letter gain from baseline in BCVA - Study Eye
Statistical analysis description:	
Week 84	
Comparison groups	Brolucizumab 6 mg v Aflibercept 2 mg
Number of subjects included in analysis	739
Analysis specification	Pre-specified
Analysis type	
Method	Regression, Logistic
Parameter estimate	Difference in proportions
Point estimate	-3.8
Confidence interval	
level	95 %
sides	2-sided
lower limit	-9.9
upper limit	2.8

Statistical analysis title	>=15 letter gain from baseline in BCVA - Study Eye
Statistical analysis description:	
Week 88	
Comparison groups	Brolucizumab 6 mg v Aflibercept 2 mg
Number of subjects included in analysis	739
Analysis specification	Pre-specified
Analysis type	
Method	Regression, Logistic
Parameter estimate	Difference in proportions
Point estimate	-5.8
Confidence interval	
level	95 %
sides	2-sided
lower limit	-11.8
upper limit	0.3

Statistical analysis title	>=15 letter gain from baseline in BCVA - Study Eye
Statistical analysis description:	
Week 92	
Comparison groups	Brolucizumab 6 mg v Aflibercept 2 mg
Number of subjects included in analysis	739
Analysis specification	Pre-specified
Analysis type	
Method	Regression, Logistic
Parameter estimate	Difference in proportions
Point estimate	-1.7
Confidence interval	
level	95 %
sides	2-sided
lower limit	-7.9
upper limit	4.5

Statistical analysis title	>=15 letter gain from baseline in BCVA - Study Eye
Statistical analysis description:	
Week 96	
Comparison groups	Brolucizumab 6 mg v Aflibercept 2 mg
Number of subjects included in analysis	739
Analysis specification	Pre-specified
Analysis type	
Method	Regression, Logistic
Parameter estimate	Difference in proportions
Point estimate	-2.4

Confidence interval	
level	95 %
sides	2-sided
lower limit	-8.8
upper limit	4.1

Secondary: Percentage of subjects with ≥ 10 letter gain from baseline in BCVA (letters read) at each post-baseline visit - Study Eye

End point title	Percentage of subjects with ≥ 10 letter gain from baseline in BCVA (letters read) at each post-baseline visit - Study Eye
-----------------	--

End point description:

BCVA (with spectacles or other visual corrective devices) was assessed using ETDRS testing at 4 meters and reported in letters read correctly. Baseline was defined as the last measurement prior to first treatment. An increase (gain) in letters read from the baseline assessment indicates improvement. 95% confidence interval (CI) for binomial proportions was based on Clopper-Pearson exact method. One eye (study eye) contributed to the analysis.

End point type	Secondary
----------------	-----------

End point timeframe:

Baseline, Weeks 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44, 48, 52, 56, 60, 64, 68, 72, 76, 80, 84, 88, 92, 96

End point values	Brolucizumab 6 mg	Aflibercept 2 mg		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	370	369		
Units: percentage of subjects				
number (confidence interval 95%)				
Change from baseline at Week 4	20.0 (16.0 to 24.4)	22.2 (18.1 to 26.8)		
Change from baseline at Week 8	26.8 (22.3 to 31.6)	32.8 (28.0 to 37.8)		
Change from baseline at Week 12	32.4 (27.7 to 37.5)	36.0 (31.1 to 41.2)		
Change from baseline at Week 16	36.5 (31.6 to 41.6)	36.9 (31.9 to 42.0)		
Change from baseline at Week 20	33.8 (29.0 to 38.9)	38.2 (33.2 to 43.4)		
Change from baseline at Week 24	35.7 (30.8 to 40.8)	39.3 (34.3 to 44.5)		
Change from baseline at Week 28	40.3 (35.2 to 45.5)	42.5 (37.4 to 47.8)		
Change from baseline at Week 32	41.1 (36.0 to 46.3)	43.4 (38.2 to 48.6)		
Change from baseline at Week 36	40.3 (35.2 to 45.5)	45.5 (40.4 to 50.8)		
Change from baseline at Week 40	43.5 (38.4 to 48.7)	46.3 (41.2 to 51.6)		
Change from baseline at Week 44	42.4 (37.3 to 47.6)	45.3 (40.1 to 50.5)		
Change from baseline at Week 48	44.1 (38.9 to 49.3)	45.8 (40.6 to 51.0)		
Change from baseline at Week 52	44.9 (39.7 to 50.1)	45.8 (40.6 to 51.0)		

Change from baseline at Week 56	43.0 (37.9 to 48.2)	45.5 (40.4 to 50.8)		
Change from baseline at Week 60	42.2 (37.1 to 47.4)	44.7 (39.6 to 49.9)		
Change from baseline at Week 64	44.3 (39.2 to 49.5)	45.8 (40.6 to 51.0)		
Change from baseline at Week 68	43.5 (38.4 to 48.7)	45.0 (39.8 to 50.2)		
Change from baseline at Week 72	41.1 (36.0 to 46.3)	44.4 (39.3 to 49.7)		
Change from baseline at Week 76	45.4 (40.3 to 50.6)	44.7 (39.6 to 49.9)		
Change from baseline at Week 80	43.8 (38.7 to 49.0)	44.2 (39.0 to 49.4)		
Change from baseline at Week 84	40.8 (35.8 to 46.0)	44.2 (39.0 to 49.4)		
Change from baseline at Week 88	43.2 (38.1 to 48.5)	45.5 (40.4 to 50.8)		
Change from baseline at Week 92	45.4 (40.3 to 50.6)	43.4 (38.2 to 48.6)		
Change from baseline at Week 96	45.1 (40.0 to 50.4)	45.0 (39.8 to 50.2)		

Statistical analyses

Statistical analysis title	>=10 letter gain from baseline in BCVA - Study Eye
Statistical analysis description:	
Week 4	
Comparison groups	Brolucizumab 6 mg v Aflibercept 2 mg
Number of subjects included in analysis	739
Analysis specification	Pre-specified
Analysis type	
Method	Regression, Logistic
Parameter estimate	Difference in proportions
Point estimate	-2.1
Confidence interval	
level	95 %
sides	2-sided
lower limit	-7.6
upper limit	3.8

Statistical analysis title	>=10 letter gain from baseline in BCVA - Study Eye
Statistical analysis description:	
Week 8	
Comparison groups	Brolucizumab 6 mg v Aflibercept 2 mg

Number of subjects included in analysis	739
Analysis specification	Pre-specified
Analysis type	
Method	Regression, Logistic
Parameter estimate	Difference in proportions
Point estimate	-6
Confidence interval	
level	95 %
sides	2-sided
lower limit	-13
upper limit	0.1

Statistical analysis title	>=10 letter gain from baseline in BCVA - Study Eye
Statistical analysis description:	
Week 12	
Comparison groups	Brolucizumab 6 mg v Aflibercept 2 mg
Number of subjects included in analysis	739
Analysis specification	Pre-specified
Analysis type	
Method	Regression, Logistic
Parameter estimate	Difference in proportions
Point estimate	-3.8
Confidence interval	
level	95 %
sides	2-sided
lower limit	-10.1
upper limit	2.4

Statistical analysis title	>=10 letter gain from baseline in BCVA - Study Eye
Statistical analysis description:	
Week 16	
Comparison groups	Brolucizumab 6 mg v Aflibercept 2 mg
Number of subjects included in analysis	739
Analysis specification	Pre-specified
Analysis type	
Method	Regression, Logistic
Parameter estimate	Difference in proportions
Point estimate	-0.5
Confidence interval	
level	95 %
sides	2-sided
lower limit	-7.3
upper limit	6.3

Statistical analysis title	>=10 letter gain from baseline in BCVA - Study Eye
Statistical analysis description:	
Week 20	
Comparison groups	Brolucizumab 6 mg v Aflibercept 2 mg
Number of subjects included in analysis	739
Analysis specification	Pre-specified
Analysis type	
Method	Regression, Logistic
Parameter estimate	Difference in proportions
Point estimate	-4.6
Confidence interval	
level	95 %
sides	2-sided
lower limit	-11.2
upper limit	2.2

Statistical analysis title	>=10 letter gain from baseline in BCVA - Study Eye
Statistical analysis description:	
Week 24	
Comparison groups	Brolucizumab 6 mg v Aflibercept 2 mg
Number of subjects included in analysis	739
Analysis specification	Pre-specified
Analysis type	
Method	Regression, Logistic
Parameter estimate	Difference in proportions
Point estimate	-3.7
Confidence interval	
level	95 %
sides	2-sided
lower limit	-10.7
upper limit	3

Statistical analysis title	>=10 letter gain from baseline in BCVA - Study Eye
Statistical analysis description:	
Week 28	
Comparison groups	Brolucizumab 6 mg v Aflibercept 2 mg
Number of subjects included in analysis	739
Analysis specification	Pre-specified
Analysis type	
Method	Regression, Logistic
Parameter estimate	Difference in proportions
Point estimate	-2.4

Confidence interval	
level	95 %
sides	2-sided
lower limit	-9.6
upper limit	4

Statistical analysis title	>=10 letter gain from baseline in BCVA - Study Eye
Statistical analysis description:	
Week 32	
Comparison groups	Brolucizumab 6 mg v Aflibercept 2 mg
Number of subjects included in analysis	739
Analysis specification	Pre-specified
Analysis type	
Method	Regression, Logistic
Parameter estimate	Difference in proportions
Point estimate	-2.6
Confidence interval	
level	95 %
sides	2-sided
lower limit	-9.4
upper limit	4.5

Statistical analysis title	>=10 letter gain from baseline in BCVA - Study Eye
Statistical analysis description:	
Week 36	
Comparison groups	Brolucizumab 6 mg v Aflibercept 2 mg
Number of subjects included in analysis	739
Analysis specification	Pre-specified
Analysis type	
Method	Regression, Logistic
Parameter estimate	Difference in proportions
Point estimate	-5.4
Confidence interval	
level	95 %
sides	2-sided
lower limit	-12.1
upper limit	1.1

Statistical analysis title	>=10 letter gain from baseline in BCVA - Study Eye
Statistical analysis description:	
Week 40	
Comparison groups	Brolucizumab 6 mg v Aflibercept 2 mg

Number of subjects included in analysis	739
Analysis specification	Pre-specified
Analysis type	
Method	Regression, Logistic
Parameter estimate	Difference in proportions
Point estimate	-3.1
Confidence interval	
level	95 %
sides	2-sided
lower limit	-9.9
upper limit	3.5

Statistical analysis title	>=10 letter gain from baseline in BCVA - Study Eye
Statistical analysis description:	
Week 44	
Comparison groups	Brolucizumab 6 mg v Aflibercept 2 mg
Number of subjects included in analysis	739
Analysis specification	Pre-specified
Analysis type	
Method	Regression, Logistic
Parameter estimate	Difference in proportions
Point estimate	-3
Confidence interval	
level	95 %
sides	2-sided
lower limit	-10.3
upper limit	4.2

Statistical analysis title	>=10 letter gain from baseline in BCVA - Study Eye
Statistical analysis description:	
Week 48	
Comparison groups	Brolucizumab 6 mg v Aflibercept 2 mg
Number of subjects included in analysis	739
Analysis specification	Pre-specified
Analysis type	
Method	Regression, Logistic
Parameter estimate	Difference in proportions
Point estimate	-1.9
Confidence interval	
level	95 %
sides	2-sided
lower limit	-8.7
upper limit	4.7

Statistical analysis title	>=10 letter gain from baseline in BCVA - Study Eye
Statistical analysis description:	
Week 52	
Comparison groups	Brolucizumab 6 mg v Aflibercept 2 mg
Number of subjects included in analysis	739
Analysis specification	Pre-specified
Analysis type	
Method	Regression, Logistic
Parameter estimate	Difference in proportions
Point estimate	-1.3
Confidence interval	
level	95 %
sides	2-sided
lower limit	-8
upper limit	5.7

Statistical analysis title	>=10 letter gain from baseline in BCVA - Study Eye
Statistical analysis description:	
Week 56	
Comparison groups	Brolucizumab 6 mg v Aflibercept 2 mg
Number of subjects included in analysis	739
Analysis specification	Pre-specified
Analysis type	
Method	Regression, Logistic
Parameter estimate	Difference in proportions
Point estimate	-2.8
Confidence interval	
level	95 %
sides	2-sided
lower limit	-9.8
upper limit	4.3

Statistical analysis title	>=10 letter gain from baseline in BCVA - Study Eye
Statistical analysis description:	
Week 60	
Comparison groups	Brolucizumab 6 mg v Aflibercept 2 mg
Number of subjects included in analysis	739
Analysis specification	Pre-specified
Analysis type	
Method	Regression, Logistic
Parameter estimate	Difference in proportions
Point estimate	-2.8

Confidence interval	
level	95 %
sides	2-sided
lower limit	-9.6
upper limit	4.2

Statistical analysis title	>=10 letter gain from baseline in BCVA - Study Eye
Statistical analysis description:	
Week 64	
Comparison groups	Brolucizumab 6 mg v Aflibercept 2 mg
Number of subjects included in analysis	739
Analysis specification	Pre-specified
Analysis type	
Method	Regression, Logistic
Parameter estimate	Difference in proportions
Point estimate	-1.7
Confidence interval	
level	95 %
sides	2-sided
lower limit	-8.8
upper limit	5.4

Statistical analysis title	>=10 letter gain from baseline in BCVA - Study Eye
Statistical analysis description:	
Week 68	
Comparison groups	Brolucizumab 6 mg v Aflibercept 2 mg
Number of subjects included in analysis	739
Analysis specification	Pre-specified
Analysis type	
Method	Regression, Logistic
Parameter estimate	Difference in proportions
Point estimate	-1.7
Confidence interval	
level	95 %
sides	2-sided
lower limit	-8.4
upper limit	5

Statistical analysis title	>=10 letter gain from baseline in BCVA - Study Eye
Statistical analysis description:	
Week 72	
Comparison groups	Brolucizumab 6 mg v Aflibercept 2 mg

Number of subjects included in analysis	739
Analysis specification	Pre-specified
Analysis type	
Method	Regression, Logistic
Parameter estimate	Difference in proportions
Point estimate	-3.6
Confidence interval	
level	95 %
sides	2-sided
lower limit	-10.4
upper limit	2.9

Statistical analysis title	>=10 letter gain from baseline in BCVA - Study Eye
Statistical analysis description:	
Week 76	
Comparison groups	Brolucizumab 6 mg v Aflibercept 2 mg
Number of subjects included in analysis	739
Analysis specification	Pre-specified
Analysis type	
Method	Regression, Logistic
Parameter estimate	Difference in proportions
Point estimate	0.5
Confidence interval	
level	95 %
sides	2-sided
lower limit	-6.5
upper limit	7.2

Statistical analysis title	>=10 letter gain from baseline in BCVA - Study Eye
Statistical analysis description:	
Week 80	
Comparison groups	Brolucizumab 6 mg v Aflibercept 2 mg
Number of subjects included in analysis	739
Analysis specification	Pre-specified
Analysis type	
Method	Regression, Logistic
Parameter estimate	Difference in proportions
Point estimate	-0.7
Confidence interval	
level	95 %
sides	2-sided
lower limit	-7.5
upper limit	6.1

Statistical analysis title	>=10 letter gain from baseline in BCVA - Study Eye
Statistical analysis description:	
Week 84	
Comparison groups	Brolucizumab 6 mg v Aflibercept 2 mg
Number of subjects included in analysis	739
Analysis specification	Pre-specified
Analysis type	
Method	Regression, Logistic
Parameter estimate	Difference in proportions
Point estimate	-3.5
Confidence interval	
level	95 %
sides	2-sided
lower limit	-10.4
upper limit	3.1

Statistical analysis title	>=10 letter gain from baseline in BCVA - Study Eye
Statistical analysis description:	
Week 88	
Comparison groups	Brolucizumab 6 mg v Aflibercept 2 mg
Number of subjects included in analysis	739
Analysis specification	Pre-specified
Analysis type	
Method	Regression, Logistic
Parameter estimate	Difference in proportions
Point estimate	-2.5
Confidence interval	
level	95 %
sides	2-sided
lower limit	-9.6
upper limit	3.9

Statistical analysis title	>=10 letter gain from baseline in BCVA - Study Eye
Statistical analysis description:	
Week 92	
Comparison groups	Brolucizumab 6 mg v Aflibercept 2 mg
Number of subjects included in analysis	739
Analysis specification	Pre-specified
Analysis type	
Method	Regression, Logistic
Parameter estimate	Difference in proportions
Point estimate	1.9

Confidence interval	
level	95 %
sides	2-sided
lower limit	-5
upper limit	8.3

Statistical analysis title	>=10 letter gain from baseline in BCVA - Study Eye
Statistical analysis description:	
Week 96	
Comparison groups	Brolucizumab 6 mg v Aflibercept 2 mg
Number of subjects included in analysis	739
Analysis specification	Pre-specified
Analysis type	
Method	Regression, Logistic
Parameter estimate	Difference in proportions
Point estimate	0.1
Confidence interval	
level	95 %
sides	2-sided
lower limit	-7
upper limit	6.8

Secondary: Percentage of subjects with >=5 letter gain from baseline in BCVA (letters read) at each post-baseline visit - Study Eye

End point title	Percentage of subjects with >=5 letter gain from baseline in BCVA (letters read) at each post-baseline visit - Study Eye
End point description:	
BCVA (with spectacles or other visual corrective devices) was assessed using ETDRS testing at 4 meters and reported in letters read correctly. Baseline was defined as the last measurement prior to first treatment. An increase (gain) in letters read from the baseline assessment indicates improvement. 95% confidence interval (CI) for binomial proportions was based on Clopper-Pearson exact method. One eye (study eye) contributed to the analysis.	
End point type	Secondary
End point timeframe:	
Baseline, Weeks 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44, 48, 52, 56, 60, 64, 68, 72, 76, 80, 84, 88, 92, 96	

End point values	Brolucizumab 6 mg	Aflibercept 2 mg		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	370	369		
Units: percentage of subjects				
number (confidence interval 95%)				
Change from baseline at Week 4	41.6 (36.5 to 46.8)	45.3 (40.1 to 50.5)		

Change from baseline at Week 8	50.0 (44.8 to 55.2)	53.1 (47.9 to 58.3)		
Change from baseline at Week 12	55.1 (49.9 to 60.3)	58.5 (53.3 to 63.6)		
Change from baseline at Week 16	55.4 (50.2 to 60.5)	56.6 (51.4 to 61.8)		
Change from baseline at Week 20	55.9 (50.7 to 61.1)	61.0 (55.8 to 66.0)		
Change from baseline at Week 24	58.1 (52.9 to 63.2)	61.0 (55.8 to 66.0)		
Change from baseline at Week 28	60.0 (54.8 to 65.0)	65.6 (60.5 to 70.4)		
Change from baseline at Week 32	64.1 (58.9 to 68.9)	65.6 (60.5 to 70.4)		
Change from baseline at Week 36	63.2 (58.1 to 68.2)	65.3 (60.2 to 70.2)		
Change from baseline at Week 40	63.0 (57.8 to 67.9)	64.0 (58.8 to 68.9)		
Change from baseline at Week 44	64.6 (59.5 to 69.5)	65.9 (60.8 to 70.7)		
Change from baseline at Week 48	64.6 (59.5 to 69.5)	64.5 (59.4 to 69.4)		
Change from baseline at Week 52	63.0 (57.8 to 67.9)	65.3 (60.2 to 70.2)		
Change from baseline at Week 56	62.7 (57.6 to 67.6)	64.2 (59.1 to 69.1)		
Change from baseline at Week 60	62.2 (57.0 to 67.1)	62.6 (57.4 to 67.6)		
Change from baseline at Week 64	65.7 (60.6 to 70.5)	63.1 (58.0 to 68.1)		
Change from baseline at Week 68	62.2 (57.0 to 67.1)	63.4 (58.3 to 68.3)		
Change from baseline at Week 72	63.0 (57.8 to 67.9)	61.5 (56.3 to 66.5)		
Change from baseline at Week 76	63.8 (58.7 to 68.7)	61.5 (56.3 to 66.5)		
Change from baseline at Week 80	65.1 (60.0 to 70.0)	60.7 (55.5 to 65.7)		
Change from baseline at Week 84	61.9 (56.7 to 66.9)	64.2 (59.1 to 69.1)		
Change from baseline at Week 88	63.2 (58.1 to 68.2)	62.1 (56.9 to 67.0)		
Change from baseline at Week 92	64.6 (59.5 to 69.5)	60.7 (55.5 to 65.7)		
Change from baseline at Week 96	64.1 (58.9 to 68.9)	60.7 (55.5 to 65.7)		

Statistical analyses

Statistical analysis title	>=5 letter gain from baseline in BCVA - Study Eye
Statistical analysis description:	
Week 4	
Comparison groups	Brolucizumab 6 mg v Aflibercept 2 mg

Number of subjects included in analysis	739
Analysis specification	Pre-specified
Analysis type	
Method	Regression, Logistic
Parameter estimate	Difference in proportions
Point estimate	-3.5
Confidence interval	
level	95 %
sides	2-sided
lower limit	-10.4
upper limit	3.6

Statistical analysis title	>=5 letter gain from baseline in BCVA - Study Eye
Statistical analysis description:	
Week 8	
Comparison groups	Brolucizumab 6 mg v Aflibercept 2 mg
Number of subjects included in analysis	739
Analysis specification	Pre-specified
Analysis type	
Method	Regression, Logistic
Parameter estimate	Difference in proportions
Point estimate	-3.2
Confidence interval	
level	95 %
sides	2-sided
lower limit	-10.2
upper limit	3.7

Statistical analysis title	>=5 letter gain from baseline in BCVA - Study Eye
Statistical analysis description:	
Week 12	
Comparison groups	Brolucizumab 6 mg v Aflibercept 2 mg
Number of subjects included in analysis	739
Analysis specification	Pre-specified
Analysis type	
Method	Regression, Logistic
Parameter estimate	Difference in proportions
Point estimate	-3.7
Confidence interval	
level	95 %
sides	2-sided
lower limit	-10.7
upper limit	3.3

Statistical analysis title	>=5 letter gain from baseline in BCVA - Study Eye
Statistical analysis description:	
Week 16	
Comparison groups	Brolucizumab 6 mg v Aflibercept 2 mg
Number of subjects included in analysis	739
Analysis specification	Pre-specified
Analysis type	
Method	Regression, Logistic
Parameter estimate	Difference in proportions
Point estimate	-1.4
Confidence interval	
level	95 %
sides	2-sided
lower limit	-8.4
upper limit	5.7

Statistical analysis title	>=5 letter gain from baseline in BCVA - Study Eye
Statistical analysis description:	
Week 20	
Comparison groups	Brolucizumab 6 mg v Aflibercept 2 mg
Number of subjects included in analysis	739
Analysis specification	Pre-specified
Analysis type	
Method	Regression, Logistic
Parameter estimate	Difference in proportions
Point estimate	-5.3
Confidence interval	
level	95 %
sides	2-sided
lower limit	-12.3
upper limit	1.5

Statistical analysis title	>=5 letter gain from baseline in BCVA - Study Eye
Statistical analysis description:	
Week 24	
Comparison groups	Brolucizumab 6 mg v Aflibercept 2 mg
Number of subjects included in analysis	739
Analysis specification	Pre-specified
Analysis type	
Method	Regression, Logistic
Parameter estimate	Difference in proportions
Point estimate	-3.2

Confidence interval	
level	95 %
sides	2-sided
lower limit	-9.9
upper limit	3.7

Statistical analysis title	>=5 letter gain from baseline in BCVA - Study Eye
Statistical analysis description:	
Week 28	
Comparison groups	Brolucizumab 6 mg v Aflibercept 2 mg
Number of subjects included in analysis	739
Analysis specification	Pre-specified
Analysis type	
Method	Regression, Logistic
Parameter estimate	Difference in proportions
Point estimate	-5.9
Confidence interval	
level	95 %
sides	2-sided
lower limit	-12.8
upper limit	0.7

Statistical analysis title	>=5 letter gain from baseline in BCVA - Study Eye
Statistical analysis description:	
Week 32	
Comparison groups	Brolucizumab 6 mg v Aflibercept 2 mg
Number of subjects included in analysis	739
Analysis specification	Pre-specified
Analysis type	
Method	Regression, Logistic
Parameter estimate	Difference in proportions
Point estimate	-1.9
Confidence interval	
level	95 %
sides	2-sided
lower limit	-8.2
upper limit	4.8

Statistical analysis title	>=5 letter gain from baseline in BCVA - Study Eye
Statistical analysis description:	
Week 36	
Comparison groups	Brolucizumab 6 mg v Aflibercept 2 mg

Number of subjects included in analysis	739
Analysis specification	Pre-specified
Analysis type	
Method	Regression, Logistic
Parameter estimate	Difference in proportions
Point estimate	-2.3
Confidence interval	
level	95 %
sides	2-sided
lower limit	-9.2
upper limit	4.2

Statistical analysis title	>=5 letter gain from baseline in BCVA - Study Eye
Statistical analysis description:	
Week 40	
Comparison groups	Brolucizumab 6 mg v Aflibercept 2 mg
Number of subjects included in analysis	739
Analysis specification	Pre-specified
Analysis type	
Method	Regression, Logistic
Parameter estimate	Difference in proportions
Point estimate	-1.3
Confidence interval	
level	95 %
sides	2-sided
lower limit	-8.2
upper limit	5.6

Statistical analysis title	>=5 letter gain from baseline in BCVA - Study Eye
Statistical analysis description:	
Week 44	
Comparison groups	Brolucizumab 6 mg v Aflibercept 2 mg
Number of subjects included in analysis	739
Analysis specification	Pre-specified
Analysis type	
Method	Regression, Logistic
Parameter estimate	Difference in proportions
Point estimate	-1.5
Confidence interval	
level	95 %
sides	2-sided
lower limit	-8.5
upper limit	5

Statistical analysis title	>=5 letter gain from baseline in BCVA - Study Eye
Statistical analysis description:	
Week 48	
Comparison groups	Brolucizumab 6 mg v Aflibercept 2 mg
Number of subjects included in analysis	739
Analysis specification	Pre-specified
Analysis type	
Method	Regression, Logistic
Parameter estimate	Difference in proportions
Point estimate	-0.2
Confidence interval	
level	95 %
sides	2-sided
lower limit	-7.4
upper limit	6.2

Statistical analysis title	>=5 letter gain from baseline in BCVA - Study Eye
Statistical analysis description:	
Week 52	
Comparison groups	Brolucizumab 6 mg v Aflibercept 2 mg
Number of subjects included in analysis	739
Analysis specification	Pre-specified
Analysis type	
Method	Regression, Logistic
Parameter estimate	Difference in proportions
Point estimate	-2.7
Confidence interval	
level	95 %
sides	2-sided
lower limit	-9.8
upper limit	4

Statistical analysis title	>=5 letter gain from baseline in BCVA - Study Eye
Statistical analysis description:	
Week 56	
Comparison groups	Brolucizumab 6 mg v Aflibercept 2 mg
Number of subjects included in analysis	739
Analysis specification	Pre-specified
Analysis type	
Method	Regression, Logistic
Parameter estimate	Difference in proportions
Point estimate	-1.7

Confidence interval	
level	95 %
sides	2-sided
lower limit	-8.6
upper limit	4.8

Statistical analysis title	>=5 letter gain from baseline in BCVA - Study Eye
Statistical analysis description:	
Week 60	
Comparison groups	Brolucizumab 6 mg v Aflibercept 2 mg
Number of subjects included in analysis	739
Analysis specification	Pre-specified
Analysis type	
Method	Regression, Logistic
Parameter estimate	Difference in proportions
Point estimate	-0.7
Confidence interval	
level	95 %
sides	2-sided
lower limit	-7.8
upper limit	6.1

Statistical analysis title	>=5 letter gain from baseline in BCVA - Study Eye
Statistical analysis description:	
Week 64	
Comparison groups	Brolucizumab 6 mg v Aflibercept 2 mg
Number of subjects included in analysis	739
Analysis specification	Pre-specified
Analysis type	
Method	Regression, Logistic
Parameter estimate	Difference in proportions
Point estimate	2.3
Confidence interval	
level	95 %
sides	2-sided
lower limit	-4.5
upper limit	9.2

Statistical analysis title	>=5 letter gain from baseline in BCVA - Study Eye
Statistical analysis description:	
Week 68	
Comparison groups	Brolucizumab 6 mg v Aflibercept 2 mg

Number of subjects included in analysis	739
Analysis specification	Pre-specified
Analysis type	
Method	Regression, Logistic
Parameter estimate	Difference in proportions
Point estimate	-1.5
Confidence interval	
level	95 %
sides	2-sided
lower limit	-8.6
upper limit	4.9

Statistical analysis title	>=5 letter gain from baseline in BCVA - Study Eye
Statistical analysis description:	
Week 72	
Comparison groups	Brolucizumab 6 mg v Aflibercept 2 mg
Number of subjects included in analysis	739
Analysis specification	Pre-specified
Analysis type	
Method	Regression, Logistic
Parameter estimate	Difference in proportions
Point estimate	1.1
Confidence interval	
level	95 %
sides	2-sided
lower limit	-5.8
upper limit	7.5

Statistical analysis title	>=5 letter gain from baseline in BCVA - Study Eye
Statistical analysis description:	
Week 76	
Comparison groups	Brolucizumab 6 mg v Aflibercept 2 mg
Number of subjects included in analysis	739
Analysis specification	Pre-specified
Analysis type	
Method	Regression, Logistic
Parameter estimate	Difference in proportions
Point estimate	2
Confidence interval	
level	95 %
sides	2-sided
lower limit	-5.1
upper limit	8.4

Statistical analysis title	>=5 letter gain from baseline in BCVA - Study Eye
Statistical analysis description:	
Week 80	
Comparison groups	Brolucizumab 6 mg v Aflibercept 2 mg
Number of subjects included in analysis	739
Analysis specification	Pre-specified
Analysis type	
Method	Regression, Logistic
Parameter estimate	Difference in proportions
Point estimate	4.2
Confidence interval	
level	95 %
sides	2-sided
lower limit	-2.8
upper limit	10.9

Statistical analysis title	>=5 letter gain from baseline in BCVA - Study Eye
Statistical analysis description:	
Week 84	
Comparison groups	Brolucizumab 6 mg v Aflibercept 2 mg
Number of subjects included in analysis	739
Analysis specification	Pre-specified
Analysis type	
Method	Regression, Logistic
Parameter estimate	Difference in proportions
Point estimate	-2.7
Confidence interval	
level	95 %
sides	2-sided
lower limit	-9.3
upper limit	4.1

Statistical analysis title	>=5 letter gain from baseline in BCVA - Study Eye
Statistical analysis description:	
Week 88	
Comparison groups	Brolucizumab 6 mg v Aflibercept 2 mg
Number of subjects included in analysis	739
Analysis specification	Pre-specified
Analysis type	
Method	Regression, Logistic
Parameter estimate	Difference in proportions
Point estimate	0.9

Confidence interval	
level	95 %
sides	2-sided
lower limit	-6.1
upper limit	7.7

Statistical analysis title	>=5 letter gain from baseline in BCVA - Study Eye
Statistical analysis description:	
Week 92	
Comparison groups	Brolucizumab 6 mg v Aflibercept 2 mg
Number of subjects included in analysis	739
Analysis specification	Pre-specified
Analysis type	
Method	Regression, Logistic
Parameter estimate	Difference in proportions
Point estimate	3.7
Confidence interval	
level	95 %
sides	2-sided
lower limit	-3
upper limit	10.4

Statistical analysis title	>=5 letter gain from baseline in BCVA - Study Eye
Statistical analysis description:	
Week 96	
Comparison groups	Brolucizumab 6 mg v Aflibercept 2 mg
Number of subjects included in analysis	739
Analysis specification	Pre-specified
Analysis type	
Method	Regression, Logistic
Parameter estimate	Difference in proportions
Point estimate	3.1
Confidence interval	
level	95 %
sides	2-sided
lower limit	-3.9
upper limit	10

Secondary: Percentage of Subjects With >=15 Letter Loss From Baseline in BCVA (Letters Read) at Each Post-baseline Visit - Study Eye

End point title	Percentage of Subjects With >=15 Letter Loss From Baseline in BCVA (Letters Read) at Each Post-baseline Visit - Study Eye
-----------------	---

End point description:

BCVA (with spectacles or other visual corrective devices) was assessed using ETDRS testing at 4 meters

and reported in letters read correctly. Baseline was defined as the last measurement prior to first treatment. An increase (gain) in letters read from the baseline assessment indicates improvement. 95% confidence interval (CI) for binomial proportions was based on Clopper-Pearson exact method. One eye (study eye) contributed to the analysis.

End point type	Secondary
End point timeframe:	
Baseline, Weeks 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44, 48, 52, 56, 60, 64, 68, 72, 76, 80, 84, 88, 92, 96	

End point values	Brolucizumab 6 mg	Aflibercept 2 mg		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	370	369		
Units: percentage of subjects				
number (confidence interval 95%)				
Change from baseline at Week 4	1.1 (0.3 to 2.7)	1.1 (0.3 to 2.8)		
Change from baseline at Week 8	1.1 (0.3 to 2.7)	1.6 (0.6 to 3.5)		
Change from baseline at Week 12	1.9 (0.8 to 3.9)	1.9 (0.8 to 3.9)		
Change from baseline at Week 16	2.2 (0.9 to 4.2)	2.2 (0.9 to 4.2)		
Change from baseline at Week 20	3.5 (1.9 to 5.9)	3.0 (1.5 to 5.3)		
Change from baseline at Week 24	2.7 (1.3 to 4.9)	3.3 (1.7 to 5.6)		
Change from baseline at Week 28	3.0 (1.5 to 5.3)	3.5 (1.9 to 5.9)		
Change from baseline at Week 32	3.2 (1.7 to 5.6)	3.8 (2.1 to 6.3)		
Change from baseline at Week 36	3.8 (2.1 to 6.3)	3.5 (1.9 to 5.9)		
Change from baseline at Week 40	5.4 (3.3 to 8.2)	4.3 (2.5 to 6.9)		
Change from baseline at Week 44	4.6 (2.7 to 7.3)	4.6 (2.7 to 7.3)		
Change from baseline at Week 48	3.8 (2.1 to 6.3)	4.9 (2.9 to 7.6)		
Change from baseline at Week 52	4.6 (2.7 to 7.3)	5.7 (3.6 to 8.6)		
Change from baseline at Week 56	5.9 (3.8 to 8.9)	5.4 (3.3 to 8.2)		
Change from baseline at Week 60	6.2 (4.0 to 9.2)	5.7 (3.6 to 8.6)		
Change from baseline at Week 64	6.8 (4.4 to 9.8)	6.2 (4.0 to 9.2)		
Change from baseline at Week 68	5.4 (3.3 to 8.2)	6.5 (4.2 to 9.5)		
Change from baseline at Week 72	7.3 (4.9 to 10.4)	6.5 (4.2 to 9.5)		
Change from baseline at Week 76	6.8 (4.4 to 9.8)	6.2 (4.0 to 9.2)		
Change from baseline at Week 80	7.0 (4.6 to 10.1)	6.2 (4.0 to 9.2)		
Change from baseline at Week 84	7.3 (4.9 to 10.4)	7.3 (4.9 to 10.5)		
Change from baseline at Week 88	6.8 (4.4 to 9.8)	7.0 (4.7 to 10.2)		
Change from baseline at Week 92	7.0 (4.6 to 10.1)	7.6 (5.1 to 10.8)		
Change from baseline at Week 96	7.0 (4.6 to 10.1)	7.6 (5.1 to 10.8)		

Statistical analyses

Statistical analysis title	>=15 letter loss from baseline in BCVA - Study Eye
----------------------------	--

Statistical analysis description:

Week 4

Comparison groups	Brolucizumab 6 mg v Aflibercept 2 mg
Number of subjects included in analysis	739
Analysis specification	Pre-specified
Analysis type	
Method	Regression, Logistic
Parameter estimate	Difference in proportions
Point estimate	0
Confidence interval	
level	95 %
sides	2-sided
lower limit	-1.6
upper limit	1.4

Statistical analysis title

>=15 letter loss from baseline in BCVA - Study Eye

Statistical analysis description:

Week 8

Comparison groups	Brolucizumab 6 mg v Aflibercept 2 mg
Number of subjects included in analysis	739
Analysis specification	Pre-specified
Analysis type	
Method	Regression, Logistic
Parameter estimate	Difference in proportions
Point estimate	-0.6
Confidence interval	
level	95 %
sides	2-sided
lower limit	-2.3
upper limit	1.1

Statistical analysis title

>=15 letter loss from baseline in BCVA - Study Eye

Statistical analysis description:

Week 12

Comparison groups	Brolucizumab 6 mg v Aflibercept 2 mg
Number of subjects included in analysis	739
Analysis specification	Pre-specified
Analysis type	
Method	Regression, Logistic
Parameter estimate	Difference in proportions
Point estimate	0
Confidence interval	
level	95 %
sides	2-sided
lower limit	-1.9
upper limit	2.2

Statistical analysis title	>=15 letter loss from baseline in BCVA - Study Eye
Statistical analysis description:	
Week 16	
Comparison groups	Brolucizumab 6 mg v Aflibercept 2 mg
Number of subjects included in analysis	739
Analysis specification	Pre-specified
Analysis type	
Method	Regression, Logistic
Parameter estimate	Difference in proportions
Point estimate	0
Confidence interval	
level	95 %
sides	2-sided
lower limit	-2.1
upper limit	2.3

Statistical analysis title	>=15 letter loss from baseline in BCVA - Study Eye
Statistical analysis description:	
Week 20	
Comparison groups	Brolucizumab 6 mg v Aflibercept 2 mg
Number of subjects included in analysis	739
Analysis specification	Pre-specified
Analysis type	
Method	Regression, Logistic
Parameter estimate	Difference in proportions
Point estimate	0.6
Confidence interval	
level	95 %
sides	2-sided
lower limit	-2
upper limit	3.3

Statistical analysis title	>=15 letter loss from baseline in BCVA - Study Eye
Statistical analysis description:	
Week 24	
Comparison groups	Brolucizumab 6 mg v Aflibercept 2 mg
Number of subjects included in analysis	739
Analysis specification	Pre-specified
Analysis type	
Method	Regression, Logistic
Parameter estimate	Difference in proportions
Point estimate	-0.5

Confidence interval	
level	95 %
sides	2-sided
lower limit	-3
upper limit	2.2

Statistical analysis title	>=15 letter loss from baseline in BCVA - Study Eye
Statistical analysis description:	
Week 28	
Comparison groups	Brolucizumab 6 mg v Aflibercept 2 mg
Number of subjects included in analysis	739
Analysis specification	Pre-specified
Analysis type	
Method	Regression, Logistic
Parameter estimate	Difference in proportions
Point estimate	-0.5
Confidence interval	
level	95 %
sides	2-sided
lower limit	-3
upper limit	2.3

Statistical analysis title	>=15 letter loss from baseline in BCVA - Study Eye
Statistical analysis description:	
Week 32	
Comparison groups	Brolucizumab 6 mg v Aflibercept 2 mg
Number of subjects included in analysis	739
Analysis specification	Pre-specified
Analysis type	
Method	Regression, Logistic
Parameter estimate	Difference in proportions
Point estimate	-0.5
Confidence interval	
level	95 %
sides	2-sided
lower limit	-3.2
upper limit	2.5

Statistical analysis title	>=15 letter loss from baseline in BCVA - Study Eye
Statistical analysis description:	
Week 36	
Comparison groups	Brolucizumab 6 mg v Aflibercept 2 mg

Number of subjects included in analysis	739
Analysis specification	Pre-specified
Analysis type	
Method	Regression, Logistic
Parameter estimate	Difference in proportions
Point estimate	0.4
Confidence interval	
level	95 %
sides	2-sided
lower limit	-2.3
upper limit	3.3

Statistical analysis title	>=15 letter loss from baseline in BCVA - Study Eye
Statistical analysis description:	
Week 40	
Comparison groups	Brolucizumab 6 mg v Aflibercept 2 mg
Number of subjects included in analysis	739
Analysis specification	Pre-specified
Analysis type	
Method	Regression, Logistic
Parameter estimate	Difference in proportions
Point estimate	1.2
Confidence interval	
level	95 %
sides	2-sided
lower limit	-1.7
upper limit	4.6

Statistical analysis title	>=15 letter loss from baseline in BCVA - Study Eye
Statistical analysis description:	
Week 44	
Comparison groups	Brolucizumab 6 mg v Aflibercept 2 mg
Number of subjects included in analysis	739
Analysis specification	Pre-specified
Analysis type	
Method	Regression, Logistic
Parameter estimate	Difference in proportions
Point estimate	0.1
Confidence interval	
level	95 %
sides	2-sided
lower limit	-2.7
upper limit	3.4

Statistical analysis title	>=15 letter loss from baseline in BCVA - Study Eye
Statistical analysis description:	
Week 48	
Comparison groups	Brolucizumab 6 mg v Aflibercept 2 mg
Number of subjects included in analysis	739
Analysis specification	Pre-specified
Analysis type	
Method	Regression, Logistic
Parameter estimate	Difference in proportions
Point estimate	-1
Confidence interval	
level	95 %
sides	2-sided
lower limit	-3.9
upper limit	2.2

Statistical analysis title	>=15 letter loss from baseline in BCVA - Study Eye
Statistical analysis description:	
Week 52	
Comparison groups	Brolucizumab 6 mg v Aflibercept 2 mg
Number of subjects included in analysis	739
Analysis specification	Pre-specified
Analysis type	
Method	Regression, Logistic
Parameter estimate	Difference in proportions
Point estimate	-1
Confidence interval	
level	95 %
sides	2-sided
lower limit	-4.3
upper limit	2.3

Statistical analysis title	>=15 letter loss from baseline in BCVA - Study Eye
Statistical analysis description:	
Week 56	
Comparison groups	Brolucizumab 6 mg v Aflibercept 2 mg
Number of subjects included in analysis	739
Analysis specification	Pre-specified
Analysis type	
Method	Regression, Logistic
Parameter estimate	Difference in proportions
Point estimate	0.6

Confidence interval	
level	95 %
sides	2-sided
lower limit	-2.8
upper limit	3.9

Statistical analysis title	>=15 letter loss from baseline in BCVA - Study Eye
Statistical analysis description:	
Week 60	
Comparison groups	Brolucizumab 6 mg v Aflibercept 2 mg
Number of subjects included in analysis	739
Analysis specification	Pre-specified
Analysis type	
Method	Regression, Logistic
Parameter estimate	Difference in proportions
Point estimate	0.6
Confidence interval	
level	95 %
sides	2-sided
lower limit	-2.5
upper limit	4.2

Statistical analysis title	>=15 letter loss from baseline in BCVA - Study Eye
Statistical analysis description:	
Week 64	
Comparison groups	Brolucizumab 6 mg v Aflibercept 2 mg
Number of subjects included in analysis	739
Analysis specification	Pre-specified
Analysis type	
Method	Regression, Logistic
Parameter estimate	Difference in proportions
Point estimate	0.7
Confidence interval	
level	95 %
sides	2-sided
lower limit	-2.7
upper limit	4.5

Statistical analysis title	>=15 letter loss from baseline in BCVA - Study Eye
Statistical analysis description:	
Week 68	
Comparison groups	Brolucizumab 6 mg v Aflibercept 2 mg

Number of subjects included in analysis	739
Analysis specification	Pre-specified
Analysis type	
Method	Regression, Logistic
Parameter estimate	Difference in proportions
Point estimate	-0.9
Confidence interval	
level	95 %
sides	2-sided
lower limit	-4.2
upper limit	2.6

Statistical analysis title	>=15 letter loss from baseline in BCVA - Study Eye
Statistical analysis description:	
Week 72	
Comparison groups	Brolucizumab 6 mg v Aflibercept 2 mg
Number of subjects included in analysis	739
Analysis specification	Pre-specified
Analysis type	
Method	Regression, Logistic
Parameter estimate	Difference in proportions
Point estimate	0.9
Confidence interval	
level	95 %
sides	2-sided
lower limit	-2.5
upper limit	4.5

Statistical analysis title	>=15 letter loss from baseline in BCVA - Study Eye
Statistical analysis description:	
Week 76	
Comparison groups	Brolucizumab 6 mg v Aflibercept 2 mg
Number of subjects included in analysis	739
Analysis specification	Pre-specified
Analysis type	
Method	Regression, Logistic
Parameter estimate	Difference in proportions
Point estimate	0.7
Confidence interval	
level	95 %
sides	2-sided
lower limit	-2.5
upper limit	4.4

Statistical analysis title	>=15 letter loss from baseline in BCVA - Study Eye
Statistical analysis description:	
Week 80	
Comparison groups	Brolucizumab 6 mg v Aflibercept 2 mg
Number of subjects included in analysis	739
Analysis specification	Pre-specified
Analysis type	
Method	Regression, Logistic
Parameter estimate	Difference in proportions
Point estimate	0.9
Confidence interval	
level	95 %
sides	2-sided
lower limit	-2.4
upper limit	4.6

Statistical analysis title	>=15 letter loss from baseline in BCVA - Study Eye
Statistical analysis description:	
Week 84	
Comparison groups	Brolucizumab 6 mg v Aflibercept 2 mg
Number of subjects included in analysis	739
Analysis specification	Pre-specified
Analysis type	
Method	Regression, Logistic
Parameter estimate	Difference in proportions
Point estimate	0.2
Confidence interval	
level	95 %
sides	2-sided
lower limit	-3.1
upper limit	4.1

Statistical analysis title	>=15 letter loss from baseline in BCVA - Study Eye
Statistical analysis description:	
Week 88	
Comparison groups	Brolucizumab 6 mg v Aflibercept 2 mg
Number of subjects included in analysis	739
Analysis specification	Pre-specified
Analysis type	
Method	Regression, Logistic
Parameter estimate	Difference in proportions
Point estimate	-0.2

Confidence interval	
level	95 %
sides	2-sided
lower limit	-3.5
upper limit	3.6

Statistical analysis title	>=15 letter loss from baseline in BCVA - Study Eye
Statistical analysis description:	
Week 92	
Comparison groups	Brolucizumab 6 mg v Aflibercept 2 mg
Number of subjects included in analysis	739
Analysis specification	Pre-specified
Analysis type	
Method	Regression, Logistic
Parameter estimate	Difference in proportions
Point estimate	-0.4
Confidence interval	
level	95 %
sides	2-sided
lower limit	-3.8
upper limit	3.3

Statistical analysis title	>=15 letter loss from baseline in BCVA - Study Eye
Statistical analysis description:	
Week 96	
Comparison groups	Brolucizumab 6 mg v Aflibercept 2 mg
Number of subjects included in analysis	739
Analysis specification	Pre-specified
Analysis type	
Method	Regression, Logistic
Parameter estimate	Difference in proportions
Point estimate	-0.4
Confidence interval	
level	95 %
sides	2-sided
lower limit	-3.8
upper limit	3.3

Secondary: Percentage of subjects with >=10 letter loss from baseline in BCVA (letters read) at each post-baseline visit - Study Eye

End point title	Percentage of subjects with >=10 letter loss from baseline in BCVA (letters read) at each post-baseline visit - Study Eye
-----------------	---

End point description:

BCVA (with spectacles or other visual corrective devices) was assessed using ETDRS testing at 4 meters

and reported in letters read correctly. Baseline was defined as the last measurement prior to first treatment. An increase (gain) in letters read from the baseline assessment indicates improvement. 95% confidence interval (CI) for binomial proportions was based on Clopper-Pearson exact method. One eye (study eye) contributed to the analysis.

End point type	Secondary
End point timeframe:	
Baseline, Weeks 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44, 48, 52, 56, 60, 64, 68, 72, 76, 80, 84, 88, 92, 96	

End point values	Brolucizumab 6 mg	Aflibercept 2 mg		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	370	369		
Units: percentage of subjects				
number (confidence interval 95%)				
Change from baseline at Week 4	1.9 (0.8 to 3.9)	2.4 (1.1 to 4.6)		
Change from baseline at Week 8	2.2 (0.9 to 4.2)	2.2 (0.9 to 4.2)		
Change from baseline at Week 12	2.7 (1.3 to 4.9)	3.0 (1.5 to 5.3)		
Change from baseline at Week 16	3.8 (2.1 to 6.3)	5.1 (3.1 to 7.9)		
Change from baseline at Week 20	5.9 (3.8 to 8.9)	4.6 (2.7 to 7.3)		
Change from baseline at Week 24	5.1 (3.1 to 7.9)	6.0 (3.8 to 8.9)		
Change from baseline at Week 28	5.9 (3.8 to 8.9)	5.7 (3.6 to 8.6)		
Change from baseline at Week 32	5.9 (3.8 to 8.9)	6.2 (4.0 to 9.2)		
Change from baseline at Week 36	6.5 (4.2 to 9.5)	6.2 (4.0 to 9.2)		
Change from baseline at Week 40	7.0 (4.6 to 10.1)	6.0 (3.8 to 8.9)		
Change from baseline at Week 44	8.6 (6.0 to 12.0)	6.2 (4.0 to 9.2)		
Change from baseline at Week 48	6.8 (4.4 to 9.8)	7.3 (4.9 to 10.5)		
Change from baseline at Week 52	8.1 (5.5 to 11.4)	7.3 (4.9 to 10.5)		
Change from baseline at Week 56	9.2 (6.4 to 12.6)	8.1 (5.6 to 11.4)		
Change from baseline at Week 60	8.1 (5.5 to 11.4)	7.3 (4.9 to 10.5)		
Change from baseline at Week 64	8.4 (5.8 to 11.7)	8.7 (6.0 to 12.0)		
Change from baseline at Week 68	7.6 (5.1 to 10.8)	8.4 (5.8 to 11.7)		
Change from baseline at Week 72	7.8 (5.3 to 11.1)	8.1 (5.6 to 11.4)		
Change from baseline at Week 76	9.5 (6.7 to 12.9)	9.2 (6.5 to 12.6)		
Change from baseline at Week 80	9.2 (6.4 to 12.6)	10.0 (7.2 to 13.6)		
Change from baseline at Week 84	9.5 (6.7 to 12.9)	9.5 (6.7 to 12.9)		
Change from baseline at Week 88	8.9 (6.2 to 12.3)	9.8 (6.9 to 13.3)		
Change from baseline at Week 92	9.2 (6.4 to 12.6)	11.1 (8.1 to 14.8)		
Change from baseline at Week 96	9.2 (6.4 to 12.6)	10.3 (7.4 to 13.9)		

Statistical analyses

Statistical analysis title	>=10 letter loss from baseline in BCVA - Study Eye
Statistical analysis description:	
Week 4	
Comparison groups	Brolucizumab 6 mg v Aflibercept 2 mg
Number of subjects included in analysis	739
Analysis specification	Pre-specified
Analysis type	
Method	Regression, Logistic
Parameter estimate	Difference in proportions
Point estimate	-0.5
Confidence interval	
level	95 %
sides	2-sided
lower limit	-2.6
upper limit	1.6

Statistical analysis title	>=10 letter loss from baseline in BCVA - Study Eye
Statistical analysis description:	
Week 8	
Comparison groups	Brolucizumab 6 mg v Aflibercept 2 mg
Number of subjects included in analysis	739
Analysis specification	Pre-specified
Analysis type	
Method	Regression, Logistic
Parameter estimate	Difference in proportions
Point estimate	0
Confidence interval	
level	95 %
sides	2-sided
lower limit	-2.2
upper limit	2.1

Statistical analysis title	>=10 letter loss from baseline in BCVA - Study Eye
Statistical analysis description:	
Week 12	
Comparison groups	Brolucizumab 6 mg v Aflibercept 2 mg

Number of subjects included in analysis	739
Analysis specification	Pre-specified
Analysis type	
Method	Regression, Logistic
Parameter estimate	Difference in proportions
Point estimate	-0.3
Confidence interval	
level	95 %
sides	2-sided
lower limit	-2.8
upper limit	2.2

Statistical analysis title	>=10 letter loss from baseline in BCVA - Study Eye
Statistical analysis description:	
Week 16	
Comparison groups	Brolucizumab 6 mg v Aflibercept 2 mg
Number of subjects included in analysis	739
Analysis specification	Pre-specified
Analysis type	
Method	Regression, Logistic
Parameter estimate	Difference in proportions
Point estimate	-1.4
Confidence interval	
level	95 %
sides	2-sided
lower limit	-4.4
upper limit	1.7

Statistical analysis title	>=10 letter loss from baseline in BCVA - Study Eye
Statistical analysis description:	
Week 20	
Comparison groups	Brolucizumab 6 mg v Aflibercept 2 mg
Number of subjects included in analysis	739
Analysis specification	Pre-specified
Analysis type	
Method	Regression, Logistic
Parameter estimate	Difference in proportions
Point estimate	1.4
Confidence interval	
level	95 %
sides	2-sided
lower limit	-1.7
upper limit	4.9

Statistical analysis title	>=10 letter loss from baseline in BCVA - Study Eye
Statistical analysis description:	
Week 24	
Comparison groups	Brolucizumab 6 mg v Aflibercept 2 mg
Number of subjects included in analysis	739
Analysis specification	Pre-specified
Analysis type	
Method	Regression, Logistic
Parameter estimate	Difference in proportions
Point estimate	-0.7
Confidence interval	
level	95 %
sides	2-sided
lower limit	-3.9
upper limit	2.8

Statistical analysis title	>=10 letter loss from baseline in BCVA - Study Eye
Statistical analysis description:	
Week 28	
Comparison groups	Brolucizumab 6 mg v Aflibercept 2 mg
Number of subjects included in analysis	739
Analysis specification	Pre-specified
Analysis type	
Method	Regression, Logistic
Parameter estimate	Difference in proportions
Point estimate	0.3
Confidence interval	
level	95 %
sides	2-sided
lower limit	-3.2
upper limit	3.8

Statistical analysis title	>=10 letter loss from baseline in BCVA - Study Eye
Statistical analysis description:	
Week 32	
Comparison groups	Brolucizumab 6 mg v Aflibercept 2 mg
Number of subjects included in analysis	739
Analysis specification	Pre-specified
Analysis type	
Method	Regression, Logistic
Parameter estimate	Difference in proportions
Point estimate	-0.1

Confidence interval	
level	95 %
sides	2-sided
lower limit	-3.8
upper limit	3.5

Statistical analysis title	>=10 letter loss from baseline in BCVA - Study Eye
Statistical analysis description:	
Week 36	
Comparison groups	Brolucizumab 6 mg v Aflibercept 2 mg
Number of subjects included in analysis	739
Analysis specification	Pre-specified
Analysis type	
Method	Regression, Logistic
Parameter estimate	Difference in proportions
Point estimate	0.3
Confidence interval	
level	95 %
sides	2-sided
lower limit	-3
upper limit	4.2

Statistical analysis title	>=10 letter loss from baseline in BCVA - Study Eye
Statistical analysis description:	
Week 40	
Comparison groups	Brolucizumab 6 mg v Aflibercept 2 mg
Number of subjects included in analysis	739
Analysis specification	Pre-specified
Analysis type	
Method	Regression, Logistic
Parameter estimate	Difference in proportions
Point estimate	1.2
Confidence interval	
level	95 %
sides	2-sided
lower limit	-2.4
upper limit	5.1

Statistical analysis title	>=10 letter loss from baseline in BCVA - Study Eye
Statistical analysis description:	
Week 44	
Comparison groups	Brolucizumab 6 mg v Aflibercept 2 mg

Number of subjects included in analysis	739
Analysis specification	Pre-specified
Analysis type	
Method	Regression, Logistic
Parameter estimate	Difference in proportions
Point estimate	2.5
Confidence interval	
level	95 %
sides	2-sided
lower limit	-1.1
upper limit	6.5

Statistical analysis title	>=10 letter loss from baseline in BCVA - Study Eye
Statistical analysis description:	
Week 48	
Comparison groups	Brolucizumab 6 mg v Aflibercept 2 mg
Number of subjects included in analysis	739
Analysis specification	Pre-specified
Analysis type	
Method	Regression, Logistic
Parameter estimate	Difference in proportions
Point estimate	-0.4
Confidence interval	
level	95 %
sides	2-sided
lower limit	-4
upper limit	3.3

Statistical analysis title	>=10 letter loss from baseline in BCVA - Study Eye
Statistical analysis description:	
Week 52	
Comparison groups	Brolucizumab 6 mg v Aflibercept 2 mg
Number of subjects included in analysis	739
Analysis specification	Pre-specified
Analysis type	
Method	Regression, Logistic
Parameter estimate	Difference in proportions
Point estimate	0.9
Confidence interval	
level	95 %
sides	2-sided
lower limit	-2.8
upper limit	4.7

Statistical analysis title	>=10 letter loss from baseline in BCVA - Study Eye
Statistical analysis description:	
Week 56	
Comparison groups	Brolucizumab 6 mg v Aflibercept 2 mg
Number of subjects included in analysis	739
Analysis specification	Pre-specified
Analysis type	
Method	Regression, Logistic
Parameter estimate	Difference in proportions
Point estimate	1.2
Confidence interval	
level	95 %
sides	2-sided
lower limit	-2.8
upper limit	5.5

Statistical analysis title	>=10 letter loss from baseline in BCVA - Study Eye
Statistical analysis description:	
Week 60	
Comparison groups	Brolucizumab 6 mg v Aflibercept 2 mg
Number of subjects included in analysis	739
Analysis specification	Pre-specified
Analysis type	
Method	Regression, Logistic
Parameter estimate	Difference of proportions
Point estimate	1
Confidence interval	
level	95 %
sides	2-sided
lower limit	-2.6
upper limit	4.7

Statistical analysis title	>=10 letter loss from baseline in BCVA - Study Eye
Statistical analysis description:	
Week 64	
Comparison groups	Brolucizumab 6 mg v Aflibercept 2 mg
Number of subjects included in analysis	739
Analysis specification	Pre-specified
Analysis type	
Method	Regression, Logistic
Parameter estimate	Difference in proportions
Point estimate	-0.1

Confidence interval	
level	95 %
sides	2-sided
lower limit	-4
upper limit	4.3

Statistical analysis title	>=10 letter loss from baseline in BCVA - Study Eye
Statistical analysis description:	
Week 68	
Comparison groups	Brolucizumab 6 mg v Aflibercept 2 mg
Number of subjects included in analysis	739
Analysis specification	Pre-specified
Analysis type	
Method	Regression, Logistic
Parameter estimate	Difference in proportions
Point estimate	-0.6
Confidence interval	
level	95 %
sides	2-sided
lower limit	-4.2
upper limit	3.6

Statistical analysis title	>=10 letter loss from baseline in BCVA - Study Eye
Statistical analysis description:	
Week 72	
Comparison groups	Brolucizumab 6 mg v Aflibercept 2 mg
Number of subjects included in analysis	739
Analysis specification	Pre-specified
Analysis type	
Method	Regression, Logistic
Parameter estimate	Difference in proportions
Point estimate	-0.1
Confidence interval	
level	95 %
sides	2-sided
lower limit	-4
upper limit	3.7

Statistical analysis title	>=10 letter loss from baseline in BCVA - Study Eye
Statistical analysis description:	
Week 76	
Comparison groups	Brolucizumab 6 mg v Aflibercept 2 mg

Number of subjects included in analysis	739
Analysis specification	Pre-specified
Analysis type	
Method	Regression, Logistic
Parameter estimate	Difference in proportions
Point estimate	0.4
Confidence interval	
level	95 %
sides	2-sided
lower limit	-3.5
upper limit	4.7

Statistical analysis title	>=10 letter loss from baseline in BCVA - Study Eye
Statistical analysis description:	
Week 80	
Comparison groups	Brolucizumab 6 mg v Aflibercept 2 mg
Number of subjects included in analysis	739
Analysis specification	Pre-specified
Analysis type	
Method	Regression, Logistic
Parameter estimate	Difference in proportions
Point estimate	-0.7
Confidence interval	
level	95 %
sides	2-sided
lower limit	-4.5
upper limit	3.4

Statistical analysis title	>=10 letter loss from baseline in BCVA - Study Eye
Statistical analysis description:	
Week 84	
Comparison groups	Brolucizumab 6 mg v Aflibercept 2 mg
Number of subjects included in analysis	739
Analysis specification	Pre-specified
Analysis type	
Method	Regression, Logistic
Parameter estimate	Difference in proportions
Point estimate	0.2
Confidence interval	
level	95 %
sides	2-sided
lower limit	-3.6
upper limit	4.5

Statistical analysis title	>=10 letter loss from baseline in BCVA - Study Eye
Statistical analysis description:	
Week 92	
Comparison groups	Brolucizumab 6 mg v Aflibercept 2 mg
Number of subjects included in analysis	739
Analysis specification	Pre-specified
Analysis type	
Method	Regression, Logistic
Parameter estimate	Difference in proportions
Point estimate	-1.8
Confidence interval	
level	95 %
sides	2-sided
lower limit	-5.7
upper limit	2.6

Statistical analysis title	>=10 letter loss from baseline in BCVA - Study Eye
Statistical analysis description:	
Week 88	
Comparison groups	Brolucizumab 6 mg v Aflibercept 2 mg
Number of subjects included in analysis	739
Analysis specification	Pre-specified
Analysis type	
Method	Regression, Logistic
Parameter estimate	Difference in proportions
Point estimate	-0.7
Confidence interval	
level	95 %
sides	2-sided
lower limit	-4.5
upper limit	3.6

Statistical analysis title	>=10 letter loss from baseline in BCVA - Study Eye
Statistical analysis description:	
Week 96	
Comparison groups	Brolucizumab 6 mg v Aflibercept 2 mg
Number of subjects included in analysis	739
Analysis specification	Pre-specified
Analysis type	
Method	Regression, Logistic
Parameter estimate	Difference in proportions
Point estimate	-1

Confidence interval	
level	95 %
sides	2-sided
lower limit	-4.9
upper limit	3.2

Secondary: Percentage of subjects with ≥ 5 letter loss from baseline in BCVA (letters read) at each post-baseline visit - Study Eye

End point title	Percentage of subjects with ≥ 5 letter loss from baseline in BCVA (letters read) at each post-baseline visit - Study Eye
-----------------	---

End point description:

BCVA (with spectacles or other visual corrective devices) was assessed using ETDRS testing at 4 meters and reported in letters read correctly. Baseline was defined as the last measurement prior to first treatment. An increase (gain) in letters read from the baseline assessment indicates improvement. 95% confidence interval (CI) for binomial proportions was based on Clopper-Pearson exact method. One eye (study eye) contributed to the analysis.

End point type	Secondary
----------------	-----------

End point timeframe:

Baseline, Weeks 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44, 48, 52, 56, 60, 64, 68, 72, 76, 80, 84, 88, 92, 96

End point values	Brolucizumab 6 mg	Aflibercept 2 mg		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	370	369		
Units: percentage of subjects				
number (confidence interval 95%)				
Change from baseline at Week 4	6.2 (4.0 to 9.2)	6.5 (4.2 to 9.5)		
Change from baseline at Week 8	7.8 (5.3 to 11.1)	8.4 (5.8 to 11.7)		
Change from baseline at Week 12	8.4 (5.8 to 11.7)	9.5 (6.7 to 12.9)		
Change from baseline at Week 16	10.8 (7.8 to 14.4)	8.9 (6.2 to 12.3)		
Change from baseline at Week 20	11.6 (8.5 to 15.3)	8.1 (5.6 to 11.4)		
Change from baseline at Week 24	13.0 (9.7 to 16.8)	10.0 (7.2 to 13.6)		
Change from baseline at Week 28	11.4 (8.3 to 15.0)	8.9 (6.2 to 12.3)		
Change from baseline at Week 32	12.2 (9.0 to 15.9)	11.1 (8.1 to 14.8)		
Change from baseline at Week 36	12.7 (9.5 to 16.5)	9.5 (6.7 to 12.9)		
Change from baseline at Week 40	11.9 (8.8 to 15.6)	11.1 (8.1 to 14.8)		
Change from baseline at Week 44	11.9 (8.8 to 15.6)	9.2 (6.5 to 12.6)		
Change from baseline at Week 48	11.1 (8.1 to 14.7)	11.9 (8.8 to 15.7)		
Change from baseline at Week 52	13.2 (10.0 to 17.1)	11.4 (8.3 to 15.1)		

Change from baseline at Week 56	13.2 (10.0 to 17.1)	11.7 (8.6 to 15.4)		
Change from baseline at Week 60	12.7 (9.5 to 16.5)	11.7 (8.6 to 15.4)		
Change from baseline at Week 64	12.7 (9.5 to 16.5)	12.5 (9.3 to 16.3)		
Change from baseline at Week 68	13.8 (10.4 to 17.7)	12.2 (9.0 to 16.0)		
Change from baseline at Week 72	14.1 (10.7 to 18.0)	13.6 (10.2 to 17.5)		
Change from baseline at Week 76	14.1 (10.7 to 18.0)	13.6 (10.2 to 17.5)		
Change from baseline at Week 80	13.8 (10.4 to 17.7)	15.2 (11.7 to 19.3)		
Change from baseline at Week 84	14.1 (10.7 to 18.0)	14.6 (11.2 to 18.7)		
Change from baseline at Week 88	13.0 (9.7 to 16.8)	14.4 (10.9 to 18.4)		
Change from baseline at Week 92	14.3 (10.9 to 18.3)	16.0 (12.4 to 20.1)		
Change from baseline at Week 96	14.3 (10.9 to 18.3)	14.6 (11.2 to 18.7)		

Statistical analyses

Statistical analysis title	>=5 letter loss from baseline in BCVA - Study Eye
Statistical analysis description:	
Week 4	
Comparison groups	Brolucizumab 6 mg v Aflibercept 2 mg
Number of subjects included in analysis	739
Analysis specification	Pre-specified
Analysis type	
Method	Regression, Logistic
Parameter estimate	Difference in proportions
Point estimate	-0.2
Confidence interval	
level	95 %
sides	2-sided
lower limit	-3.5
upper limit	3.5

Statistical analysis title	>=5 letter loss from baseline in BCVA - Study Eye
Statistical analysis description:	
Week 8	
Comparison groups	Brolucizumab 6 mg v Aflibercept 2 mg

Number of subjects included in analysis	739
Analysis specification	Pre-specified
Analysis type	
Method	Regression, Logistic
Parameter estimate	Difference in proportions
Point estimate	-0.5
Confidence interval	
level	95 %
sides	2-sided
lower limit	-4.4
upper limit	3.4

Statistical analysis title	>=5 letter loss from baseline in BCVA - Study Eye
Statistical analysis description:	
Week 12	
Comparison groups	Brolucizumab 6 mg v Aflibercept 2 mg
Number of subjects included in analysis	739
Analysis specification	Pre-specified
Analysis type	
Method	Regression, Logistic
Parameter estimate	Difference in proportions
Point estimate	-1
Confidence interval	
level	95 %
sides	2-sided
lower limit	-5
upper limit	3.1

Statistical analysis title	>=5 letter loss from baseline in BCVA - Study Eye
Statistical analysis description:	
Week 16	
Comparison groups	Brolucizumab 6 mg v Aflibercept 2 mg
Number of subjects included in analysis	739
Analysis specification	Pre-specified
Analysis type	
Method	Regression, Logistic
Parameter estimate	Difference in proportions
Point estimate	1.9
Confidence interval	
level	95 %
sides	2-sided
lower limit	-1.9
upper limit	6.2

Statistical analysis title	>=5 letter loss from baseline in BCVA - Study Eye
Statistical analysis description:	
Week 20	
Comparison groups	Brolucizumab 6 mg v Aflibercept 2 mg
Number of subjects included in analysis	739
Analysis specification	Pre-specified
Analysis type	
Method	Regression, Logistic
Parameter estimate	Difference in proportions
Point estimate	3.7
Confidence interval	
level	95 %
sides	2-sided
lower limit	-0.4
upper limit	7.8

Statistical analysis title	>=5 letter loss from baseline in BCVA - Study Eye
Statistical analysis description:	
Number of subjects with >=5 letter loss from baseline in BCVA (letters read) at each post-baseline visit - Week 24	
Comparison groups	Brolucizumab 6 mg v Aflibercept 2 mg
Number of subjects included in analysis	739
Analysis specification	Pre-specified
Analysis type	
Method	Regression, Logistic
Parameter estimate	Difference in proportions
Point estimate	3.1
Confidence interval	
level	95 %
sides	2-sided
lower limit	-1.3
upper limit	7.8

Statistical analysis title	>=5 letter loss from baseline in BCVA - Study Eye
Statistical analysis description:	
Week 28	
Comparison groups	Brolucizumab 6 mg v Aflibercept 2 mg
Number of subjects included in analysis	739
Analysis specification	Pre-specified
Analysis type	
Method	Regression, Logistic
Parameter estimate	Difference in proportions
Point estimate	2.6

Confidence interval	
level	95 %
sides	2-sided
lower limit	-1.7
upper limit	7.3

Statistical analysis title	>=5 letter loss from baseline in BCVA - Study Eye
Statistical analysis description:	
Week 32	
Comparison groups	Brolucizumab 6 mg v Aflibercept 2 mg
Number of subjects included in analysis	739
Analysis specification	Pre-specified
Analysis type	
Method	Regression, Logistic
Parameter estimate	Difference in proportions
Point estimate	1.2
Confidence interval	
level	95 %
sides	2-sided
lower limit	-3.2
upper limit	5.9

Statistical analysis title	>=5 letter loss from baseline in BCVA - Study Eye
Statistical analysis description:	
Week 36	
Comparison groups	Brolucizumab 6 mg v Aflibercept 2 mg
Number of subjects included in analysis	739
Analysis specification	Pre-specified
Analysis type	
Method	Regression, Logistic
Parameter estimate	Difference in proportions
Point estimate	3.4
Confidence interval	
level	95 %
sides	2-sided
lower limit	-0.7
upper limit	8.3

Statistical analysis title	>=5 letter loss from baseline in BCVA - Study Eye
Statistical analysis description:	
Week 40	
Comparison groups	Brolucizumab 6 mg v Aflibercept 2 mg

Number of subjects included in analysis	739
Analysis specification	Pre-specified
Analysis type	
Method	Regression, Logistic
Parameter estimate	Difference in proportions
Point estimate	1
Confidence interval	
level	95 %
sides	2-sided
lower limit	-3.8
upper limit	5.6

Statistical analysis title	>=5 letter loss from baseline in BCVA - Study Eye
Statistical analysis description:	
Week 44	
Comparison groups	Brolucizumab 6 mg v Aflibercept 2 mg
Number of subjects included in analysis	739
Analysis specification	Pre-specified
Analysis type	
Method	Regression, Logistic
Parameter estimate	Difference in proportions
Point estimate	2.9
Confidence interval	
level	95 %
sides	2-sided
lower limit	-1.4
upper limit	7

Statistical analysis title	>=5 letter loss from baseline in BCVA - Study Eye
Statistical analysis description:	
Week 48	
Comparison groups	Brolucizumab 6 mg v Aflibercept 2 mg
Number of subjects included in analysis	739
Analysis specification	Pre-specified
Analysis type	
Method	Regression, Logistic
Parameter estimate	Difference in proportions
Point estimate	-0.7
Confidence interval	
level	95 %
sides	2-sided
lower limit	-5.1
upper limit	3.7

Statistical analysis title	>=5 letter loss from baseline in BCVA - Study Eye
Statistical analysis description:	
Week 52	
Comparison groups	Brolucizumab 6 mg v Aflibercept 2 mg
Number of subjects included in analysis	739
Analysis specification	Pre-specified
Analysis type	
Method	Regression, Logistic
Parameter estimate	Difference in proportions
Point estimate	2.1
Confidence interval	
level	95 %
sides	2-sided
lower limit	-2.5
upper limit	6.7

Statistical analysis title	>=5 letter loss from baseline in BCVA - Study Eye
Statistical analysis description:	
Week 56	
Comparison groups	Brolucizumab 6 mg v Aflibercept 2 mg
Number of subjects included in analysis	739
Analysis specification	Pre-specified
Analysis type	
Method	Regression, Logistic
Parameter estimate	Difference in proportions
Point estimate	1.8
Confidence interval	
level	95 %
sides	2-sided
lower limit	-2.8
upper limit	6.4

Statistical analysis title	>=5 letter loss from baseline in BCVA - Study Eye
Statistical analysis description:	
Week 60	
Comparison groups	Brolucizumab 6 mg v Aflibercept 2 mg
Number of subjects included in analysis	739
Analysis specification	Pre-specified
Analysis type	
Method	Regression, Logistic
Parameter estimate	Difference in proportions
Point estimate	1.2

Confidence interval	
level	95 %
sides	2-sided
lower limit	-3.6
upper limit	5.8

Statistical analysis title	>=5 letter loss from baseline in BCVA - Study Eye
Statistical analysis description:	
Week 64	
Comparison groups	Brolucizumab 6 mg v Aflibercept 2 mg
Number of subjects included in analysis	739
Analysis specification	Pre-specified
Analysis type	
Method	Regression, Logistic
Parameter estimate	Difference in proportions
Point estimate	0.5
Confidence interval	
level	95 %
sides	2-sided
lower limit	-4
upper limit	5.4

Statistical analysis title	>=5 letter loss from baseline in BCVA - Study Eye
Statistical analysis description:	
Week 68	
Comparison groups	Brolucizumab 6 mg v Aflibercept 2 mg
Number of subjects included in analysis	739
Analysis specification	Pre-specified
Analysis type	
Method	Regression, Logistic
Parameter estimate	Difference in proportions
Point estimate	1.8
Confidence interval	
level	95 %
sides	2-sided
lower limit	-2.8
upper limit	6.4

Statistical analysis title	>=5 letter loss from baseline in BCVA - Study Eye
Statistical analysis description:	
Week 72	
Comparison groups	Brolucizumab 6 mg v Aflibercept 2 mg

Number of subjects included in analysis	739
Analysis specification	Pre-specified
Analysis type	
Method	Regression, Logistic
Parameter estimate	Difference in proportions
Point estimate	0.7
Confidence interval	
level	95 %
sides	2-sided
lower limit	-4.3
upper limit	5.7

Statistical analysis title	>=5 letter loss from baseline in BCVA - Study Eye
Statistical analysis description:	
Week 76	
Comparison groups	Brolucizumab 6 mg v Aflibercept 2 mg
Number of subjects included in analysis	739
Analysis specification	Pre-specified
Analysis type	
Method	Regression, Logistic
Parameter estimate	Difference in proportions
Point estimate	0.7
Confidence interval	
level	95 %
sides	2-sided
lower limit	-4.4
upper limit	5.8

Statistical analysis title	>=5 letter loss from baseline in BCVA - Study Eye
Statistical analysis description:	
Week 80	
Comparison groups	Brolucizumab 6 mg v Aflibercept 2 mg
Number of subjects included in analysis	739
Analysis specification	Pre-specified
Analysis type	
Method	Regression, Logistic
Parameter estimate	Difference in proportions
Point estimate	-1.2
Confidence interval	
level	95 %
sides	2-sided
lower limit	-6
upper limit	3.6

Statistical analysis title	>=5 letter loss from baseline in BCVA - Study Eye
Statistical analysis description:	
Week 84	
Comparison groups	Brolucizumab 6 mg v Aflibercept 2 mg
Number of subjects included in analysis	739
Analysis specification	Pre-specified
Analysis type	
Method	Regression, Logistic
Parameter estimate	Difference in proportions
Point estimate	-0.4
Confidence interval	
level	95 %
sides	2-sided
lower limit	-5.2
upper limit	4.5

Statistical analysis title	>=5 letter loss from baseline in BCVA - Study Eye
Statistical analysis description:	
Week 88	
Comparison groups	Brolucizumab 6 mg v Aflibercept 2 mg
Number of subjects included in analysis	739
Analysis specification	Pre-specified
Analysis type	
Method	Regression, Logistic
Parameter estimate	Difference in proportions
Point estimate	-1.2
Confidence interval	
level	95 %
sides	2-sided
lower limit	-5.7
upper limit	3.6

Statistical analysis title	>=5 letter loss from baseline in BCVA - Study Eye
Statistical analysis description:	
Week 92	
Comparison groups	Brolucizumab 6 mg v Aflibercept 2 mg
Number of subjects included in analysis	739
Analysis specification	Pre-specified
Analysis type	
Method	Regression, Logistic
Parameter estimate	Difference in proportions
Point estimate	-1.5

Confidence interval	
level	95 %
sides	2-sided
lower limit	-6.5
upper limit	3.4

Statistical analysis title	>=5 letter loss from baseline in BCVA - Study Eye
Statistical analysis description:	
Week 96	
Comparison groups	Brolucizumab 6 mg v Aflibercept 2 mg
Number of subjects included in analysis	739
Analysis specification	Pre-specified
Analysis type	
Method	Regression, Logistic
Parameter estimate	Difference in proportions
Point estimate	-0.1
Confidence interval	
level	95 %
sides	2-sided
lower limit	-5.1
upper limit	4.8

Secondary: Percentage of Subjects with BCVA of 73 Letters Read or More at Each Visit - Study Eye

End point title	Percentage of Subjects with BCVA of 73 Letters Read or More at Each Visit - Study Eye
End point description:	
BCVA (with spectacles or other visual corrective devices) was assessed using ETDRS testing at 4 meters and reported in letters read correctly (0-100 letters). A score of 65 to 70 letters represents a low to moderate visual acuity. Baseline was defined as the last measurement prior to first treatment. 95% confidence interval (CI) for binomial proportions was based on Clopper-Pearson exact method. One eye (study eye) contributed to the analysis.	
End point type	Secondary
End point timeframe:	
Baseline, Weeks 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44, 48, 52, 56, 60, 64, 68, 72, 76, 80, 84, 88, 92, 96	

End point values	Brolucizumab 6 mg	Aflibercept 2 mg		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	370	369		
Units: percentage of subjects				
number (confidence interval 95%)				
Baseline	21.4 (17.3 to 25.9)	17.9 (14.1 to 22.2)		

Week 4	31.9 (27.2 to 36.9)	34.7 (29.8 to 39.8)		
Week 8	40.3 (35.2 to 45.5)	41.2 (36.1 to 46.4)		
Week 12	43.5 (38.4 to 48.7)	44.7 (39.6 to 49.9)		
Week 16	44.1 (38.9 to 49.3)	42.5 (37.4 to 47.8)		
Week 20	44.1 (38.9 to 49.3)	45.0 (39.8 to 50.2)		
Week 24	45.4 (40.3 to 50.6)	47.4 (42.2 to 52.7)		
Week 28	48.6 (43.4 to 53.9)	50.4 (45.2 to 55.6)		
Week 32	47.8 (42.6 to 53.1)	49.6 (44.4 to 54.8)		
Week 36	47.6 (42.4 to 52.8)	49.9 (44.6 to 55.1)		
Week 40	48.9 (43.7 to 54.1)	49.3 (44.1 to 54.5)		
Week 44	50.3 (45.1 to 55.5)	50.4 (45.2 to 55.6)		
Week 48	51.4 (46.1 to 56.6)	49.6 (44.4 to 54.8)		
Week 52	49.7 (44.5 to 54.9)	50.1 (44.9 to 55.4)		
Week 56	50.5 (45.3 to 55.7)	50.9 (45.7 to 56.2)		
Week 60	48.9 (43.7 to 54.1)	52.3 (47.1 to 57.5)		
Week 64	49.2 (44.0 to 54.4)	50.7 (45.5 to 55.9)		
Week 68	48.9 (43.7 to 54.1)	50.7 (45.5 to 55.9)		
Week 72	48.9 (43.7 to 54.1)	49.3 (44.1 to 54.5)		
Week 76	48.9 (43.7 to 54.1)	49.9 (44.6 to 55.1)		
Week 80	51.9 (46.7 to 57.1)	50.1 (44.9 to 55.4)		
Week 84	48.4 (43.2 to 53.6)	49.6 (44.4 to 54.8)		
Week 88	50.5 (45.3 to 55.7)	50.7 (45.5 to 55.9)		
Week 92	50.5 (45.3 to 55.7)	49.9 (44.6 to 55.1)		
Week 96	48.1 (42.9 to 53.3)	49.1 (43.8 to 54.3)		

Statistical analyses

Statistical analysis title	Prct Subj BCVA of 73 Ltrs Read or More - Study Eye
Statistical analysis description:	
Week 4	
Comparison groups	Brolucizumab 6 mg v Aflibercept 2 mg

Number of subjects included in analysis	739
Analysis specification	Pre-specified
Analysis type	
Method	Regression, Logistic
Parameter estimate	Difference in proportions
Point estimate	-4
Confidence interval	
level	95 %
sides	2-sided
lower limit	-9.2
upper limit	1.6

Statistical analysis title	Prct Subj BCVA of 73 Ltrs Read or More - Study Eye
Statistical analysis description:	
Week 8	
Comparison groups	Brolucizumab 6 mg v Aflibercept 2 mg
Number of subjects included in analysis	739
Analysis specification	Pre-specified
Analysis type	
Method	Regression, Logistic
Parameter estimate	Difference in proportions
Point estimate	-2.1
Confidence interval	
level	95 %
sides	2-sided
lower limit	-8.1
upper limit	3.7

Statistical analysis title	Prct Subj BCVA of 73 Ltrs Read or More - Study Eye
Statistical analysis description:	
Week 12	
Comparison groups	Brolucizumab 6 mg v Aflibercept 2 mg
Number of subjects included in analysis	739
Analysis specification	Pre-specified
Analysis type	
Method	Regression, Logistic
Parameter estimate	Difference in proportions
Point estimate	-2.5
Confidence interval	
level	95 %
sides	2-sided
lower limit	-8.4
upper limit	3.5

Statistical analysis title	Prct Subj BCVA of 73 Ltrs Read or More - Study Eye
Statistical analysis description:	
Week 16	
Comparison groups	Brolucizumab 6 mg v Aflibercept 2 mg
Number of subjects included in analysis	739
Analysis specification	Pre-specified
Analysis type	
Method	Regression, Logistic
Parameter estimate	Difference in proportions
Point estimate	0.3
Confidence interval	
level	95 %
sides	2-sided
lower limit	-5.4
upper limit	6.7

Statistical analysis title	Prct Subj BCVA of 73 Ltrs Read or More - Study Eye
Statistical analysis description:	
Week 20	
Comparison groups	Brolucizumab 6 mg v Aflibercept 2 mg
Number of subjects included in analysis	739
Analysis specification	Pre-specified
Analysis type	
Method	Regression, Logistic
Parameter estimate	Difference in proportions
Point estimate	-2.2
Confidence interval	
level	95 %
sides	2-sided
lower limit	-8.2
upper limit	4

Statistical analysis title	Prct Subj BCVA of 73 Ltrs Read or More - Study Eye
Statistical analysis description:	
Week 24	
Comparison groups	Brolucizumab 6 mg v Aflibercept 2 mg
Number of subjects included in analysis	739
Analysis specification	Pre-specified
Analysis type	
Method	Regression, Logistic
Parameter estimate	Difference in proportions
Point estimate	-3.1

Confidence interval	
level	95 %
sides	2-sided
lower limit	-9
upper limit	3.3

Statistical analysis title	Prct Subj BCVA of 73 Ltrs Read or More - Study Eye
Statistical analysis description:	
Week 28	
Comparison groups	Brolucizumab 6 mg v Aflibercept 2 mg
Number of subjects included in analysis	739
Analysis specification	Pre-specified
Analysis type	
Method	Regression, Logistic
Parameter estimate	Difference in proportions
Point estimate	-3.2
Confidence interval	
level	95 %
sides	2-sided
lower limit	-9.3
upper limit	2.5

Statistical analysis title	Prct Subj BCVA of 73 Ltrs Read or More - Study Eye
Statistical analysis description:	
Week 32	
Comparison groups	Brolucizumab 6 mg v Aflibercept 2 mg
Number of subjects included in analysis	739
Analysis specification	Pre-specified
Analysis type	
Method	Regression, Logistic
Parameter estimate	Difference in proportions
Point estimate	-3.1
Confidence interval	
level	95 %
sides	2-sided
lower limit	-9.6
upper limit	2.8

Statistical analysis title	Prct Subj BCVA of 73 Ltrs Read or More - Study Eye
Statistical analysis description:	
Week 36	
Comparison groups	Brolucizumab 6 mg v Aflibercept 2 mg

Number of subjects included in analysis	739
Analysis specification	Pre-specified
Analysis type	
Method	Regression, Logistic
Parameter estimate	Difference in proportions
Point estimate	-3.7
Confidence interval	
level	95 %
sides	2-sided
lower limit	-9.6
upper limit	2.2

Statistical analysis title	Prct Subj BCVA of 73 Ltrs Read or More - Study Eye
Statistical analysis description:	
Week 40	
Comparison groups	Brolucizumab 6 mg v Aflibercept 2 mg
Number of subjects included in analysis	739
Analysis specification	Pre-specified
Analysis type	
Method	Regression, Logistic
Parameter estimate	Difference in proportions
Point estimate	-1.7
Confidence interval	
level	95 %
sides	2-sided
lower limit	-7.6
upper limit	4.2

Statistical analysis title	Prct Subj BCVA of 73 Ltrs Read or More - Study Eye
Statistical analysis description:	
Week 44	
Comparison groups	Brolucizumab 6 mg v Aflibercept 2 mg
Number of subjects included in analysis	739
Analysis specification	Pre-specified
Analysis type	
Method	Regression, Logistic
Parameter estimate	Difference in proportions
Point estimate	-1.4
Confidence interval	
level	95 %
sides	2-sided
lower limit	-7.5
upper limit	5

Statistical analysis title	Prct Subj BCVA of 73 Ltrs Read or More - Study Eye
Statistical analysis description:	
Week 48	
Comparison groups	Brolucizumab 6 mg v Aflibercept 2 mg
Number of subjects included in analysis	739
Analysis specification	Pre-specified
Analysis type	
Method	Regression, Logistic
Parameter estimate	Difference in proportions
Point estimate	0.4
Confidence interval	
level	95 %
sides	2-sided
lower limit	-5.4
upper limit	6.1

Statistical analysis title	Prct Subj BCVA of 73 Ltrs Read or More - Study Eye
Statistical analysis description:	
Week 52	
Comparison groups	Brolucizumab 6 mg v Aflibercept 2 mg
Number of subjects included in analysis	739
Analysis specification	Pre-specified
Analysis type	
Method	Regression, Logistic
Parameter estimate	Difference in proportions
Point estimate	-1.8
Confidence interval	
level	95 %
sides	2-sided
lower limit	-7.7
upper limit	4.5

Statistical analysis title	Prct Subj BCVA of 73 Ltrs Read or More - Study Eye
Statistical analysis description:	
Week 56	
Comparison groups	Brolucizumab 6 mg v Aflibercept 2 mg
Number of subjects included in analysis	739
Analysis specification	Pre-specified
Analysis type	
Method	Regression, Logistic
Parameter estimate	Difference in proportions
Point estimate	-1.9

Confidence interval	
level	95 %
sides	2-sided
lower limit	-7.7
upper limit	4

Statistical analysis title	Prct Subj BCVA of 73 Ltrs Read or More - Study Eye
Statistical analysis description:	
Week 60	
Comparison groups	Brolucizumab 6 mg v Aflibercept 2 mg
Number of subjects included in analysis	739
Analysis specification	Pre-specified
Analysis type	
Method	Regression, Logistic
Parameter estimate	Difference in proportions
Point estimate	-4.7
Confidence interval	
level	95 %
sides	2-sided
lower limit	-10.8
upper limit	1.4

Statistical analysis title	Prct Subj BCVA of 73 Ltrs Read or More - Study Eye
Statistical analysis description:	
Week 64	
Comparison groups	Brolucizumab 6 mg v Aflibercept 2 mg
Number of subjects included in analysis	739
Analysis specification	Pre-specified
Analysis type	
Method	Regression, Logistic
Parameter estimate	Difference in proportions
Point estimate	-2.8
Confidence interval	
level	95 %
sides	2-sided
lower limit	-8.9
upper limit	3.2

Statistical analysis title	Prct Subj BCVA of 73 Ltrs Read or More - Study Eye
Statistical analysis description:	
Week 68	
Comparison groups	Brolucizumab 6 mg v Aflibercept 2 mg

Number of subjects included in analysis	739
Analysis specification	Pre-specified
Analysis type	
Method	Regression, Logistic
Parameter estimate	Difference in proportions
Point estimate	-3.1
Confidence interval	
level	95 %
sides	2-sided
lower limit	-9.5
upper limit	2.9

Statistical analysis title	Prct Subj BCVA of 73 Ltrs Read or More - Study Eye
Statistical analysis description:	
Week 72	
Comparison groups	Brolucizumab 6 mg v Aflibercept 2 mg
Number of subjects included in analysis	739
Analysis specification	Pre-specified
Analysis type	
Method	Regression, Logistic
Parameter estimate	Difference in proportions
Point estimate	-1.6
Confidence interval	
level	95 %
sides	2-sided
lower limit	-7.9
upper limit	4.5

Statistical analysis title	Prct Subj BCVA of 73 Ltrs Read or More - Study Eye
Statistical analysis description:	
Week 76	
Comparison groups	Brolucizumab 6 mg v Aflibercept 2 mg
Number of subjects included in analysis	739
Analysis specification	Pre-specified
Analysis type	
Method	Regression, Logistic
Parameter estimate	Difference in proportions
Point estimate	-2
Confidence interval	
level	95 %
sides	2-sided
lower limit	-8.1
upper limit	4.1

Statistical analysis title	Prct Subj BCVA of 73 Ltrs Read or More - Study Eye
Statistical analysis description:	
Week 80	
Comparison groups	Brolucizumab 6 mg v Aflibercept 2 mg
Number of subjects included in analysis	739
Analysis specification	Pre-specified
Analysis type	
Method	Regression, Logistic
Parameter estimate	Difference in proportions
Point estimate	0.5
Confidence interval	
level	95 %
sides	2-sided
lower limit	-5.6
upper limit	6.6

Statistical analysis title	Prct Subj BCVA of 73 Ltrs Read or More - Study Eye
Statistical analysis description:	
Week 84	
Comparison groups	Brolucizumab 6 mg v Aflibercept 2 mg
Number of subjects included in analysis	739
Analysis specification	Pre-specified
Analysis type	
Method	Regression, Logistic
Parameter estimate	Difference in proportions
Point estimate	-2.4
Confidence interval	
level	95 %
sides	2-sided
lower limit	-8.3
upper limit	3.8

Statistical analysis title	Prct Subj BCVA of 73 Ltrs Read or More - Study Eye
Statistical analysis description:	
Week 88	
Comparison groups	Brolucizumab 6 mg v Aflibercept 2 mg
Number of subjects included in analysis	739
Analysis specification	Pre-specified
Analysis type	
Method	Regression, Logistic
Parameter estimate	Difference in proportions
Point estimate	-1.3

Confidence interval	
level	95 %
sides	2-sided
lower limit	-7.4
upper limit	4.5

Statistical analysis title	Prct Subj BCVA of 73 Ltrs Read or More - Study Eye
Statistical analysis description:	
Week 92	
Comparison groups	Brolucizumab 6 mg v Aflibercept 2 mg
Number of subjects included in analysis	739
Analysis specification	Pre-specified
Analysis type	
Method	Regression, Logistic
Parameter estimate	Difference in proportions
Point estimate	-0.5
Confidence interval	
level	95 %
sides	2-sided
lower limit	-6.5
upper limit	5.8

Statistical analysis title	Prct Subj BCVA of 73 Ltrs Read or More - Study Eye
Statistical analysis description:	
Week 96	
Comparison groups	Brolucizumab 6 mg v Aflibercept 2 mg
Number of subjects included in analysis	739
Analysis specification	Pre-specified
Analysis type	
Method	Regression, Logistic
Parameter estimate	Difference in proportions
Point estimate	-2
Confidence interval	
level	95 %
sides	2-sided
lower limit	-8.1
upper limit	4.1

Secondary: Change from baseline in central subfield thickness (CSFT) at each post-baseline visit - Study Eye

End point title	Change from baseline in central subfield thickness (CSFT) at each post-baseline visit - Study Eye
-----------------	---

End point description:

CSFT (the average retinal thickness of the circular area within 1 millimeter diameter around the foveal

center) was assessed using Spectral-Domain Optical Coherence Tomography (SD-OCT), a non-invasive measurement which produces cross-sectional and 3-dimensional images of the eye. A negative change value indicates an improvement, while a positive change value indicates a worsening. One eye (study eye) contributed to the analysis.

End point type	Secondary
End point timeframe:	
Baseline, Weeks 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44, 48, 52, 56, 60, 64, 68, 72, 76, 80, 84, 88, 92, 96	

End point values	Brolucizumab 6 mg	Aflibercept 2 mg		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	370	369		
Units: micrometers				
arithmetic mean (standard deviation)				
Change from baseline at Week 4	-160.7 (± 126.55)	-149.2 (± 111.60)		
Change from baseline at Week 8	-181.8 (± 142.11)	-159.6 (± 120.93)		
Change from baseline at Week 12	-190.5 (± 148.05)	-167.6 (± 123.66)		
Change from baseline at Week 16	-170.9 (± 152.48)	-137.7 (± 136.76)		
Change from baseline at Week 20	-161.0 (± 151.81)	-165.3 (± 132.70)		
Change from baseline at Week 24	-177.8 (± 150.62)	-137.3 (± 139.32)		
Change from baseline at Week 28	-182.7 (± 156.04)	-166.6 (± 138.22)		
Change from baseline at Week 32	-168.9 (± 157.61)	-142.6 (± 135.87)		
Change from baseline at Week 36	-192.6 (± 156.51)	-170.2 (± 131.42)		
Change from baseline at Week 40	-183.4 (± 156.83)	-146.5 (± 142.69)		
Change from baseline at Week 44	-183.8 (± 161.42)	-172.7 (± 135.06)		
Change from baseline at Week 48	-189.8 (± 158.35)	-147.8 (± 144.97)		
Change from baseline at Week 52	-193.8 (± 157.22)	-173.9 (± 134.84)		
Change from baseline at Week 56	-184.9 (± 162.66)	-149.9 (± 145.37)		
Change from baseline at Week 60	-195.4 (± 161.34)	-172.2 (± 136.58)		
Change from baseline at Week 64	-190.9 (± 160.06)	-153.1 (± 144.45)		
Change from baseline at Week 68	-188.4 (± 161.63)	-172.9 (± 136.76)		
Change from baseline at Week 72	-192.3 (± 160.70)	-153.1 (± 145.02)		
Change from baseline at Week 76	-193.1 (± 162.00)	-173.1 (± 138.96)		
Change from baseline at Week 80	-188.2 (± 165.90)	-155.6 (± 147.09)		
Change from baseline at Week 84	-196.2 (± 161.97)	-173.4 (± 142.11)		

Change from baseline at Week 88	-192.7 (\pm 162.46)	-158.3 (\pm 147.24)		
Change from baseline at Week 92	-194.9 (\pm 162.35)	-173.9 (\pm 142.30)		
Change from baseline at Week 96	-193.6 (\pm 163.97)	-159.3 (\pm 146.26)		

Statistical analyses

Statistical analysis title	Chg from BL in CSFT - Study Eye
Statistical analysis description:	
Week 4	
Comparison groups	Brolucizumab 6 mg v Aflibercept 2 mg
Number of subjects included in analysis	739
Analysis specification	Pre-specified
Analysis type	
Method	ANOVA
Parameter estimate	Least Squares Mean Difference
Point estimate	-17.7
Confidence interval	
level	95 %
sides	2-sided
lower limit	-32.6
upper limit	-2.9
Variability estimate	Standard error of the mean
Dispersion value	7.57

Statistical analysis title	Chg from BL in CSFT - Study Eye
Statistical analysis description:	
Week 8	
Comparison groups	Brolucizumab 6 mg v Aflibercept 2 mg
Number of subjects included in analysis	739
Analysis specification	Pre-specified
Analysis type	
Method	ANOVA
Parameter estimate	Least Squares Mean Difference
Point estimate	-29.5
Confidence interval	
level	95 %
sides	2-sided
lower limit	-45.6
upper limit	-13.4
Variability estimate	Standard error of the mean
Dispersion value	8.18

Statistical analysis title	Chg from BL in CSFT - Study Eye
Statistical analysis description:	
Week 12	
Comparison groups	Brolucizumab 6 mg v Aflibercept 2 mg
Number of subjects included in analysis	739
Analysis specification	Pre-specified
Analysis type	
Method	ANOVA
Parameter estimate	Least Squares Mean Difference
Point estimate	-30.3
Confidence interval	
level	95 %
sides	2-sided
lower limit	-46.9
upper limit	-13.7
Variability estimate	Standard error of the mean
Dispersion value	8.45

Statistical analysis title	Chg from BL in CSFT - Study Eye
Statistical analysis description:	
Week 16	
Comparison groups	Brolucizumab 6 mg v Aflibercept 2 mg
Number of subjects included in analysis	739
Analysis specification	Pre-specified
Analysis type	
Method	ANOVA
Parameter estimate	Least Squares Mean Difference
Point estimate	-40.2
Confidence interval	
level	95 %
sides	2-sided
lower limit	-58.9
upper limit	-21.6
Variability estimate	Standard error of the mean
Dispersion value	9.51

Statistical analysis title	Chg from BL in CSFT - Study Eye
Statistical analysis description:	
Week 20	
Comparison groups	Brolucizumab 6 mg v Aflibercept 2 mg

Number of subjects included in analysis	739
Analysis specification	Pre-specified
Analysis type	
Method	ANOVA
Parameter estimate	Least Squares Mean Difference
Point estimate	-2.9
Confidence interval	
level	95 %
sides	2-sided
lower limit	-20.9
upper limit	15
Variability estimate	Standard error of the mean
Dispersion value	9.12

Statistical analysis title	Chg from BL in CSFT - Study Eye
Statistical analysis description:	
Week 24	
Comparison groups	Brolucizumab 6 mg v Aflibercept 2 mg
Number of subjects included in analysis	739
Analysis specification	Pre-specified
Analysis type	
Method	ANOVA
Parameter estimate	Least Squares Mean Difference
Point estimate	-47.8
Confidence interval	
level	95 %
sides	2-sided
lower limit	-66.3
upper limit	-29.3
Variability estimate	Standard error of the mean
Dispersion value	9.42

Statistical analysis title	Chg from BL in CSFT - Study Eye
Statistical analysis description:	
Week 28	
Comparison groups	Brolucizumab 6 mg v Aflibercept 2 mg
Number of subjects included in analysis	739
Analysis specification	Pre-specified
Analysis type	
Method	ANOVA
Parameter estimate	Least Squares Mean Difference
Point estimate	-23.7

Confidence interval	
level	95 %
sides	2-sided
lower limit	-42
upper limit	-5.4
Variability estimate	Standard error of the mean
Dispersion value	9.34

Statistical analysis title	Chg from BL in CSFT - Study Eye
Statistical analysis description:	
Week 32	
Comparison groups	Brolucizumab 6 mg v Aflibercept 2 mg
Number of subjects included in analysis	739
Analysis specification	Pre-specified
Analysis type	
Method	ANOVA
Parameter estimate	Least Squares Mean Difference
Point estimate	-33.7
Confidence interval	
level	95 %
sides	2-sided
lower limit	-52.4
upper limit	-15
Variability estimate	Standard error of the mean
Dispersion value	9.54

Statistical analysis title	Chg from BL in CSFT - Study Eye
Statistical analysis description:	
Week 36	
Comparison groups	Brolucizumab 6 mg v Aflibercept 2 mg
Number of subjects included in analysis	739
Analysis specification	Pre-specified
Analysis type	
Method	ANOVA
Parameter estimate	Least Squares Mean Difference
Point estimate	-30.4
Confidence interval	
level	95 %
sides	2-sided
lower limit	-48
upper limit	-12.9
Variability estimate	Standard error of the mean
Dispersion value	8.94

Statistical analysis title	Chg from BL in CSFT - Study Eye
Statistical analysis description:	
Week 40	
Comparison groups	Brolucizumab 6 mg v Aflibercept 2 mg
Number of subjects included in analysis	739
Analysis specification	Pre-specified
Analysis type	
Method	ANOVA
Parameter estimate	Least Squares Mean Difference
Point estimate	-44.7
Confidence interval	
level	95 %
sides	2-sided
lower limit	-63.5
upper limit	-25.9
Variability estimate	Standard error of the mean
Dispersion value	9.57

Statistical analysis title	Chg from BL in CSFT - Study Eye
Statistical analysis description:	
Week 44	
Comparison groups	Brolucizumab 6 mg v Aflibercept 2 mg
Number of subjects included in analysis	739
Analysis specification	Pre-specified
Analysis type	
Method	ANOVA
Parameter estimate	Least Squares Mean Difference
Point estimate	-19.2
Confidence interval	
level	95 %
sides	2-sided
lower limit	-37.3
upper limit	-1.1
Variability estimate	Standard error of the mean
Dispersion value	9.24

Statistical analysis title	Chg from BL in CSFT - Study Eye
Statistical analysis description:	
Week 48	
Comparison groups	Brolucizumab 6 mg v Aflibercept 2 mg

Number of subjects included in analysis	739
Analysis specification	Pre-specified
Analysis type	
Method	ANOVA
Parameter estimate	Least Squares Mean Difference
Point estimate	-49.9
Confidence interval	
level	95 %
sides	2-sided
lower limit	-68.9
upper limit	-30.9
Variability estimate	Standard error of the mean
Dispersion value	9.68

Statistical analysis title	Chg from BL in CSFT - Study Eye
Statistical analysis description:	
Week 52	
Comparison groups	Brolucizumab 6 mg v Aflibercept 2 mg
Number of subjects included in analysis	739
Analysis specification	Pre-specified
Analysis type	
Method	ANOVA
Parameter estimate	Least Squares Mean Difference
Point estimate	-28.1
Confidence interval	
level	95 %
sides	2-sided
lower limit	-45.8
upper limit	-10.4
Variability estimate	Standard error of the mean
Dispersion value	9.01

Statistical analysis title	Chg from BL in CSFT - Study Eye
Statistical analysis description:	
Week 56	
Comparison groups	Brolucizumab 6 mg v Aflibercept 2 mg
Number of subjects included in analysis	739
Analysis specification	Pre-specified
Analysis type	
Method	ANOVA
Parameter estimate	Least Squares Mean Difference
Point estimate	-43.1

Confidence interval	
level	95 %
sides	2-sided
lower limit	-62.4
upper limit	-23.7
Variability estimate	Standard error of the mean
Dispersion value	9.86

Statistical analysis title	Chg from BL in CSFT - Study Eye
Statistical analysis description:	
Week 60	
Comparison groups	Brolucizumab 6 mg v Aflibercept 2 mg
Number of subjects included in analysis	739
Analysis specification	Pre-specified
Analysis type	
Method	ANOVA
Parameter estimate	Least Squares Mean Difference
Point estimate	-31.1
Confidence interval	
level	95 %
sides	2-sided
lower limit	-49.5
upper limit	-12.8
Variability estimate	Standard error of the mean
Dispersion value	9.34

Statistical analysis title	Chg from BL in CSFT - Study Eye
Statistical analysis description:	
Week 64	
Comparison groups	Brolucizumab 6 mg v Aflibercept 2 mg
Number of subjects included in analysis	739
Analysis specification	Pre-specified
Analysis type	
Method	ANOVA
Parameter estimate	Least Squares Mean Difference
Point estimate	-45.8
Confidence interval	
level	95 %
sides	2-sided
lower limit	-64.9
upper limit	-26.8
Variability estimate	Standard error of the mean
Dispersion value	9.7

Statistical analysis title	Chg from BL in CSFT - Study Eye
Statistical analysis description:	
Week 68	
Comparison groups	Brolucizumab 6 mg v Aflibercept 2 mg
Number of subjects included in analysis	739
Analysis specification	Pre-specified
Analysis type	
Method	ANOVA
Parameter estimate	Least Squares Mean Difference
Point estimate	-23.7
Confidence interval	
level	95 %
sides	2-sided
lower limit	-42
upper limit	-5.4
Variability estimate	Standard error of the mean
Dispersion value	9.31

Statistical analysis title	Chg from BL in CSFT - Study Eye
Statistical analysis description:	
Week 72	
Comparison groups	Brolucizumab 6 mg v Aflibercept 2 mg
Number of subjects included in analysis	739
Analysis specification	Pre-specified
Analysis type	
Method	ANOVA
Parameter estimate	Least Squares Mean Difference
Point estimate	-47.3
Confidence interval	
level	95 %
sides	2-sided
lower limit	-66.4
upper limit	-28.3
Variability estimate	Standard error of the mean
Dispersion value	9.69

Statistical analysis title	Chg from BL in CSFT - Study Eye
Statistical analysis description:	
Week 76	
Comparison groups	Brolucizumab 6 mg v Aflibercept 2 mg

Number of subjects included in analysis	739
Analysis specification	Pre-specified
Analysis type	
Method	ANOVA
Parameter estimate	Least Squares Mean Difference
Point estimate	-28
Confidence interval	
level	95 %
sides	2-sided
lower limit	-46.5
upper limit	-9.5
Variability estimate	Standard error of the mean
Dispersion value	9.43

Statistical analysis title	Chg from BL in CSFT - Study Eye
Statistical analysis description:	
Week 80	
Comparison groups	Brolucizumab 6 mg v Aflibercept 2 mg
Number of subjects included in analysis	739
Analysis specification	Pre-specified
Analysis type	
Method	ANOVA
Parameter estimate	Least Squares Mean Difference
Point estimate	-40.9
Confidence interval	
level	95 %
sides	2-sided
lower limit	-60.4
upper limit	-21.4
Variability estimate	Standard error of the mean
Dispersion value	9.94

Statistical analysis title	Chg from BL in CSFT - Study Eye
Statistical analysis description:	
Week 84	
Comparison groups	Brolucizumab 6 mg v Aflibercept 2 mg
Number of subjects included in analysis	739
Analysis specification	Pre-specified
Analysis type	
Method	ANOVA
Parameter estimate	Least Squares Mean Difference
Point estimate	-31

Confidence interval	
level	95 %
sides	2-sided
lower limit	-49.6
upper limit	-12.4
Variability estimate	Standard error of the mean
Dispersion value	9.48

Statistical analysis title	Chg from BL in CSFT - Study Eye
Statistical analysis description:	
Week 88	
Comparison groups	Brolucizumab 6 mg v Aflibercept 2 mg
Number of subjects included in analysis	739
Analysis specification	Pre-specified
Analysis type	
Method	ANOVA
Parameter estimate	Least Squares Mean Difference
Point estimate	-42.6
Confidence interval	
level	95 %
sides	2-sided
lower limit	-61.9
upper limit	-23.3
Variability estimate	Standard error of the mean
Dispersion value	9.84

Statistical analysis title	Chg from BL in CSFT - Study Eye
Statistical analysis description:	
Week 92	
Comparison groups	Brolucizumab 6 mg v Aflibercept 2 mg
Number of subjects included in analysis	739
Analysis specification	Pre-specified
Analysis type	
Method	ANOVA
Parameter estimate	Least Squares Mean Difference
Point estimate	-29.1
Confidence interval	
level	95 %
sides	2-sided
lower limit	-47.9
upper limit	-10.3
Variability estimate	Standard error of the mean
Dispersion value	9.56

Statistical analysis title	Chg from BL in CSFT - Study Eye
Statistical analysis description:	
Week 96	
Comparison groups	Brolucizumab 6 mg v Aflibercept 2 mg
Number of subjects included in analysis	739
Analysis specification	Pre-specified
Analysis type	
Method	ANOVA
Parameter estimate	Least Squares Mean Difference
Point estimate	-42.6
Confidence interval	
level	95 %
sides	2-sided
lower limit	-62
upper limit	-23.3
Variability estimate	Standard error of the mean
Dispersion value	9.87

Secondary: Average change from baseline in CSFT over the period Week 36 through Week 48 - Study Eye

End point title	Average change from baseline in CSFT over the period Week 36 through Week 48 - Study Eye
End point description:	
CSFT (the average retinal thickness of the circular area within 1 millimeter diameter around the foveal center) was assessed using SD-OCT, a non-invasive measurement which produces cross-sectional and 3-dimensional images of the eye. A negative change value indicates an improvement, while a positive change value indicates a worsening. One eye (study eye) contributed to the analysis.	
End point type	Secondary
End point timeframe:	
Baseline, Weeks 36, 40, 44, 48	

End point values	Brolucizumab 6 mg	Aflibercept 2 mg		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	370	369		
Units: micrometers				
arithmetic mean (standard deviation)	-187.4 (± 155.58)	-159.3 (± 135.92)		

Statistical analyses

Statistical analysis title	Av chg from BL in CSFT Wk 36-Week 48 - Study Eye
Comparison groups	Brolucizumab 6 mg v Aflibercept 2 mg

Number of subjects included in analysis	739
Analysis specification	Pre-specified
Analysis type	
Method	ANOVA
Parameter estimate	Least Squares Mean Difference
Point estimate	-36.1
Confidence interval	
level	95 %
sides	2-sided
lower limit	-54
upper limit	-18.1
Variability estimate	Standard error of the mean
Dispersion value	9.13

Secondary: Average change from baseline in CSFT over the period Week 84 through Week 96 - Study Eye

End point title	Average change from baseline in CSFT over the period Week 84 through Week 96 - Study Eye
End point description:	CSFT (the average retinal thickness of the circular area within 1 millimeter diameter around the foveal center) was assessed using SD-OCT, a non-invasive measurement which produces cross-sectional and 3-dimensional images of the eye. A negative change value indicates an improvement, while a positive change value indicates a worsening. One eye (study eye) contributed to the analysis.
End point type	Secondary
End point timeframe:	Baseline, Weeks 84, 88, 92, 96

End point values	Brolucizumab 6 mg	Aflibercept 2 mg		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	370	369		
Units: micrometers				
arithmetic mean (standard deviation)	-194.3 (\pm 161.24)	-166.2 (\pm 142.81)		

Statistical analyses

Statistical analysis title	Av chg from BL in CSFT Wk 84-96 - Study Eye
Comparison groups	Brolucizumab 6 mg v Aflibercept 2 mg
Number of subjects included in analysis	739
Analysis specification	Pre-specified
Analysis type	
Method	ANOVA
Parameter estimate	Least Squares Mean Difference
Point estimate	-36.3

Confidence interval	
level	95 %
sides	2-sided
lower limit	-55.1
upper limit	-17.6
Variability estimate	Standard error of the mean
Dispersion value	9.56

Secondary: Average change from baseline in CSFT over the period Week 4 through Week 48/96 - Study Eye

End point title	Average change from baseline in CSFT over the period Week 4 through Week 48/96 - Study Eye
-----------------	--

End point description:

CSFT (the average retinal thickness of the circular area within 1 millimeter diameter around the foveal center) was assessed using SD-OCT, a non-invasive measurement which produces cross-sectional and 3-dimensional images of the eye. A negative change value indicates an improvement, while a positive change value indicates a worsening. One eye (study eye) contributed to the analysis.

End point type	Secondary
----------------	-----------

End point timeframe:

Baseline, Weeks 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44, 48, 52, 56, 60, 64, 68, 72, 76, 80, 84, 88, 92, 96

End point values	Brolucizumab 6 mg	Aflibercept 2 mg		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	370	369		
Units: micrometers				
arithmetic mean (standard deviation)				
Change from baseline over the period Week 4 to 48	-178.7 (± 145.33)	-155.3 (± 126.83)		
Change from baseline over the period Week 4 to 96	-185.4 (± 151.35)	-159.7 (± 131.74)		

Statistical analyses

Statistical analysis title	Av chg from BL in CSFT Wk 4-48 - Study Eye
----------------------------	--

Statistical analysis description:

Week 4 to Week 48

Comparison groups	Brolucizumab 6 mg v Aflibercept 2 mg
Number of subjects included in analysis	739
Analysis specification	Pre-specified
Analysis type	
Method	ANOVA
Parameter estimate	Least Squares Mean Difference
Point estimate	-30.8

Confidence interval	
level	95 %
sides	2-sided
lower limit	-47.6
upper limit	-14.1
Variability estimate	Standard error of the mean
Dispersion value	8.53

Statistical analysis title	Av chg from BL in CSFT Wk 4-96 - Study Eye
Statistical analysis description: Week 4 to Week 96	
Comparison groups	Brolucizumab 6 mg v Aflibercept 2 mg
Number of subjects included in analysis	739
Analysis specification	Pre-specified
Analysis type	
Method	ANOVA
Parameter estimate	Least Squares Mean Difference
Point estimate	-33.5
Confidence interval	
level	95 %
sides	2-sided
lower limit	-50.8
upper limit	-16.1
Variability estimate	Standard error of the mean
Dispersion value	8.84

Secondary: Change from baseline in choroidal neovascularization (CNV) lesion size at Week 12, Week 48, and Week 96 - Study Eye

End point title	Change from baseline in choroidal neovascularization (CNV) lesion size at Week 12, Week 48, and Week 96 - Study Eye
End point description: CNV lesion size (the area of new blood vessels in the choroid layer of the retina) size was measured using fluorescein angiography (FA). A negative change value indicates a reduction in lesion size, whereas a positive change value indicates an increase. An increase in CNV lesion size may indicate progression of the underlying disease. Only one eye (study eye) contributed to the analysis.	
End point type	Secondary
End point timeframe: Baseline, Weeks 12, 48, 96	

End point values	Brolucizumab 6 mg	Aflibercept 2 mg		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	370	369		
Units: millimeters squared				
arithmetic mean (standard deviation)				
Change from baseline at Week 12	-2.2 (\pm 2.71)	-2.5 (\pm 4.02)		
Change from baseline at Week 48	-2.3 (\pm 2.76)	-2.5 (\pm 4.04)		
Change from baseline at Week 96	-2.5 (\pm 2.77)	-2.7 (\pm 4.03)		

Statistical analyses

Statistical analysis title	Chg from BL in CNV lesion size at Wk 12- Study Eye
Statistical analysis description: Week 12	
Comparison groups	Brolucizumab 6 mg v Aflibercept 2 mg
Number of subjects included in analysis	739
Analysis specification	Pre-specified
Analysis type	
Method	ANOVA
Parameter estimate	Least Squares Mean Difference
Point estimate	0.3
Confidence interval	
level	95 %
sides	2-sided
lower limit	0
upper limit	0.7
Variability estimate	Standard error of the mean
Dispersion value	0.18

Statistical analysis title	Chg from BL in CNV lesion size at Wk 48- Study Eye
Statistical analysis description: Week 48	
Comparison groups	Brolucizumab 6 mg v Aflibercept 2 mg
Number of subjects included in analysis	739
Analysis specification	Pre-specified
Analysis type	
Method	ANOVA
Parameter estimate	Least Squares Mean Difference
Point estimate	0.3
Confidence interval	
level	95 %
sides	2-sided
lower limit	-0.1
upper limit	0.6
Variability estimate	Standard error of the mean
Dispersion value	0.17

Statistical analysis title	Chg from BL in CNV lesion size at Wk 96- Study Eye
Statistical analysis description:	
Week 96	
Comparison groups	Brolucizumab 6 mg v Aflibercept 2 mg
Number of subjects included in analysis	739
Analysis specification	Pre-specified
Analysis type	
Method	ANOVA
Parameter estimate	Least Squares Mean Difference
Point estimate	0.3
Confidence interval	
level	95 %
sides	2-sided
lower limit	0
upper limit	0.6
Variability estimate	Standard error of the mean
Dispersion value	0.16

Secondary: Change from baseline in central subfield neurosensory retinal thickness (CSFTns) at each post-baseline visit - Study Eye

End point title	Change from baseline in central subfield neurosensory retinal thickness (CSFTns) at each post-baseline visit - Study Eye
End point description:	
CSFTns was assessed using SD-OCT. A negative change value indicates an improvement, while a positive change value indicates a worsening. One eye (study eye) contributed to the analysis.	
End point type	Secondary
End point timeframe:	
Baseline, Weeks 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44, 48, 52, 56, 60, 64, 68, 72, 76, 80, 84, 88, 92, 96	

End point values	Brolucizumab 6 mg	Aflibercept 2 mg		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	370	369		
Units: micrometers				
arithmetic mean (standard deviation)				
Change from baseline at Week 4	-51.7 (± 91.79)	-44.2 (± 80.37)		
Change from baseline at Week 8	-55.0 (± 94.92)	-45.4 (± 84.99)		
Change from baseline at Week 12	-52.7 (± 96.89)	-42.4 (± 85.48)		
Change from baseline at Week 16	-50.5 (± 98.30)	-41.2 (± 84.78)		
Change from baseline at Week 20	-49.2 (± 95.87)	-48.1 (± 88.08)		

Change from baseline at Week 24	-53.4 (± 98.35)	-41.8 (± 90.17)		
Change from baseline at Week 28	-56.4 (± 99.86)	-47.3 (± 87.90)		
Change from baseline at Week 32	-49.8 (± 99.41)	-42.0 (± 90.50)		
Change from baseline at Week 36	-59.1 (± 101.18)	-47.8 (± 89.64)		
Change from baseline at Week 40	-55.9 (± 100.01)	-43.2 (± 91.94)		
Change from baseline at Week 44	-56.2 (± 106.65)	-47.1 (± 90.03)		
Change from baseline at Week 48	-54.8 (± 100.28)	-41.8 (± 93.99)		
Change from baseline at Week 52	-58.4 (± 102.35)	-49.1 (± 90.31)		
Change from baseline at Week 56	-57.3 (± 100.85)	-45.8 (± 91.95)		
Change from baseline at Week 60	-60.3 (± 100.56)	-49.3 (± 90.52)		
Change from baseline at Week 64	-58.0 (± 100.89)	-47.5 (± 92.59)		
Change from baseline at Week 68	-56.7 (± 100.16)	-49.5 (± 91.20)		
Change from baseline at Week 72	-58.6 (± 101.34)	-47.3 (± 92.25)		
Change from baseline at Week 76	-59.7 (± 101.61)	-50.2 (± 91.51)		
Change from baseline at Week 80	-57.8 (± 102.92)	-47.6 (± 92.34)		
Change from baseline at Week 84	-60.4 (± 102.80)	-50.6 (± 92.57)		
Change from baseline at Week 88	-59.7 (± 101.97)	-49.1 (± 94.52)		
Change from baseline at Week 92	-60.1 (± 102.00)	-51.0 (± 91.79)		
Change from baseline at Week 96	-58.9 (± 102.48)	-49.4 (± 94.86)		

Statistical analyses

Statistical analysis title	Chg from BL in CSFTns - Study Eye
Statistical analysis description:	
Week 4	
Comparison groups	Brolucizumab 6 mg v Aflibercept 2 mg
Number of subjects included in analysis	739
Analysis specification	Pre-specified
Analysis type	
Method	ANOVA
Parameter estimate	Least Squares Mean Difference
Point estimate	-2.1
Confidence interval	
level	95 %
sides	2-sided
lower limit	-11.6
upper limit	7.3

Variability estimate	Standard error of the mean
Dispersion value	4.8

Statistical analysis title	Chg from BL in CSFTns - Study Eye
Statistical analysis description: Week 8	
Comparison groups	Brolucizumab 6 mg v Aflibercept 2 mg
Number of subjects included in analysis	739
Analysis specification	Pre-specified
Analysis type	
Method	ANOVA
Parameter estimate	Least Squares Mean Difference
Point estimate	-3.8
Confidence interval	
level	95 %
sides	2-sided
lower limit	-13.6
upper limit	6
Variability estimate	Standard error of the mean
Dispersion value	4.98

Statistical analysis title	Chg from BL in CSFTns - Study Eye
Statistical analysis description: Week 12	
Comparison groups	Brolucizumab 6 mg v Aflibercept 2 mg
Number of subjects included in analysis	739
Analysis specification	Pre-specified
Analysis type	
Method	ANOVA
Parameter estimate	Least Squares Mean Difference
Point estimate	-4.5
Confidence interval	
level	95 %
sides	2-sided
lower limit	-14.3
upper limit	5.3
Variability estimate	Standard error of the mean
Dispersion value	4.98

Statistical analysis title	Chg from BL in CSFTns - Study Eye
Statistical analysis description: Week 16	
Comparison groups	Brolucizumab 6 mg v Aflibercept 2 mg

Number of subjects included in analysis	739
Analysis specification	Pre-specified
Analysis type	
Method	ANOVA
Parameter estimate	Least Squares Mean Difference
Point estimate	-3.7
Confidence interval	
level	95 %
sides	2-sided
lower limit	-13.7
upper limit	6.4
Variability estimate	Standard error of the mean
Dispersion value	5.12

Statistical analysis title	Chg from BL in CSFTns - Study Eye
Statistical analysis description:	
Week 20	
Comparison groups	Aflibercept 2 mg v Brolucizumab 6 mg
Number of subjects included in analysis	739
Analysis specification	Pre-specified
Analysis type	
Method	ANOVA
Parameter estimate	Least Squares Mean Difference
Point estimate	4.6
Confidence interval	
level	95 %
sides	2-sided
lower limit	-5.5
upper limit	14.6
Variability estimate	Standard error of the mean
Dispersion value	5.11

Statistical analysis title	Chg from BL in CSFTns - Study Eye
Statistical analysis description:	
Week 24	
Comparison groups	Brolucizumab 6 mg v Aflibercept 2 mg
Number of subjects included in analysis	739
Analysis specification	Pre-specified
Analysis type	
Method	ANOVA
Parameter estimate	Least Squares Mean Difference
Point estimate	-5.8

Confidence interval	
level	95 %
sides	2-sided
lower limit	-16.3
upper limit	4.7
Variability estimate	Standard error of the mean
Dispersion value	5.35

Statistical analysis title	Chg from BL in CSFTns - Study Eye
Statistical analysis description:	
Week 28	
Comparison groups	Brolucizumab 6 mg v Aflibercept 2 mg
Number of subjects included in analysis	739
Analysis specification	Pre-specified
Analysis type	
Method	ANOVA
Parameter estimate	Least Squares Mean Difference
Point estimate	-3.1
Confidence interval	
level	95 %
sides	2-sided
lower limit	-13.1
upper limit	7
Variability estimate	Standard error of the mean
Dispersion value	5.13

Statistical analysis title	Chg from BL in CSFTns - Study Eye
Statistical analysis description:	
Week 32	
Comparison groups	Brolucizumab 6 mg v Aflibercept 2 mg
Number of subjects included in analysis	739
Analysis specification	Pre-specified
Analysis type	
Method	ANOVA
Parameter estimate	Least Squares Mean Difference
Point estimate	-2
Confidence interval	
level	95 %
sides	2-sided
lower limit	-12.6
upper limit	8.5
Variability estimate	Standard error of the mean
Dispersion value	5.37

Statistical analysis title	Chg from BL in CSFTns - Study Eye
Statistical analysis description:	
Week 36	
Comparison groups	Brolucizumab 6 mg v Aflibercept 2 mg
Number of subjects included in analysis	739
Analysis specification	Pre-specified
Analysis type	
Method	ANOVA
Parameter estimate	Least Squares Mean Difference
Point estimate	-5
Confidence interval	
level	95 %
sides	2-sided
lower limit	-15.2
upper limit	5.1
Variability estimate	Standard error of the mean
Dispersion value	5.15

Statistical analysis title	Chg from BL in CSFTns - Study Eye
Statistical analysis description:	
Week 40	
Comparison groups	Brolucizumab 6 mg v Aflibercept 2 mg
Number of subjects included in analysis	739
Analysis specification	Pre-specified
Analysis type	
Method	ANOVA
Parameter estimate	Least Squares Mean Difference
Point estimate	-6.6
Confidence interval	
level	95 %
sides	2-sided
lower limit	-17
upper limit	3.8
Variability estimate	Standard error of the mean
Dispersion value	5.3

Statistical analysis title	Chg from BL in CSFTns - Study Eye
Statistical analysis description:	
Week 44	
Comparison groups	Brolucizumab 6 mg v Aflibercept 2 mg

Number of subjects included in analysis	739
Analysis specification	Pre-specified
Analysis type	
Method	ANOVA
Parameter estimate	Least Squares Mean Difference
Point estimate	-2.8
Confidence interval	
level	95 %
sides	2-sided
lower limit	-13.4
upper limit	7.9
Variability estimate	Standard error of the mean
Dispersion value	5.42

Statistical analysis title	Chg from BL in CSFTns - Study Eye
Statistical analysis description:	
Week 48	
Comparison groups	Brolucizumab 6 mg v Aflibercept 2 mg
Number of subjects included in analysis	739
Analysis specification	Pre-specified
Analysis type	
Method	ANOVA
Parameter estimate	Least Squares Mean Difference
Point estimate	-7
Confidence interval	
level	95 %
sides	2-sided
lower limit	-17.6
upper limit	3.7
Variability estimate	Standard error of the mean
Dispersion value	5.4

Statistical analysis title	Chg from BL in CSFTns - Study Eye
Statistical analysis description:	
Week 52	
Comparison groups	Brolucizumab 6 mg v Aflibercept 2 mg
Number of subjects included in analysis	739
Analysis specification	Pre-specified
Analysis type	
Method	ANOVA
Parameter estimate	Least Squares Mean Difference
Point estimate	-2.7

Confidence interval	
level	95 %
sides	2-sided
lower limit	-12.9
upper limit	7.5
Variability estimate	Standard error of the mean
Dispersion value	5.19

Statistical analysis title	Chg from BL in CSFTns - Study Eye
Statistical analysis description:	
Week 56	
Comparison groups	Brolucizumab 6 mg v Aflibercept 2 mg
Number of subjects included in analysis	739
Analysis specification	Pre-specified
Analysis type	
Method	ANOVA
Parameter estimate	Least Squares Mean Difference
Point estimate	-5
Confidence interval	
level	95 %
sides	2-sided
lower limit	-15.4
upper limit	5.4
Variability estimate	Standard error of the mean
Dispersion value	5.31

Statistical analysis title	Chg from BL in CSFTns - Study Eye
Statistical analysis description:	
Week 60	
Comparison groups	Brolucizumab 6 mg v Aflibercept 2 mg
Number of subjects included in analysis	739
Analysis specification	Pre-specified
Analysis type	
Method	ANOVA
Parameter estimate	Least Squares Mean Difference
Point estimate	-4.2
Confidence interval	
level	95 %
sides	2-sided
lower limit	-14.3
upper limit	5.9
Variability estimate	Standard error of the mean
Dispersion value	5.15

Statistical analysis title	Chg from BL in CSFTns - Study Eye
Statistical analysis description:	
Week 64	
Comparison groups	Brolucizumab 6 mg v Aflibercept 2 mg
Number of subjects included in analysis	739
Analysis specification	Pre-specified
Analysis type	
Method	ANOVA
Parameter estimate	Least Squares Mean Difference
Point estimate	-3.9
Confidence interval	
level	95 %
sides	2-sided
lower limit	-14.2
upper limit	6.4
Variability estimate	Standard error of the mean
Dispersion value	5.24

Statistical analysis title	Chg from BL in CSFTns - Study Eye
Statistical analysis description:	
Week 68	
Comparison groups	Brolucizumab 6 mg v Aflibercept 2 mg
Number of subjects included in analysis	739
Analysis specification	Pre-specified
Analysis type	
Method	ANOVA
Parameter estimate	Least Squares Mean Difference
Point estimate	-0.6
Confidence interval	
level	95 %
sides	2-sided
lower limit	-10.7
upper limit	9.6
Variability estimate	Standard error of the mean
Dispersion value	5.17

Statistical analysis title	Chg from BL in CSFTns - Study Eye
Statistical analysis description:	
Week 72	
Comparison groups	Brolucizumab 6 mg v Aflibercept 2 mg

Number of subjects included in analysis	739
Analysis specification	Pre-specified
Analysis type	
Method	ANOVA
Parameter estimate	Least Squares Mean Difference
Point estimate	-4.6
Confidence interval	
level	95 %
sides	2-sided
lower limit	-14.8
upper limit	5.7
Variability estimate	Standard error of the mean
Dispersion value	5.24

Statistical analysis title	Chg from BL in CSFTns - Study Eye
Statistical analysis description:	
Week 76	
Comparison groups	Brolucizumab 6 mg v Aflibercept 2 mg
Number of subjects included in analysis	739
Analysis specification	Pre-specified
Analysis type	
Method	ANOVA
Parameter estimate	Least Squares Mean Difference
Point estimate	-2.8
Confidence interval	
level	95 %
sides	2-sided
lower limit	-13.1
upper limit	7.4
Variability estimate	Standard error of the mean
Dispersion value	5.23

Statistical analysis title	Chg from BL in CSFTns - Study Eye
Statistical analysis description:	
Week 80	
Comparison groups	Brolucizumab 6 mg v Aflibercept 2 mg
Number of subjects included in analysis	739
Analysis specification	Pre-specified
Analysis type	
Method	ANOVA
Parameter estimate	Least Squares Mean Difference
Point estimate	-3.7

Confidence interval	
level	95 %
sides	2-sided
lower limit	-14.1
upper limit	6.8
Variability estimate	Standard error of the mean
Dispersion value	5.33

Statistical analysis title	Chg from BL in CSFTns - Study Eye
Statistical analysis description:	
Week 84	
Comparison groups	Brolucizumab 6 mg v Aflibercept 2 mg
Number of subjects included in analysis	739
Analysis specification	Pre-specified
Analysis type	
Method	ANOVA
Parameter estimate	Least Squares Mean Difference
Point estimate	-3.1
Confidence interval	
level	95 %
sides	2-sided
lower limit	-13.5
upper limit	7.3
Variability estimate	Standard error of the mean
Dispersion value	5.3

Statistical analysis title	Chg from BL in CSFTns - Study Eye
Statistical analysis description:	
Week 88	
Comparison groups	Brolucizumab 6 mg v Aflibercept 2 mg
Number of subjects included in analysis	739
Analysis specification	Pre-specified
Analysis type	
Method	ANOVA
Parameter estimate	Least Squares Mean Difference
Point estimate	-4
Confidence interval	
level	95 %
sides	2-sided
lower limit	-14.6
upper limit	6.5
Variability estimate	Standard error of the mean
Dispersion value	5.39

Statistical analysis title	Chg from BL in CSFTns - Study Eye
Statistical analysis description:	
Week 92	
Comparison groups	Brolucizumab 6 mg v Aflibercept 2 mg
Number of subjects included in analysis	739
Analysis specification	Pre-specified
Analysis type	
Method	ANOVA
Parameter estimate	Least Squares Mean Difference
Point estimate	-2.3
Confidence interval	
level	95 %
sides	2-sided
lower limit	-12.6
upper limit	8
Variability estimate	Standard error of the mean
Dispersion value	5.25

Statistical analysis title	Chg from BL in CSFTns - Study Eye
Statistical analysis description:	
Week 96	
Comparison groups	Brolucizumab 6 mg v Aflibercept 2 mg
Number of subjects included in analysis	739
Analysis specification	Pre-specified
Analysis type	
Method	ANOVA
Parameter estimate	Least Squares Mean Difference
Point estimate	-3
Confidence interval	
level	95 %
sides	2-sided
lower limit	-13.6
upper limit	7.7
Variability estimate	Standard error of the mean
Dispersion value	5.42

Secondary: Percentage of subjects with presence of subretinal fluid at each post-baseline visit - Study Eye

End point title	Percentage of subjects with presence of subretinal fluid at each post-baseline visit - Study Eye
End point description:	
Subretinal fluid was assessed using SD-OCT and recorded as Present/Absent. The presence of subretinal fluid is an indicator of underlying disease. One eye (study eye) contributed to the analysis.	
End point type	Secondary
End point timeframe:	
Weeks 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44, 48, 52, 56, 60, 64, 68, 72, 76, 80, 84, 88, 92, 96	

End point values	Brolucizumab 6 mg	Aflibercept 2 mg		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	370	369		
Units: percentage of subjects				
number (confidence interval 95%)				
Week 4	29.2 (24.6 to 34.1)	36.9 (31.9 to 42.0)		
Week 8	14.1 (10.7 to 18.0)	22.8 (18.6 to 27.4)		
Week 12	13.5 (10.2 to 17.4)	20.6 (16.6 to 25.1)		
Week 16	21.1 (17.0 to 25.6)	35.5 (30.6 to 40.6)		
Week 20	25.1 (20.8 to 29.9)	22.5 (18.3 to 27.1)		
Week 24	17.3 (13.6 to 21.5)	36.9 (31.9 to 42.0)		
Week 28	15.9 (12.4 to 20.1)	22.0 (17.8 to 26.5)		
Week 32	24.1 (19.8 to 28.7)	34.4 (29.6 to 39.5)		
Week 36	13.5 (10.2 to 17.4)	21.7 (17.6 to 26.2)		
Week 40	18.1 (14.3 to 22.4)	33.9 (29.1 to 39.0)		
Week 44	23.8 (19.5 to 28.5)	21.7 (17.6 to 26.2)		
Week 48	17.6 (13.8 to 21.8)	33.9 (29.1 to 39.0)		
Week 52	19.7 (15.8 to 24.2)	22.8 (18.6 to 27.4)		
Week 56	24.3 (20.0 to 29.0)	33.6 (28.8 to 38.7)		
Week 60	20.0 (16.0 to 24.4)	24.4 (20.1 to 29.1)		
Week 64	20.3 (16.3 to 24.7)	35.5 (30.6 to 40.6)		
Week 68	23.2 (19.0 to 27.9)	23.6 (19.3 to 28.2)		
Week 72	17.8 (14.1 to 22.1)	34.7 (29.8 to 39.8)		
Week 76	21.6 (17.5 to 26.2)	23.0 (18.8 to 27.7)		
Week 80	22.7 (18.5 to 27.3)	33.9 (29.1 to 39.0)		
Week 84	18.9 (15.1 to 23.3)	24.7 (20.3 to 29.4)		
Week 88	19.7 (15.8 to 24.2)	31.7 (27.0 to 36.7)		
Week 92	17.3 (13.6 to 21.5)	22.8 (18.6 to 27.4)		
Week 96	15.7 (12.1 to 19.8)	30.4 (25.7 to 35.3)		

Statistical analyses

Statistical analysis title	Percentage of subj with SRF - Study Eye
Statistical analysis description:	
Week 4	
Comparison groups	Brolucizumab 6 mg v Aflibercept 2 mg
Number of subjects included in analysis	739
Analysis specification	Pre-specified
Analysis type	
Method	Regression, Logistic
Parameter estimate	Difference in proportions
Point estimate	-6.6
Confidence interval	
level	95 %
sides	2-sided
lower limit	-13.2
upper limit	-0.3

Statistical analysis title	Percentage of subj with SRF - Study Eye
Statistical analysis description:	
Week 8	
Comparison groups	Brolucizumab 6 mg v Aflibercept 2 mg
Number of subjects included in analysis	739
Analysis specification	Pre-specified
Analysis type	
Method	Regression, Logistic
Parameter estimate	Difference in proportions
Point estimate	-8.5
Confidence interval	
level	95 %
sides	2-sided
lower limit	-13.8
upper limit	-3

Statistical analysis title	Percentage of subj with SRF - Study Eye
Statistical analysis description:	
Week 12	
Comparison groups	Brolucizumab 6 mg v Aflibercept 2 mg

Number of subjects included in analysis	739
Analysis specification	Pre-specified
Analysis type	
Method	Regression, Logistic
Parameter estimate	Difference in proportions
Point estimate	-6.9
Confidence interval	
level	95 %
sides	2-sided
lower limit	-12.2
upper limit	-1.7

Statistical analysis title	Percentage of subj with SRF - Study Eye
Statistical analysis description:	
Week 16	
Comparison groups	Brolucizumab 6 mg v Aflibercept 2 mg
Number of subjects included in analysis	739
Analysis specification	Pre-specified
Analysis type	
Method	Regression, Logistic
Parameter estimate	Difference in proportions
Point estimate	-14.2
Confidence interval	
level	95 %
sides	2-sided
lower limit	-20.8
upper limit	-8.3

Statistical analysis title	Percentage of subj with SRF - Study Eye
Statistical analysis description:	
Week 20	
Comparison groups	Brolucizumab 6 mg v Aflibercept 2 mg
Number of subjects included in analysis	739
Analysis specification	Pre-specified
Analysis type	
Method	Regression, Logistic
Parameter estimate	Difference in proportions
Point estimate	3.1
Confidence interval	
level	95 %
sides	2-sided
lower limit	-2.9
upper limit	9.6

Statistical analysis title	Percentage of subj with SRF - Study Eye
Statistical analysis description:	
Week 24	
Comparison groups	Brolucizumab 6 mg v Aflibercept 2 mg
Number of subjects included in analysis	739
Analysis specification	Pre-specified
Analysis type	
Method	Regression, Logistic
Parameter estimate	Difference in proportions
Point estimate	-19.2
Confidence interval	
level	95 %
sides	2-sided
lower limit	-25.5
upper limit	-13

Statistical analysis title	Percentage of subj with SRF - Study Eye
Statistical analysis description:	
Week 28	
Comparison groups	Brolucizumab 6 mg v Aflibercept 2 mg
Number of subjects included in analysis	739
Analysis specification	Pre-specified
Analysis type	
Method	Regression, Logistic
Parameter estimate	Difference in proportions
Point estimate	-5.9
Confidence interval	
level	95 %
sides	2-sided
lower limit	-11.6
upper limit	-0.4

Statistical analysis title	Percentage of subj with SRF - Study Eye
Statistical analysis description:	
Week 32	
Comparison groups	Brolucizumab 6 mg v Aflibercept 2 mg
Number of subjects included in analysis	739
Analysis specification	Pre-specified
Analysis type	
Method	Regression, Logistic
Parameter estimate	Difference in proportions
Point estimate	-9.8

Confidence interval	
level	95 %
sides	2-sided
lower limit	-16.5
upper limit	-3.5

Statistical analysis title	Percentage of subj with SRF - Study Eye
Statistical analysis description:	
Week 36	
Comparison groups	Brolucizumab 6 mg v Aflibercept 2 mg
Number of subjects included in analysis	739
Analysis specification	Pre-specified
Analysis type	
Method	Regression, Logistic
Parameter estimate	Difference in proportions
Point estimate	-8
Confidence interval	
level	95 %
sides	2-sided
lower limit	-13.6
upper limit	-2.5

Statistical analysis title	Percentage of subj with SRF - Study Eye
Statistical analysis description:	
Week 40	
Comparison groups	Brolucizumab 6 mg v Aflibercept 2 mg
Number of subjects included in analysis	739
Analysis specification	Pre-specified
Analysis type	
Method	Regression, Logistic
Parameter estimate	Difference in proportions
Point estimate	-15.4
Confidence interval	
level	95 %
sides	2-sided
lower limit	-21.5
upper limit	-9.4

Statistical analysis title	Percentage of subj with SRF - Study Eye
Statistical analysis description:	
Week 44	
Comparison groups	Brolucizumab 6 mg v Aflibercept 2 mg

Number of subjects included in analysis	739
Analysis specification	Pre-specified
Analysis type	
Method	Regression, Logistic
Parameter estimate	Difference in proportions
Point estimate	2.5
Confidence interval	
level	95 %
sides	2-sided
lower limit	-3.2
upper limit	8.4

Statistical analysis title	Percentage of subj with SRF - Study Eye
Statistical analysis description:	
Week 48	
Comparison groups	Brolucizumab 6 mg v Aflibercept 2 mg
Number of subjects included in analysis	739
Analysis specification	Pre-specified
Analysis type	
Method	Regression, Logistic
Parameter estimate	Difference in proportions
Point estimate	-15.9
Confidence interval	
level	95 %
sides	2-sided
lower limit	-22.4
upper limit	-10.4

Statistical analysis title	Percentage of subj with SRF - Study Eye
Statistical analysis description:	
Week 52	
Comparison groups	Brolucizumab 6 mg v Aflibercept 2 mg
Number of subjects included in analysis	739
Analysis specification	Pre-specified
Analysis type	
Method	Regression, Logistic
Parameter estimate	Difference in proportions
Point estimate	-2.7
Confidence interval	
level	95 %
sides	2-sided
lower limit	-8.5
upper limit	3.1

Statistical analysis title	Percentage of subj with SRF - Study Eye
Statistical analysis description:	
Week 56	
Comparison groups	Brolucizumab 6 mg v Aflibercept 2 mg
Number of subjects included in analysis	739
Analysis specification	Pre-specified
Analysis type	
Method	Regression, Logistic
Parameter estimate	Difference in proportions
Point estimate	-9
Confidence interval	
level	95 %
sides	2-sided
lower limit	-15.7
upper limit	-2.9

Statistical analysis title	Percentage of subj with SRF - Study Eye
Statistical analysis description:	
Week 60	
Comparison groups	Brolucizumab 6 mg v Aflibercept 2 mg
Number of subjects included in analysis	739
Analysis specification	Pre-specified
Analysis type	
Method	Regression, Logistic
Parameter estimate	Difference in proportions
Point estimate	-3.9
Confidence interval	
level	95 %
sides	2-sided
lower limit	-9.8
upper limit	2.2

Statistical analysis title	Percentage of subj with SRF - Study Eye
Statistical analysis description:	
Week 64	
Comparison groups	Brolucizumab 6 mg v Aflibercept 2 mg
Number of subjects included in analysis	739
Analysis specification	Pre-specified
Analysis type	
Method	Regression, Logistic
Parameter estimate	Difference in proportions
Point estimate	-15.1

Confidence interval	
level	95 %
sides	2-sided
lower limit	-21.3
upper limit	-8.4

Statistical analysis title	Percentage of subj with SRF - Study Eye
Statistical analysis description:	
Week 68	
Comparison groups	Brolucizumab 6 mg v Aflibercept 2 mg
Number of subjects included in analysis	739
Analysis specification	Pre-specified
Analysis type	
Method	Regression, Logistic
Parameter estimate	Difference in proportions
Point estimate	0.1
Confidence interval	
level	95 %
sides	2-sided
lower limit	-6.1
upper limit	6.2

Statistical analysis title	Percentage of subj with SRF - Study Eye
Statistical analysis description:	
Week 72	
Comparison groups	Brolucizumab 6 mg v Aflibercept 2 mg
Number of subjects included in analysis	739
Analysis specification	Pre-specified
Analysis type	
Method	Regression, Logistic
Parameter estimate	Difference in proportions
Point estimate	-16.6
Confidence interval	
level	95 %
sides	2-sided
lower limit	-22.6
upper limit	-10.5

Statistical analysis title	Percentage of subj with SRF - Study Eye
Statistical analysis description:	
Week 76	
Comparison groups	Brolucizumab 6 mg v Aflibercept 2 mg

Number of subjects included in analysis	739
Analysis specification	Pre-specified
Analysis type	
Method	Regression, Logistic
Parameter estimate	Difference in proportions
Point estimate	-1.1
Confidence interval	
level	95 %
sides	2-sided
lower limit	-7
upper limit	5.1

Statistical analysis title	Percentage of subj with SRF - Study Eye
Statistical analysis description:	
Week 80	
Comparison groups	Brolucizumab 6 mg v Aflibercept 2 mg
Number of subjects included in analysis	739
Analysis specification	Pre-specified
Analysis type	
Method	Regression, Logistic
Parameter estimate	Difference in proportions
Point estimate	-11
Confidence interval	
level	95 %
sides	2-sided
lower limit	-17.4
upper limit	-5

Statistical analysis title	Percentage of subj with SRF - Study Eye
Statistical analysis description:	
Week 84	
Comparison groups	Brolucizumab 6 mg v Aflibercept 2 mg
Number of subjects included in analysis	739
Analysis specification	Pre-specified
Analysis type	
Method	Regression, Logistic
Parameter estimate	Difference in proportions
Point estimate	-5.3
Confidence interval	
level	95 %
sides	2-sided
lower limit	-11.3
upper limit	0.7

Statistical analysis title	Percentage of subj with SRF - Study Eye
Statistical analysis description:	
Week 88	
Comparison groups	Brolucizumab 6 mg v Aflibercept 2 mg
Number of subjects included in analysis	739
Analysis specification	Pre-specified
Analysis type	
Method	Regression, Logistic
Parameter estimate	Difference in proportions
Point estimate	-12
Confidence interval	
level	95 %
sides	2-sided
lower limit	-18.9
upper limit	-5.9

Statistical analysis title	Percentage of subj with SRF - Study Eye
Statistical analysis description:	
Week 92	
Comparison groups	Brolucizumab 6 mg v Aflibercept 2 mg
Number of subjects included in analysis	739
Analysis specification	Pre-specified
Analysis type	
Method	Regression, Logistic
Parameter estimate	Difference in proportions
Point estimate	-5.5
Confidence interval	
level	95 %
sides	2-sided
lower limit	-11.4
upper limit	0

Statistical analysis title	Percentage of subj with SRF - Study Eye
Statistical analysis description:	
Week 96	
Comparison groups	Brolucizumab 6 mg v Aflibercept 2 mg
Number of subjects included in analysis	739
Analysis specification	Pre-specified
Analysis type	
Method	Regression, Logistic
Parameter estimate	Difference in proportions
Point estimate	-14.5

Confidence interval	
level	95 %
sides	2-sided
lower limit	-20.3
upper limit	-8.3

Secondary: Percentage of subjects with presence of intraretinal fluid at each post-baseline visit - Study Eye

End point title	Percentage of subjects with presence of intraretinal fluid at each post-baseline visit - Study Eye
-----------------	--

End point description:

Intraretinal fluid was assessed using SD-OCT and recorded as Present/Absent. The presence of intraretinal fluid is an indicator of underlying disease. One eye (study eye) contributed to the analysis.

End point type	Secondary
----------------	-----------

End point timeframe:

Weeks 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44, 48, 52, 56, 60, 64, 68, 72, 76, 80, 84, 88, 92, 96

End point values	Brolucizumab 6 mg	Aflibercept 2 mg		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	370	369		
Units: percentage of subjects				
number (confidence interval 95%)				
Week 4	10.3 (7.4 to 13.8)	8.4 (5.8 to 11.7)		
Week 8	7.0 (4.6 to 10.1)	8.7 (6.0 to 12.0)		
Week 12	7.6 (5.1 to 10.8)	8.7 (6.0 to 12.0)		
Week 16	12.7 (9.5 to 16.5)	11.9 (8.8 to 15.7)		
Week 20	16.5 (12.9 to 20.7)	7.9 (5.3 to 11.1)		
Week 24	10.5 (7.6 to 14.1)	13.0 (9.7 to 16.9)		
Week 28	9.2 (6.4 to 12.6)	6.0 (3.8 to 8.9)		
Week 32	14.3 (10.9 to 18.3)	14.1 (10.7 to 18.1)		
Week 36	7.0 (4.6 to 10.1)	8.4 (5.8 to 11.7)		
Week 40	13.2 (10.0 to 17.1)	13.8 (10.5 to 17.8)		
Week 44	12.4 (9.2 to 16.2)	8.1 (5.6 to 11.4)		
Week 48	11.1 (8.1 to 14.7)	12.5 (9.3 to 16.3)		
Week 52	9.2 (6.4 to 12.6)	7.6 (5.1 to 10.8)		
Week 56	13.0 (9.7 to 16.8)	13.6 (10.2 to 17.5)		

Week 60	8.4 (5.8 to 11.7)	8.4 (5.8 to 11.7)		
Week 64	10.3 (7.4 to 13.8)	11.7 (8.6 to 15.4)		
Week 68	11.1 (8.1 to 14.7)	8.1 (5.6 to 11.4)		
Week 72	11.1 (8.1 to 14.7)	10.6 (7.6 to 14.2)		
Week 76	9.2 (6.4 to 12.6)	8.4 (5.8 to 11.7)		
Week 80	12.4 (9.2 to 16.2)	12.2 (9.0 to 16.0)		
Week 84	10.5 (7.6 to 14.1)	9.2 (6.5 to 12.6)		
Week 88	10.8 (7.8 to 14.4)	10.6 (7.6 to 14.2)		
Week 92	10.8 (7.8 to 14.4)	6.8 (4.4 to 9.8)		
Week 96	10.8 (7.8 to 14.4)	10.3 (7.4 to 13.9)		

Statistical analyses

Statistical analysis title	Percentage of subj with IRF - Study Eye
Statistical analysis description:	
Week 4	
Comparison groups	Brolucizumab 6 mg v Aflibercept 2 mg
Number of subjects included in analysis	739
Analysis specification	Pre-specified
Analysis type	
Method	Regression, Logistic
Parameter estimate	Difference in proportions
Point estimate	1.5
Confidence interval	
level	95 %
sides	2-sided
lower limit	-2.5
upper limit	5.4

Statistical analysis title	Percentage of subj with IRF - Study Eye
Statistical analysis description:	
Week 8	
Comparison groups	Brolucizumab 6 mg v Aflibercept 2 mg
Number of subjects included in analysis	739
Analysis specification	Pre-specified
Analysis type	
Method	Regression, Logistic
Parameter estimate	Difference in proportions
Point estimate	-2.1

Confidence interval	
level	95 %
sides	2-sided
lower limit	-6.1
upper limit	1.7

Statistical analysis title	Percentage of subj with IRF - Study Eye
Statistical analysis description:	
Week 12	
Comparison groups	Brolucizumab 6 mg v Aflibercept 2 mg
Number of subjects included in analysis	739
Analysis specification	Pre-specified
Analysis type	
Method	Regression, Logistic
Parameter estimate	Difference in proportions
Point estimate	-1.4
Confidence interval	
level	95 %
sides	2-sided
lower limit	-5.3
upper limit	2.2

Statistical analysis title	Percentage of subj with IRF - Study Eye
Statistical analysis description:	
Week 16	
Comparison groups	Brolucizumab 6 mg v Aflibercept 2 mg
Number of subjects included in analysis	739
Analysis specification	Pre-specified
Analysis type	
Method	Regression, Logistic
Parameter estimate	Difference in proportions
Point estimate	0.1
Confidence interval	
level	95 %
sides	2-sided
lower limit	-4.5
upper limit	4.4

Statistical analysis title	Percentage of subj with IRF - Study Eye
Statistical analysis description:	
Week 20	
Comparison groups	Brolucizumab 6 mg v Aflibercept 2 mg

Number of subjects included in analysis	739
Analysis specification	Pre-specified
Analysis type	
Method	Regression, Logistic
Parameter estimate	Difference in proportions
Point estimate	8.2
Confidence interval	
level	95 %
sides	2-sided
lower limit	3.9
upper limit	12.8

Statistical analysis title	Percentage of subj with IRF - Study Eye
Statistical analysis description:	
Week 24	
Comparison groups	Brolucizumab 6 mg v Aflibercept 2 mg
Number of subjects included in analysis	739
Analysis specification	Pre-specified
Analysis type	
Method	Regression, Logistic
Parameter estimate	Difference in proportions
Point estimate	-3.2
Confidence interval	
level	95 %
sides	2-sided
lower limit	-7.9
upper limit	1.2

Statistical analysis title	Percentage of subj with IRF - Study Eye
Statistical analysis description:	
Week 28	
Comparison groups	Brolucizumab 6 mg v Aflibercept 2 mg
Number of subjects included in analysis	739
Analysis specification	Pre-specified
Analysis type	
Method	Regression, Logistic
Parameter estimate	Difference in proportions
Point estimate	2.8
Confidence interval	
level	95 %
sides	2-sided
lower limit	-1
upper limit	6.4

Statistical analysis title	Percentage of subj with IRF - Study Eye
Statistical analysis description:	
Week 32	
Comparison groups	Brolucizumab 6 mg v Aflibercept 2 mg
Number of subjects included in analysis	739
Analysis specification	Pre-specified
Analysis type	
Method	Regression, Logistic
Parameter estimate	Difference in proportions
Point estimate	-0.5
Confidence interval	
level	95 %
sides	2-sided
lower limit	-5.5
upper limit	4

Statistical analysis title	Percentage of subj with IRF - Study Eye
Statistical analysis description:	
Week 36	
Comparison groups	Brolucizumab 6 mg v Aflibercept 2 mg
Number of subjects included in analysis	739
Analysis specification	Pre-specified
Analysis type	
Method	Regression, Logistic
Parameter estimate	Difference in proportions
Point estimate	-1.8
Confidence interval	
level	95 %
sides	2-sided
lower limit	-5.6
upper limit	1.8

Statistical analysis title	Percentage of subj with IRF - Study Eye
Statistical analysis description:	
Week 40	
Comparison groups	Brolucizumab 6 mg v Aflibercept 2 mg
Number of subjects included in analysis	739
Analysis specification	Pre-specified
Analysis type	
Method	Regression, Logistic
Parameter estimate	Difference in proportions
Point estimate	-1.3

Confidence interval	
level	95 %
sides	2-sided
lower limit	-6
upper limit	3.1

Statistical analysis title	Percentage of subj with IRF - Study Eye
Statistical analysis description:	
Week 44	
Comparison groups	Brolucizumab 6 mg v Aflibercept 2 mg
Number of subjects included in analysis	739
Analysis specification	Pre-specified
Analysis type	
Method	Regression, Logistic
Parameter estimate	Difference in proportions
Point estimate	3.8
Confidence interval	
level	95 %
sides	2-sided
lower limit	-0.5
upper limit	8

Statistical analysis title	Percentage of subj with IRF - Study Eye
Statistical analysis description:	
Week 48	
Comparison groups	Brolucizumab 6 mg v Aflibercept 2 mg
Number of subjects included in analysis	739
Analysis specification	Pre-specified
Analysis type	
Method	Regression, Logistic
Parameter estimate	Difference in proportions
Point estimate	-2
Confidence interval	
level	95 %
sides	2-sided
lower limit	-6.2
upper limit	2.2

Statistical analysis title	Percentage of subj with IRF - Study Eye
Statistical analysis description:	
Week 52	
Comparison groups	Brolucizumab 6 mg v Aflibercept 2 mg

Number of subjects included in analysis	739
Analysis specification	Pre-specified
Analysis type	
Method	Regression, Logistic
Parameter estimate	Difference in proportions
Point estimate	1.2
Confidence interval	
level	95 %
sides	2-sided
lower limit	-2.5
upper limit	5.1

Statistical analysis title	Percentage of subj with IRF - Study Eye
Statistical analysis description:	
Week 56	
Comparison groups	Brolucizumab 6 mg v Aflibercept 2 mg
Number of subjects included in analysis	739
Analysis specification	Pre-specified
Analysis type	
Method	Regression, Logistic
Parameter estimate	Difference in proportions
Point estimate	-1.2
Confidence interval	
level	95 %
sides	2-sided
lower limit	-5.9
upper limit	3.1

Statistical analysis title	Percentage of subj with IRF - Study Eye
Statistical analysis description:	
Week 60	
Comparison groups	Brolucizumab 6 mg v Aflibercept 2 mg
Number of subjects included in analysis	739
Analysis specification	Pre-specified
Analysis type	
Method	Regression, Logistic
Parameter estimate	Difference in proportions
Point estimate	-0.6
Confidence interval	
level	95 %
sides	2-sided
lower limit	-4.4
upper limit	3.4

Statistical analysis title	Percentage of subj with IRF - Study Eye
Statistical analysis description:	
Week 64	
Comparison groups	Brolucizumab 6 mg v Aflibercept 2 mg
Number of subjects included in analysis	739
Analysis specification	Pre-specified
Analysis type	
Method	Regression, Logistic
Parameter estimate	Difference in proportions
Point estimate	-1.8
Confidence interval	
level	95 %
sides	2-sided
lower limit	-6.2
upper limit	2.1

Statistical analysis title	Percentage of subj with IRF - Study Eye
Statistical analysis description:	
Week 68	
Comparison groups	Brolucizumab 6 mg v Aflibercept 2 mg
Number of subjects included in analysis	739
Analysis specification	Pre-specified
Analysis type	
Method	Regression, Logistic
Parameter estimate	Difference in proportions
Point estimate	2.6
Confidence interval	
level	95 %
sides	2-sided
lower limit	-1.2
upper limit	6.5

Statistical analysis title	Percentage of subj with IRF - Study Eye
Statistical analysis description:	
Week 72	
Comparison groups	Brolucizumab 6 mg v Aflibercept 2 mg
Number of subjects included in analysis	739
Analysis specification	Pre-specified
Analysis type	
Method	Regression, Logistic
Parameter estimate	Difference in proportions
Point estimate	0.2

Confidence interval	
level	95 %
sides	2-sided
lower limit	-4.2
upper limit	4.3

Statistical analysis title	Percentage of subj with IRF - Study Eye
Statistical analysis description:	
Week 76	
Comparison groups	Brolucizumab 6 mg v Aflibercept 2 mg
Number of subjects included in analysis	739
Analysis specification	Pre-specified
Analysis type	
Method	Regression, Logistic
Parameter estimate	Difference in proportions
Point estimate	0.4
Confidence interval	
level	95 %
sides	2-sided
lower limit	-3.5
upper limit	4.2

Statistical analysis title	Percentage of subj with IRF - Study Eye
Statistical analysis description:	
Week 80	
Comparison groups	Brolucizumab 6 mg v Aflibercept 2 mg
Number of subjects included in analysis	739
Analysis specification	Pre-specified
Analysis type	
Method	Regression, Logistic
Parameter estimate	Difference in proportions
Point estimate	-0.3
Confidence interval	
level	95 %
sides	2-sided
lower limit	-4.8
upper limit	4.3

Statistical analysis title	Percentage of subj with IRF - Study Eye
Statistical analysis description:	
Week 84	
Comparison groups	Brolucizumab 6 mg v Aflibercept 2 mg

Number of subjects included in analysis	739
Analysis specification	Pre-specified
Analysis type	
Method	Regression, Logistic
Parameter estimate	Difference in proportions
Point estimate	0.9
Confidence interval	
level	95 %
sides	2-sided
lower limit	-3.3
upper limit	5.2

Statistical analysis title	Percentage of subj with IRF - Study Eye
Statistical analysis description:	
Week 88	
Comparison groups	Brolucizumab 6 mg v Aflibercept 2 mg
Number of subjects included in analysis	739
Analysis specification	Pre-specified
Analysis type	
Method	Regression, Logistic
Parameter estimate	Difference in proportions
Point estimate	-0.1
Confidence interval	
level	95 %
sides	2-sided
lower limit	-4.5
upper limit	3.9

Statistical analysis title	Percentage of subj with IRF - Study Eye
Statistical analysis description:	
Week 92	
Comparison groups	Brolucizumab 6 mg v Aflibercept 2 mg
Number of subjects included in analysis	739
Analysis specification	Pre-specified
Analysis type	
Method	Regression, Logistic
Parameter estimate	Difference in proportions
Point estimate	3.8
Confidence interval	
level	95 %
sides	2-sided
lower limit	-0.1
upper limit	8

Statistical analysis title	Percentage of subj with IRF - Study Eye
Statistical analysis description:	
Week 96	
Comparison groups	Brolucizumab 6 mg v Aflibercept 2 mg
Number of subjects included in analysis	739
Analysis specification	Pre-specified
Analysis type	
Method	Regression, Logistic
Parameter estimate	Difference in proportions
Point estimate	0.2
Confidence interval	
level	95 %
sides	2-sided
lower limit	-4.3
upper limit	4.6

Secondary: Percentage of subjects with presence of sub-retinal pigment epithelium (RPE) fluid at each post-baseline visit - Study Eye

End point title	Percentage of subjects with presence of sub-retinal pigment epithelium (RPE) fluid at each post-baseline visit - Study Eye
End point description:	
Sub-retinal pigment epithelium (RPE) fluid was assessed using SD-OCT and recorded as Present/Absent. The presence of sub-RPE fluid is an indicator of underlying disease. One eye (study eye) contributed to the analysis.	
End point type	Secondary
End point timeframe:	
Weeks 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44, 48, 52, 56, 60, 64, 68, 72, 76, 80, 84, 88, 92, 96	

End point values	Brolucizumab 6 mg	Aflibercept 2 mg		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	370	369		
Units: percentage of subjects				
number (confidence interval 95%)				
Week 4	18.1 (14.3 to 22.4)	21.7 (17.6 to 26.2)		
Week 8	16.2 (12.6 to 20.4)	18.7 (14.9 to 23.1)		
Week 12	15.9 (12.4 to 20.1)	17.6 (13.9 to 21.9)		
Week 16	15.9 (12.4 to 20.1)	23.8 (19.6 to 28.5)		
Week 20	17.3 (13.6 to 21.5)	16.0 (12.4 to 20.1)		
Week 24	10.5 (7.6 to 14.1)	18.4 (14.6 to 22.8)		
Week 28	13.8 (10.4 to 17.7)	15.7 (12.2 to 19.8)		
Week 32	18.1 (14.3 to 22.4)	23.3 (19.1 to 28.0)		

Week 36	13.2 (10.0 to 17.1)	18.7 (14.9 to 23.1)		
Week 40	15.4 (11.9 to 19.5)	21.4 (17.3 to 26.0)		
Week 44	14.9 (11.4 to 18.9)	14.4 (10.9 to 18.4)		
Week 48	13.0 (9.7 to 16.8)	22.0 (17.8 to 26.5)		
Week 52	17.3 (13.6 to 21.5)	19.0 (15.1 to 23.3)		
Week 56	19.7 (15.8 to 24.2)	24.9 (20.6 to 29.7)		
Week 60	15.9 (12.4 to 20.1)	21.7 (17.6 to 26.2)		
Week 64	19.2 (15.3 to 23.6)	24.1 (19.8 to 28.8)		
Week 68	18.1 (14.3 to 22.4)	23.3 (19.1 to 28.0)		
Week 72	17.0 (13.3 to 21.3)	23.8 (19.6 to 28.5)		
Week 76	16.5 (12.9 to 20.7)	22.0 (17.8 to 26.5)		
Week 80	21.1 (17.0 to 25.6)	27.6 (23.1 to 32.5)		
Week 84	23.2 (19.0 to 27.9)	24.7 (20.3 to 29.4)		
Week 88	21.9 (17.8 to 26.5)	26.8 (22.4 to 31.7)		
Week 92	17.3 (13.6 to 21.5)	23.0 (18.8 to 27.7)		
Week 96	16.5 (12.9 to 20.7)	22.5 (18.3 to 27.1)		

Statistical analyses

Statistical analysis title	Percentage of subjects with sub-RPE - Study Eye
Statistical analysis description:	
Week 4	
Comparison groups	Brolucizumab 6 mg v Aflibercept 2 mg
Number of subjects included in analysis	739
Analysis specification	Pre-specified
Analysis type	
Method	Regression, Logistic
Parameter estimate	Difference in proportions
Point estimate	-3.5
Confidence interval	
level	95 %
sides	2-sided
lower limit	-8.9
upper limit	1.5

Statistical analysis title	Percentage of subjects with sub-RPE - Study Eye
----------------------------	---

Statistical analysis description:	
Week 8	
Comparison groups	Brolucizumab 6 mg v Aflibercept 2 mg
Number of subjects included in analysis	739
Analysis specification	Pre-specified
Analysis type	
Method	Regression, Logistic
Parameter estimate	Difference in proportions
Point estimate	-2.6
Confidence interval	
level	95 %
sides	2-sided
lower limit	-7.6
upper limit	2.5

Statistical analysis title	Percentage of subjects with sub-RPE - Study Eye
Statistical analysis description:	
Week 12	
Comparison groups	Brolucizumab 6 mg v Aflibercept 2 mg
Number of subjects included in analysis	739
Analysis specification	Pre-specified
Analysis type	
Method	Regression, Logistic
Parameter estimate	Difference in proportions
Point estimate	-1.6
Confidence interval	
level	95 %
sides	2-sided
lower limit	-6.9
upper limit	3.7

Statistical analysis title	Percentage of subjects with sub-RPE - Study Eye
Statistical analysis description:	
Week 16	
Comparison groups	Brolucizumab 6 mg v Aflibercept 2 mg
Number of subjects included in analysis	739
Analysis specification	Pre-specified
Analysis type	
Method	Regression, Logistic
Parameter estimate	Difference in proportions
Point estimate	-7.8
Confidence interval	
level	95 %
sides	2-sided
lower limit	-13
upper limit	-2.7

Statistical analysis title	Percentage of subjects with sub-RPE - Study Eye
Statistical analysis description:	
Week 20	
Comparison groups	Brolucizumab 6 mg v Aflibercept 2 mg
Number of subjects included in analysis	739
Analysis specification	Pre-specified
Analysis type	
Method	Regression, Logistic
Parameter estimate	Difference in proportions
Point estimate	1.3
Confidence interval	
level	95 %
sides	2-sided
lower limit	-3.6
upper limit	6.2

Statistical analysis title	Percentage of subjects with sub-RPE - Study Eye
Statistical analysis description:	
Week 24	
Comparison groups	Brolucizumab 6 mg v Aflibercept 2 mg
Number of subjects included in analysis	739
Analysis specification	Pre-specified
Analysis type	
Method	Regression, Logistic
Parameter estimate	Difference in proportions
Point estimate	-7.9
Confidence interval	
level	95 %
sides	2-sided
lower limit	-12.6
upper limit	-3.1

Statistical analysis title	Percentage of subjects with sub-RPE - Study Eye
Statistical analysis description:	
Week 28	
Comparison groups	Brolucizumab 6 mg v Aflibercept 2 mg
Number of subjects included in analysis	739
Analysis specification	Pre-specified
Analysis type	
Method	Regression, Logistic
Parameter estimate	Difference in proportions
Point estimate	-2.1

Confidence interval	
level	95 %
sides	2-sided
lower limit	-6.8
upper limit	2.7

Statistical analysis title	Percentage of subjects with sub-RPE - Study Eye
Statistical analysis description:	
Week 32	
Comparison groups	Brolucizumab 6 mg v Aflibercept 2 mg
Number of subjects included in analysis	739
Analysis specification	Pre-specified
Analysis type	
Method	Regression, Logistic
Parameter estimate	Difference in proportions
Point estimate	-5.3
Confidence interval	
level	95 %
sides	2-sided
lower limit	-10.5
upper limit	-0.3

Statistical analysis title	Percentage of subjects with sub-RPE - Study Eye
Statistical analysis description:	
Week 36	
Comparison groups	Brolucizumab 6 mg v Aflibercept 2 mg
Number of subjects included in analysis	739
Analysis specification	Pre-specified
Analysis type	
Method	Regression, Logistic
Parameter estimate	Difference in proportions
Point estimate	-5.5
Confidence interval	
level	95 %
sides	2-sided
lower limit	-10.3
upper limit	-0.4

Statistical analysis title	Percentage of subjects with sub-RPE - Study Eye
Statistical analysis description:	
Week 40	
Comparison groups	Brolucizumab 6 mg v Aflibercept 2 mg

Number of subjects included in analysis	739
Analysis specification	Pre-specified
Analysis type	
Method	Regression, Logistic
Parameter estimate	Difference in proportions
Point estimate	-6
Confidence interval	
level	95 %
sides	2-sided
lower limit	-11.2
upper limit	-0.5

Statistical analysis title	Percentage of subjects with sub-RPE - Study Eye
Statistical analysis description:	
Week 44	
Comparison groups	Brolucizumab 6 mg v Aflibercept 2 mg
Number of subjects included in analysis	739
Analysis specification	Pre-specified
Analysis type	
Method	Regression, Logistic
Parameter estimate	Difference in proportions
Point estimate	0.5
Confidence interval	
level	95 %
sides	2-sided
lower limit	-4.8
upper limit	5.6

Statistical analysis title	Percentage of subjects with sub-RPE - Study Eye
Statistical analysis description:	
Week 48	
Comparison groups	Brolucizumab 6 mg v Aflibercept 2 mg
Number of subjects included in analysis	739
Analysis specification	Pre-specified
Analysis type	
Method	Regression, Logistic
Parameter estimate	Difference in proportions
Point estimate	-9.1
Confidence interval	
level	95 %
sides	2-sided
lower limit	-13.8
upper limit	-3.9

Statistical analysis title	Percentage of subjects with sub-RPE - Study Eye
Statistical analysis description:	
Week 52	
Comparison groups	Brolucizumab 6 mg v Aflibercept 2 mg
Number of subjects included in analysis	739
Analysis specification	Pre-specified
Analysis type	
Method	Regression, Logistic
Parameter estimate	Difference in proportions
Point estimate	-1.8
Confidence interval	
level	95 %
sides	2-sided
lower limit	-7.1
upper limit	3.5

Statistical analysis title	Percentage of subjects with sub-RPE - Study Eye
Statistical analysis description:	
Week 56	
Comparison groups	Brolucizumab 6 mg v Aflibercept 2 mg
Number of subjects included in analysis	739
Analysis specification	Pre-specified
Analysis type	
Method	Regression, Logistic
Parameter estimate	Difference in proportions
Point estimate	-5.2
Confidence interval	
level	95 %
sides	2-sided
lower limit	-11.1
upper limit	0.1

Statistical analysis title	Percentage of subjects with sub-RPE - Study Eye
Statistical analysis description:	
Week 60	
Comparison groups	Brolucizumab 6 mg v Aflibercept 2 mg
Number of subjects included in analysis	739
Analysis specification	Pre-specified
Analysis type	
Method	Regression, Logistic
Parameter estimate	Difference in proportions
Point estimate	-5.6

Confidence interval	
level	95 %
sides	2-sided
lower limit	-10.9
upper limit	-0.5

Statistical analysis title	Percentage of subjects with sub-RPE - Study Eye
Statistical analysis description:	
Week 64	
Comparison groups	Brolucizumab 6 mg v Aflibercept 2 mg
Number of subjects included in analysis	739
Analysis specification	Pre-specified
Analysis type	
Method	Regression, Logistic
Parameter estimate	Difference in proportions
Point estimate	-5.1
Confidence interval	
level	95 %
sides	2-sided
lower limit	-10.9
upper limit	0.6

Statistical analysis title	Percentage of subjects with sub-RPE - Study Eye
Statistical analysis description:	
Week 68	
Comparison groups	Brolucizumab 6 mg v Aflibercept 2 mg
Number of subjects included in analysis	739
Analysis specification	Pre-specified
Analysis type	
Method	Regression, Logistic
Parameter estimate	Difference in proportions
Point estimate	-5.2
Confidence interval	
level	95 %
sides	2-sided
lower limit	-11
upper limit	-0.1

Statistical analysis title	Percentage of subjects with sub-RPE - Study Eye
Statistical analysis description:	
Week 72	
Comparison groups	Brolucizumab 6 mg v Aflibercept 2 mg

Number of subjects included in analysis	739
Analysis specification	Pre-specified
Analysis type	
Method	Regression, Logistic
Parameter estimate	Difference in proportions
Point estimate	-6.9
Confidence interval	
level	95 %
sides	2-sided
lower limit	-12.5
upper limit	-1.2

Statistical analysis title	Percentage of subjects with sub-RPE - Study Eye
Statistical analysis description:	
Week 76	
Comparison groups	Brolucizumab 6 mg v Aflibercept 2 mg
Number of subjects included in analysis	739
Analysis specification	Pre-specified
Analysis type	
Method	Regression, Logistic
Parameter estimate	Difference in proportions
Point estimate	-5.5
Confidence interval	
level	95 %
sides	2-sided
lower limit	-10.7
upper limit	-0.3

Statistical analysis title	Percentage of subjects with sub-RPE - Study Eye
Statistical analysis description:	
Week 80	
Comparison groups	Brolucizumab 6 mg v Aflibercept 2 mg
Number of subjects included in analysis	739
Analysis specification	Pre-specified
Analysis type	
Method	Regression, Logistic
Parameter estimate	Difference in proportions
Point estimate	-6.5
Confidence interval	
level	95 %
sides	2-sided
lower limit	-12.4
upper limit	-0.9

Statistical analysis title	Percentage of subjects with sub-RPE - Study Eye
Statistical analysis description:	
Week 84	
Comparison groups	Brolucizumab 6 mg v Aflibercept 2 mg
Number of subjects included in analysis	739
Analysis specification	Pre-specified
Analysis type	
Method	Regression, Logistic
Parameter estimate	Difference in proportions
Point estimate	-1.4
Confidence interval	
level	95 %
sides	2-sided
lower limit	-7
upper limit	4.4

Statistical analysis title	Percentage of subjects with sub-RPE - Study Eye
Statistical analysis description:	
Week 88	
Comparison groups	Brolucizumab 6 mg v Aflibercept 2 mg
Number of subjects included in analysis	739
Analysis specification	Pre-specified
Analysis type	
Method	Regression, Logistic
Parameter estimate	Difference in proportions
Point estimate	-4.8
Confidence interval	
level	95 %
sides	2-sided
lower limit	-10.5
upper limit	1.3

Statistical analysis title	Percentage of subjects with sub-RPE - Study Eye
Statistical analysis description:	
Week 92	
Comparison groups	Brolucizumab 6 mg v Aflibercept 2 mg
Number of subjects included in analysis	739
Analysis specification	Pre-specified
Analysis type	
Method	Regression, Logistic
Parameter estimate	Difference in proportions
Point estimate	-5.6

Confidence interval	
level	95 %
sides	2-sided
lower limit	-11.4
upper limit	0.5

Statistical analysis title	Percentage of subjects with sub-RPE - Study Eye
Statistical analysis description:	
Week 96	
Comparison groups	Brolucizumab 6 mg v Aflibercept 2 mg
Number of subjects included in analysis	739
Analysis specification	Pre-specified
Analysis type	
Method	Regression, Logistic
Parameter estimate	Difference in proportions
Point estimate	-5.9
Confidence interval	
level	95 %
sides	2-sided
lower limit	-11.5
upper limit	-0.3

Secondary: Percentage of subjects with presence of subretinal and/or intraretinal fluid (central subfield) at each post-baseline visit - Study Eye

End point title	Percentage of subjects with presence of subretinal and/or intraretinal fluid (central subfield) at each post-baseline visit - Study Eye
End point description:	
Subretinal fluid and intraretinal fluid were assessed using SD-OCT and recorded as Present/Absent. The presence of subretinal and/or intraretinal fluid is an indicator of underlying disease. 95% confidence interval (CI) for binomial proportions was based on Clopper-Pearson exact method. One eye (study eye) contributed to the analysis.	
End point type	Secondary
End point timeframe:	
Weeks 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44, 48, 52, 56, 60, 64, 68, 72, 76, 80, 84, 88, 92, 96	

End point values	Brolucizumab 6 mg	Aflibercept 2 mg		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	370	369		
Units: percentage of subjects				
number (confidence interval 95%)				
Week 4	35.9 (31.1 to 41.1)	42.8 (37.7 to 48.0)		
Week 8	20.3 (16.3 to 24.7)	29.3 (24.7 to 34.2)		

Week 12	19.2 (15.3 to 23.6)	27.6 (23.1 to 32.5)		
Week 16	29.7 (25.1 to 34.7)	44.7 (39.6 to 49.9)		
Week 20	37.8 (32.9 to 43.0)	29.8 (25.2 to 34.8)		
Week 24	25.7 (21.3 to 30.4)	45.3 (40.1 to 50.5)		
Week 28	23.8 (19.5 to 28.5)	27.4 (22.9 to 32.2)		
Week 32	34.6 (29.8 to 39.7)	43.9 (38.8 to 49.1)		
Week 36	19.5 (15.5 to 23.9)	28.5 (23.9 to 33.4)		
Week 40	28.4 (23.8 to 33.3)	44.4 (39.3 to 49.7)		
Week 44	33.0 (28.2 to 38.0)	29.3 (24.7 to 34.2)		
Week 48	25.9 (21.6 to 30.7)	43.6 (38.5 to 48.9)		
Week 52	27.0 (22.6 to 31.9)	29.5 (24.9 to 34.5)		
Week 56	34.3 (29.5 to 39.4)	43.1 (38.0 to 48.3)		
Week 60	26.8 (22.3 to 31.6)	32.0 (27.2 to 37.0)		
Week 64	28.4 (23.8 to 33.3)	43.4 (38.2 to 48.6)		
Week 68	31.9 (27.2 to 36.9)	30.6 (26.0 to 35.6)		
Week 72	27.0 (22.6 to 31.9)	41.5 (36.4 to 46.7)		
Week 76	29.5 (24.9 to 34.4)	29.8 (25.2 to 34.8)		
Week 80	32.7 (27.9 to 37.7)	42.5 (37.4 to 47.8)		
Week 84	27.3 (22.8 to 32.1)	31.4 (26.7 to 36.4)		
Week 88	28.4 (23.8 to 33.3)	38.8 (33.8 to 43.9)		
Week 92	25.7 (21.3 to 30.4)	28.2 (23.6 to 33.1)		
Week 96	24.6 (20.3 to 29.3)	38.2 (33.2 to 43.4)		

Statistical analyses

Statistical analysis title	Percent subj with SRF and/or IRF - Study Eye
Statistical analysis description: Week 4	
Comparison groups	Brolucizumab 6 mg v Aflibercept 2 mg

Number of subjects included in analysis	739
Analysis specification	Pre-specified
Analysis type	
Method	Regression, Logistic
Parameter estimate	Difference in proportions
Point estimate	-6.9
Confidence interval	
level	95 %
sides	2-sided
lower limit	-14.2
upper limit	0.2

Statistical analysis title	Percent subj with SRF and/or IRF - Study Eye
Statistical analysis description:	
Week 8	
Comparison groups	Brolucizumab 6 mg v Aflibercept 2 mg
Number of subjects included in analysis	739
Analysis specification	Pre-specified
Analysis type	
Method	Regression, Logistic
Parameter estimate	Difference in proportions
Point estimate	-9.2
Confidence interval	
level	95 %
sides	2-sided
lower limit	-15.5
upper limit	-2.5

Statistical analysis title	Percent subj with SRF and/or IRF - Study Eye
Statistical analysis description:	
Week 12	
Comparison groups	Brolucizumab 6 mg v Aflibercept 2 mg
Number of subjects included in analysis	739
Analysis specification	Pre-specified
Analysis type	
Method	Regression, Logistic
Parameter estimate	Difference in proportions
Point estimate	-8.7
Confidence interval	
level	95 %
sides	2-sided
lower limit	-15
upper limit	-2.6

Statistical analysis title	Percent subj with SRF and/or IRF - Study Eye
Statistical analysis description:	
Week 16	
Comparison groups	Brolucizumab 6 mg v Aflibercept 2 mg
Number of subjects included in analysis	739
Analysis specification	Pre-specified
Analysis type	
Method	Regression, Logistic
Parameter estimate	Difference in proportions
Point estimate	-15.7
Confidence interval	
level	95 %
sides	2-sided
lower limit	-22.9
upper limit	-9

Statistical analysis title	Percent subj with SRF and/or IRF - Study Eye
Statistical analysis description:	
Week 20	
Comparison groups	Brolucizumab 6 mg v Aflibercept 2 mg
Number of subjects included in analysis	739
Analysis specification	Pre-specified
Analysis type	
Method	Regression, Logistic
Parameter estimate	Difference in proportions
Point estimate	7.7
Confidence interval	
level	95 %
sides	2-sided
lower limit	0.9
upper limit	14.8

Statistical analysis title	Percent subj with SRF and/or IRF - Study Eye
Statistical analysis description:	
Week 24	
Comparison groups	Brolucizumab 6 mg v Aflibercept 2 mg
Number of subjects included in analysis	739
Analysis specification	Pre-specified
Analysis type	
Method	Regression, Logistic
Parameter estimate	Difference in proportions
Point estimate	-20

Confidence interval	
level	95 %
sides	2-sided
lower limit	-27.3
upper limit	-13.1

Statistical analysis title	Percent subj with SRF and/or IRF - Study Eye
Statistical analysis description:	
Week 28	
Comparison groups	Brolucizumab 6 mg v Aflibercept 2 mg
Number of subjects included in analysis	739
Analysis specification	Pre-specified
Analysis type	
Method	Regression, Logistic
Parameter estimate	Difference in proportions
Point estimate	-3.9
Confidence interval	
level	95 %
sides	2-sided
lower limit	-10.4
upper limit	2.4

Statistical analysis title	Percent subj with SRF and/or IRF - Study Eye
Statistical analysis description:	
Week 32	
Comparison groups	Brolucizumab 6 mg v Aflibercept 2 mg
Number of subjects included in analysis	739
Analysis specification	Pre-specified
Analysis type	
Method	Regression, Logistic
Parameter estimate	Difference in proportions
Point estimate	-9.7
Confidence interval	
level	95 %
sides	2-sided
lower limit	-16.7
upper limit	-2.5

Statistical analysis title	Percent subj with SRF and/or IRF - Study Eye
Statistical analysis description:	
Week 36	
Comparison groups	Brolucizumab 6 mg v Aflibercept 2 mg

Number of subjects included in analysis	739
Analysis specification	Pre-specified
Analysis type	
Method	Regression, Logistic
Parameter estimate	Difference in proportions
Point estimate	-9.4
Confidence interval	
level	95 %
sides	2-sided
lower limit	-15.8
upper limit	-3.4

Statistical analysis title	Percent subj with SRF and/or IRF - Study Eye
Statistical analysis description:	
Week 40	
Comparison groups	Brolucizumab 6 mg v Aflibercept 2 mg
Number of subjects included in analysis	739
Analysis specification	Pre-specified
Analysis type	
Method	Regression, Logistic
Parameter estimate	Difference in proportions
Point estimate	-16.5
Confidence interval	
level	95 %
sides	2-sided
lower limit	-23.4
upper limit	-9.6

Statistical analysis title	Percent subj with SRF and/or IRF - Study Eye
Statistical analysis description:	
Week 44	
Comparison groups	Brolucizumab 6 mg v Aflibercept 2 mg
Number of subjects included in analysis	739
Analysis specification	Pre-specified
Analysis type	
Method	Regression, Logistic
Parameter estimate	Difference in proportions
Point estimate	3.4
Confidence interval	
level	95 %
sides	2-sided
lower limit	-3.3
upper limit	10.4

Statistical analysis title	Percent subj with SRF and/or IRF - Study Eye
Statistical analysis description:	
Week 48	
Comparison groups	Brolucizumab 6 mg v Aflibercept 2 mg
Number of subjects included in analysis	739
Analysis specification	Pre-specified
Analysis type	
Method	Regression, Logistic
Parameter estimate	Difference in proportions
Point estimate	-18.1
Confidence interval	
level	95 %
sides	2-sided
lower limit	-24.9
upper limit	-11.8

Statistical analysis title	Percent subj with SRF and/or IRF - Study Eye
Statistical analysis description:	
Week 52	
Comparison groups	Brolucizumab 6 mg v Aflibercept 2 mg
Number of subjects included in analysis	739
Analysis specification	Pre-specified
Analysis type	
Method	Regression, Logistic
Parameter estimate	Difference in proportions
Point estimate	-3
Confidence interval	
level	95 %
sides	2-sided
lower limit	-9.2
upper limit	3.2

Statistical analysis title	Percent subj with SRF and/or IRF - Study Eye
Statistical analysis description:	
Week 56	
Comparison groups	Brolucizumab 6 mg v Aflibercept 2 mg
Number of subjects included in analysis	739
Analysis specification	Pre-specified
Analysis type	
Method	Regression, Logistic
Parameter estimate	Difference in proportions
Point estimate	-9.4

Confidence interval	
level	95 %
sides	2-sided
lower limit	-16.3
upper limit	-2.8

Statistical analysis title	Percent subj with SRF and/or IRF - Study Eye
Statistical analysis description:	
Week 60	
Comparison groups	Brolucizumab 6 mg v Aflibercept 2 mg
Number of subjects included in analysis	739
Analysis specification	Pre-specified
Analysis type	
Method	Regression, Logistic
Parameter estimate	Difference in proportions
Point estimate	-5.7
Confidence interval	
level	95 %
sides	2-sided
lower limit	-12.5
upper limit	1.1

Statistical analysis title	Percent subj with SRF and/or IRF - Study Eye
Statistical analysis description:	
Week 64	
Comparison groups	Brolucizumab 6 mg v Aflibercept 2 mg
Number of subjects included in analysis	739
Analysis specification	Pre-specified
Analysis type	
Method	Regression, Logistic
Parameter estimate	Difference in proportions
Point estimate	-15.5
Confidence interval	
level	95 %
sides	2-sided
lower limit	-21.9
upper limit	-8.5

Statistical analysis title	Percent subj with SRF and/or IRF - Study Eye
Statistical analysis description:	
Week 68	
Comparison groups	Brolucizumab 6 mg v Aflibercept 2 mg

Number of subjects included in analysis	739
Analysis specification	Pre-specified
Analysis type	
Method	Regression, Logistic
Parameter estimate	Difference in proportions
Point estimate	0.9
Confidence interval	
level	95 %
sides	2-sided
lower limit	-5.9
upper limit	7.5

Statistical analysis title	Percent subj with SRF and/or IRF - Study Eye
Statistical analysis description:	
Week 72	
Comparison groups	Brolucizumab 6 mg v Aflibercept 2 mg
Number of subjects included in analysis	739
Analysis specification	Pre-specified
Analysis type	
Method	Regression, Logistic
Parameter estimate	Difference in proportions
Point estimate	-14.9
Confidence interval	
level	95 %
sides	2-sided
lower limit	-21.4
upper limit	-8.1

Statistical analysis title	Percent subj with SRF and/or IRF - Study Eye
Statistical analysis description:	
Week 76	
Comparison groups	Brolucizumab 6 mg v Aflibercept 2 mg
Number of subjects included in analysis	739
Analysis specification	Pre-specified
Analysis type	
Method	Regression, Logistic
Parameter estimate	Difference in proportions
Point estimate	-0.8
Confidence interval	
level	95 %
sides	2-sided
lower limit	-7.5
upper limit	5.4

Statistical analysis title	Percent subj with SRF and/or IRF - Study Eye
Statistical analysis description:	
Week 80	
Comparison groups	Brolucizumab 6 mg v Aflibercept 2 mg
Number of subjects included in analysis	739
Analysis specification	Pre-specified
Analysis type	
Method	Regression, Logistic
Parameter estimate	Difference in proportions
Point estimate	-10.4
Confidence interval	
level	95 %
sides	2-sided
lower limit	-17.2
upper limit	-3.4

Statistical analysis title	Percent subj with SRF and/or IRF - Study Eye
Statistical analysis description:	
Week 84	
Comparison groups	Brolucizumab 6 mg v Aflibercept 2 mg
Number of subjects included in analysis	739
Analysis specification	Pre-specified
Analysis type	
Method	Regression, Logistic
Parameter estimate	Difference in proportions
Point estimate	-4.5
Confidence interval	
level	95 %
sides	2-sided
lower limit	-11.4
upper limit	2.3

Statistical analysis title	Percent subj with SRF and/or IRF - Study Eye
Statistical analysis description:	
Week 88	
Comparison groups	Brolucizumab 6 mg v Aflibercept 2 mg
Number of subjects included in analysis	739
Analysis specification	Pre-specified
Analysis type	
Method	Regression, Logistic
Parameter estimate	Difference in proportions
Point estimate	-11

Confidence interval	
level	95 %
sides	2-sided
lower limit	-18.2
upper limit	-4.1

Statistical analysis title	Percent subj with SRF and/or IRF - Study Eye
Statistical analysis description:	
Week 92	
Comparison groups	Brolucizumab 6 mg v Aflibercept 2 mg
Number of subjects included in analysis	739
Analysis specification	Pre-specified
Analysis type	
Method	Regression, Logistic
Parameter estimate	Difference in proportions
Point estimate	-2.9
Confidence interval	
level	95 %
sides	2-sided
lower limit	-9.4
upper limit	3.5

Statistical analysis title	Percent subj with SRF and/or IRF - Study Eye
Statistical analysis description:	
Week 96	
Comparison groups	Brolucizumab 6 mg v Aflibercept 2 mg
Number of subjects included in analysis	739
Analysis specification	Pre-specified
Analysis type	
Method	Regression, Logistic
Parameter estimate	Difference in proportions
Point estimate	-14.1
Confidence interval	
level	95 %
sides	2-sided
lower limit	-21.3
upper limit	-7.2

Secondary: Percentage of subjects with disease activity present (q8 treatment need = "yes") at Week 16 - Study Eye

End point title	Percentage of subjects with disease activity present (q8 treatment need = "yes") at Week 16 - Study Eye
-----------------	---

End point description:

A disease activity assessment (DAA) was performed to identify q8 treatment need. 95% confidence

interval (CI) for binomial proportions is based on Clopper-Pearson exact method. One eye (study eye) contributed to the analysis. Hypothesis testing not pre-specified.

End point type	Secondary
End point timeframe:	
Week 16	

End point values	Brolucizumab 6 mg	Aflibercept 2 mg		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	370	369		
Units: percentage of subjects				
number (confidence interval 95%)	22.8 (18.6 to 27.5)	32.1 (27.3 to 37.2)		

Statistical analyses

No statistical analyses for this end point

Secondary: Change from baseline in Visual Function Questionnaire (VFQ-25) Composite Score at Week 24, Week 48, Week 72, and Week 96

End point title	Change from baseline in Visual Function Questionnaire (VFQ-25) Composite Score at Week 24, Week 48, Week 72, and Week 96
-----------------	--

End point description:

The National Eye Institute Visual Function Questionnaire-25 (VFQ-25) is a validated questionnaire that collects 25 vision-targeted responses from AMD subjects. The 25 questions pertain to global vision rating (1), difficulty with near vision activities (3), difficulty with distance vision activities (3), limitations in social functioning due to vision (2), role limitations due to vision (2), dependency on others due to vision (3), mental health symptoms due to vision (4), driving difficulties (3), limitations with peripheral (1) and color vision (1), and ocular pain (2). Each response is converted to a 0 to 100 sub-scale, with the lowest and highest possible scores set at 0 and 100 points, respectively. The overall composite score (0 to 100) is obtained by averaging the 25 sub-scale scores. A high score represents better functioning.

End point type	Secondary
End point timeframe:	
Baseline, Weeks 24, 48, 72, 96	

End point values	Brolucizumab 6 mg	Aflibercept 2 mg		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	370	369		
Units: score on a scale				
arithmetic mean (standard deviation)				
Change from baseline at Week 24	3.9 (± 10.09)	3.5 (± 10.95)		
Change from baseline at Week 48	4.8 (± 11.57)	3.6 (± 11.88)		
Change from baseline at Week 72	5.0 (± 13.38)	3.2 (± 12.30)		
Change from baseline at Week 96	3.8 (± 14.06)	2.6 (± 13.11)		

Statistical analyses

No statistical analyses for this end point

Secondary: Percentage of Subjects With Induced or Boosted Anti-drug Antibody (ADA) status at Week 48 (brolucizumab only)

End point title	Percentage of Subjects With Induced or Boosted Anti-drug Antibody (ADA) status at Week 48 (brolucizumab only) ^[7]
-----------------	--

End point description:

Serum samples were collected and assessed for anti-drug antibody status. Subjects were categorized as ADA negative when one of the following was met: ADA negative at all time points (predose and postdose); ADA negative at predose and no titer values above 10 at all other time points; or ADA titer of 10 at predose but negative at all other time points. ADA induced was defined as ADA negative at predose with postdose titer value greater than or equal to a titer of 30 at any timepoint. ADA boosted was defined as ADA positive at predose with postdose titer values that increased by at least two dilutions (9-fold) from their respective predose value at any time point.

End point type	Secondary
----------------	-----------

End point timeframe:

Week 48

Notes:

[7] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period. Justification: This outcome measure was pre-specified for brolucizumab 6 mg arm only.

End point values	Brolucizumab 6 mg			
Subject group type	Reporting group			
Number of subjects analysed	370			
Units: percentage of subjects				
number (not applicable)	18.1			

Statistical analyses

No statistical analyses for this end point

Secondary: Percentage of subjects with intraretinal hemorrhage (central subfield) present at the visit while absent at baseline at each treatment - Study Eye

End point title	Percentage of subjects with intraretinal hemorrhage (central subfield) present at the visit while absent at baseline at each treatment - Study Eye
-----------------	--

End point description:

Intraretinal hemorrhage was assessed using SD-OCT and recorded as Present/Absent. The presence of intraretinal hemorrhage is an indicator of underlying disease. 95% confidence interval (CI) for binomial proportions was based on Clopper-Pearson exact method. One eye (study eye) contributed to the analysis.

End point type	Secondary
----------------	-----------

End point timeframe:

Baseline, Weeks 12, 48, 96

End point values	Brolucizumab 6 mg	Aflibercept 2 mg		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	370	369		
Units: percentage of subjects				
number (not applicable)				
Week 12	6.9	6.6		
Week 48	4.0	5.0		
Week 96	2.1	2.7		

Statistical analyses

No statistical analyses for this end point

Secondary: Percentage of subjects with subretinal hemorrhage (central subfield) present at the visit while absent at baseline at each treatment - Study Eye

End point title	Percentage of subjects with subretinal hemorrhage (central subfield) present at the visit while absent at baseline at each treatment - Study Eye
-----------------	--

End point description:

Subretinal hemorrhage was assessed using SD-OCT and recorded as Present/Absent. The presence of subretinal hemorrhage is an indicator of underlying disease. 95% confidence interval (CI) for binomial proportions was based on Clopper-Pearson exact method. One eye (study eye) contributed to the analysis.

End point type	Secondary
----------------	-----------

End point timeframe:

Baseline, Weeks 12, 48, 96

End point values	Brolucizumab 6 mg	Aflibercept 2 mg		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	370	369		
Units: percentage of subjects				
number (not applicable)				
Week 12	0.6	1.2		
Week 48	0.6	0.3		
Week 96	0.0	0.0		

Statistical analyses

Adverse events

Adverse events information

Timeframe for reporting adverse events:

Adverse Events (AE) were collected for the duration of enrollment in the study.

Adverse event reporting additional description:

AEs were obtained through solicited and spontaneous comments from subjects and through observations by the Investigator as outlined in the study protocol. This analysis population includes all subjects who received at least 1 IVT injection (Safety Analysis Set).

Assessment type	Systematic
-----------------	------------

Dictionary used

Dictionary name	MedDRA
-----------------	--------

Dictionary version	20.1
--------------------	------

Reporting groups

Reporting group title	RTH258 6mg
-----------------------	------------

Reporting group description:

RTH258 6mg

Reporting group title	Aflibercept 2mg
-----------------------	-----------------

Reporting group description:

Aflibercept 2mg

Serious adverse events	RTH258 6mg	Aflibercept 2mg	
Total subjects affected by serious adverse events			
subjects affected / exposed	79 / 370 (21.35%)	89 / 369 (24.12%)	
number of deaths (all causes)	4	7	
number of deaths resulting from adverse events	0	0	
Neoplasms benign, malignant and unspecified (incl cysts and polyps)			
Adenocarcinoma gastric			
subjects affected / exposed	1 / 370 (0.27%)	0 / 369 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Breast cancer			
subjects affected / exposed	0 / 370 (0.00%)	1 / 369 (0.27%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Breast neoplasm			
subjects affected / exposed	1 / 370 (0.27%)	1 / 369 (0.27%)	
occurrences causally related to treatment / all	0 / 1	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	

Colon cancer			
subjects affected / exposed	1 / 370 (0.27%)	0 / 369 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Colon neoplasm			
subjects affected / exposed	0 / 370 (0.00%)	1 / 369 (0.27%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Diffuse large B-cell lymphoma			
subjects affected / exposed	0 / 370 (0.00%)	1 / 369 (0.27%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Endometrial cancer			
subjects affected / exposed	1 / 370 (0.27%)	0 / 369 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Gastrointestinal carcinoma			
subjects affected / exposed	0 / 370 (0.00%)	1 / 369 (0.27%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Lung neoplasm			
subjects affected / exposed	1 / 370 (0.27%)	0 / 369 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Malignant melanoma			
subjects affected / exposed	0 / 370 (0.00%)	1 / 369 (0.27%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Meningioma			
subjects affected / exposed	1 / 370 (0.27%)	1 / 369 (0.27%)	
occurrences causally related to treatment / all	0 / 1	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Metastases to central nervous system			

subjects affected / exposed	0 / 370 (0.00%)	1 / 369 (0.27%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Metastases to peritoneum			
subjects affected / exposed	1 / 370 (0.27%)	0 / 369 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Metastatic neoplasm			
subjects affected / exposed	1 / 370 (0.27%)	0 / 369 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Neoplasm			
subjects affected / exposed	0 / 370 (0.00%)	1 / 369 (0.27%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Non-small cell lung cancer			
subjects affected / exposed	0 / 370 (0.00%)	1 / 369 (0.27%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Oesophageal carcinoma			
subjects affected / exposed	1 / 370 (0.27%)	0 / 369 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Prostate cancer			
subjects affected / exposed	2 / 370 (0.54%)	1 / 369 (0.27%)	
occurrences causally related to treatment / all	0 / 2	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Squamous cell carcinoma of lung			
subjects affected / exposed	1 / 370 (0.27%)	0 / 369 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Thyroid adenoma			

subjects affected / exposed	0 / 370 (0.00%)	1 / 369 (0.27%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Vascular disorders			
Haemorrhage			
subjects affected / exposed	1 / 370 (0.27%)	0 / 369 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 1	0 / 0	
Hypertensive crisis			
subjects affected / exposed	1 / 370 (0.27%)	1 / 369 (0.27%)	
occurrences causally related to treatment / all	0 / 1	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Hypotension			
subjects affected / exposed	0 / 370 (0.00%)	1 / 369 (0.27%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Peripheral ischaemia			
subjects affected / exposed	0 / 370 (0.00%)	1 / 369 (0.27%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Varicose vein			
subjects affected / exposed	1 / 370 (0.27%)	0 / 369 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Surgical and medical procedures			
Hip surgery			
subjects affected / exposed	1 / 370 (0.27%)	0 / 369 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Implantable defibrillator replacement			
subjects affected / exposed	0 / 370 (0.00%)	1 / 369 (0.27%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Varicose vein operation			

subjects affected / exposed	1 / 370 (0.27%)	0 / 369 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
General disorders and administration site conditions			
Cyst			
subjects affected / exposed	0 / 370 (0.00%)	1 / 369 (0.27%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Death			
subjects affected / exposed	0 / 370 (0.00%)	3 / 369 (0.81%)	
occurrences causally related to treatment / all	0 / 0	0 / 3	
deaths causally related to treatment / all	0 / 0	0 / 3	
Pyrexia			
subjects affected / exposed	0 / 370 (0.00%)	1 / 369 (0.27%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Immune system disorders			
Allergy to arthropod sting			
subjects affected / exposed	0 / 370 (0.00%)	1 / 369 (0.27%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Hypersensitivity			
subjects affected / exposed	1 / 370 (0.27%)	0 / 369 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Reproductive system and breast disorders			
Benign prostatic hyperplasia			
subjects affected / exposed	2 / 370 (0.54%)	0 / 369 (0.00%)	
occurrences causally related to treatment / all	0 / 2	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Postmenopausal haemorrhage			

subjects affected / exposed	1 / 370 (0.27%)	0 / 369 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Respiratory, thoracic and mediastinal disorders			
Acute pulmonary oedema			
subjects affected / exposed	0 / 370 (0.00%)	1 / 369 (0.27%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Chronic obstructive pulmonary disease			
subjects affected / exposed	2 / 370 (0.54%)	1 / 369 (0.27%)	
occurrences causally related to treatment / all	0 / 2	0 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	
Pleurisy			
subjects affected / exposed	0 / 370 (0.00%)	1 / 369 (0.27%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Pneumothorax			
subjects affected / exposed	1 / 370 (0.27%)	0 / 369 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Pulmonary embolism			
subjects affected / exposed	1 / 370 (0.27%)	2 / 369 (0.54%)	
occurrences causally related to treatment / all	0 / 1	0 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	
Pulmonary oedema			
subjects affected / exposed	2 / 370 (0.54%)	0 / 369 (0.00%)	
occurrences causally related to treatment / all	0 / 2	0 / 0	
deaths causally related to treatment / all	0 / 1	0 / 0	
Respiratory arrest			
subjects affected / exposed	0 / 370 (0.00%)	1 / 369 (0.27%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Respiratory failure			

subjects affected / exposed	1 / 370 (0.27%)	0 / 369 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Psychiatric disorders			
Charles Bonnet syndrome			
subjects affected / exposed	0 / 370 (0.00%)	1 / 369 (0.27%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Depression			
subjects affected / exposed	0 / 370 (0.00%)	1 / 369 (0.27%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Mental fatigue			
subjects affected / exposed	0 / 370 (0.00%)	1 / 369 (0.27%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Mood disorder due to a general medical condition			
subjects affected / exposed	1 / 370 (0.27%)	0 / 369 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Paranoid personality disorder			
subjects affected / exposed	1 / 370 (0.27%)	0 / 369 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Investigations			
Investigation			
subjects affected / exposed	0 / 370 (0.00%)	1 / 369 (0.27%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Injury, poisoning and procedural complications			
Cataract traumatic - Study eye			

subjects affected / exposed	1 / 370 (0.27%)	0 / 369 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Chest injury			
subjects affected / exposed	0 / 370 (0.00%)	1 / 369 (0.27%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 1	
Facial bones fracture			
subjects affected / exposed	1 / 370 (0.27%)	0 / 369 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Fall			
subjects affected / exposed	0 / 370 (0.00%)	2 / 369 (0.54%)	
occurrences causally related to treatment / all	0 / 0	0 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	
Femoral neck fracture			
subjects affected / exposed	1 / 370 (0.27%)	2 / 369 (0.54%)	
occurrences causally related to treatment / all	0 / 1	0 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	
Femur fracture			
subjects affected / exposed	2 / 370 (0.54%)	0 / 369 (0.00%)	
occurrences causally related to treatment / all	0 / 2	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Foot fracture			
subjects affected / exposed	1 / 370 (0.27%)	0 / 369 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Head injury			
subjects affected / exposed	0 / 370 (0.00%)	1 / 369 (0.27%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Humerus fracture			

subjects affected / exposed	0 / 370 (0.00%)	2 / 369 (0.54%)	
occurrences causally related to treatment / all	0 / 0	0 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	
Incisional hernia			
subjects affected / exposed	1 / 370 (0.27%)	0 / 369 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Injury			
subjects affected / exposed	1 / 370 (0.27%)	0 / 369 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Joint dislocation			
subjects affected / exposed	2 / 370 (0.54%)	0 / 369 (0.00%)	
occurrences causally related to treatment / all	0 / 2	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Limb traumatic amputation			
subjects affected / exposed	0 / 370 (0.00%)	1 / 369 (0.27%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Lower limb fracture			
subjects affected / exposed	3 / 370 (0.81%)	0 / 369 (0.00%)	
occurrences causally related to treatment / all	0 / 3	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Post procedural haematoma			
subjects affected / exposed	1 / 370 (0.27%)	0 / 369 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Procedural haemorrhage			
subjects affected / exposed	0 / 370 (0.00%)	1 / 369 (0.27%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Radius fracture			

subjects affected / exposed	0 / 370 (0.00%)	1 / 369 (0.27%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Rib fracture			
subjects affected / exposed	1 / 370 (0.27%)	0 / 369 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Spinal fracture			
subjects affected / exposed	0 / 370 (0.00%)	1 / 369 (0.27%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Sternal fracture			
subjects affected / exposed	1 / 370 (0.27%)	0 / 369 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Tendon rupture			
subjects affected / exposed	1 / 370 (0.27%)	0 / 369 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Thermal burn			
subjects affected / exposed	0 / 370 (0.00%)	1 / 369 (0.27%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Tibia fracture			
subjects affected / exposed	0 / 370 (0.00%)	1 / 369 (0.27%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Toxicity to various agents			
subjects affected / exposed	1 / 370 (0.27%)	0 / 369 (0.00%)	
occurrences causally related to treatment / all	0 / 2	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Cardiac disorders			
Acute myocardial infarction			

subjects affected / exposed	1 / 370 (0.27%)	0 / 369 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Angina pectoris			
subjects affected / exposed	1 / 370 (0.27%)	1 / 369 (0.27%)	
occurrences causally related to treatment / all	0 / 1	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Arrhythmia			
subjects affected / exposed	0 / 370 (0.00%)	2 / 369 (0.54%)	
occurrences causally related to treatment / all	0 / 0	0 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	
Atrial fibrillation			
subjects affected / exposed	1 / 370 (0.27%)	0 / 369 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Atrial flutter			
subjects affected / exposed	1 / 370 (0.27%)	0 / 369 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Atrioventricular block first degree			
subjects affected / exposed	1 / 370 (0.27%)	0 / 369 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Bundle branch block left			
subjects affected / exposed	1 / 370 (0.27%)	0 / 369 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Bundle branch block right			
subjects affected / exposed	1 / 370 (0.27%)	0 / 369 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Cardiac arrest			

subjects affected / exposed	0 / 370 (0.00%)	1 / 369 (0.27%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 1	
Cardiac failure			
subjects affected / exposed	2 / 370 (0.54%)	2 / 369 (0.54%)	
occurrences causally related to treatment / all	0 / 2	0 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	
Cardiac failure congestive			
subjects affected / exposed	0 / 370 (0.00%)	1 / 369 (0.27%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Cardiopulmonary failure			
subjects affected / exposed	1 / 370 (0.27%)	1 / 369 (0.27%)	
occurrences causally related to treatment / all	0 / 1	0 / 1	
deaths causally related to treatment / all	0 / 1	0 / 1	
Myocardial infarction			
subjects affected / exposed	2 / 370 (0.54%)	0 / 369 (0.00%)	
occurrences causally related to treatment / all	0 / 2	0 / 0	
deaths causally related to treatment / all	0 / 1	0 / 0	
Myocardial ischaemia			
subjects affected / exposed	0 / 370 (0.00%)	1 / 369 (0.27%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Parasystole			
subjects affected / exposed	1 / 370 (0.27%)	0 / 369 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Tachycardia			
subjects affected / exposed	0 / 370 (0.00%)	1 / 369 (0.27%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Nervous system disorders			
Carotid artery stenosis			

subjects affected / exposed	0 / 370 (0.00%)	1 / 369 (0.27%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Cerebral haemorrhage			
subjects affected / exposed	1 / 370 (0.27%)	0 / 369 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Cerebral infarction			
subjects affected / exposed	1 / 370 (0.27%)	0 / 369 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Cerebral ischaemia			
subjects affected / exposed	1 / 370 (0.27%)	0 / 369 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Cerebrovascular accident			
subjects affected / exposed	0 / 370 (0.00%)	4 / 369 (1.08%)	
occurrences causally related to treatment / all	0 / 0	0 / 4	
deaths causally related to treatment / all	0 / 0	0 / 0	
Cerebrovascular disorder			
subjects affected / exposed	0 / 370 (0.00%)	2 / 369 (0.54%)	
occurrences causally related to treatment / all	0 / 0	0 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	
Ischaemic stroke			
subjects affected / exposed	2 / 370 (0.54%)	1 / 369 (0.27%)	
occurrences causally related to treatment / all	0 / 2	1 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Migraine			
subjects affected / exposed	1 / 370 (0.27%)	0 / 369 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Myasthenia gravis			

subjects affected / exposed	0 / 370 (0.00%)	1 / 369 (0.27%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Radiculopathy			
subjects affected / exposed	0 / 370 (0.00%)	1 / 369 (0.27%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Syncope			
subjects affected / exposed	3 / 370 (0.81%)	2 / 369 (0.54%)	
occurrences causally related to treatment / all	0 / 3	0 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	
Transient ischaemic attack			
subjects affected / exposed	1 / 370 (0.27%)	2 / 369 (0.54%)	
occurrences causally related to treatment / all	1 / 1	0 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	
Vertebrobasilar insufficiency			
subjects affected / exposed	0 / 370 (0.00%)	1 / 369 (0.27%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Blood and lymphatic system disorders			
Anaemia			
subjects affected / exposed	0 / 370 (0.00%)	1 / 369 (0.27%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Iron deficiency anaemia			
subjects affected / exposed	1 / 370 (0.27%)	0 / 369 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Thrombocytopenia			
subjects affected / exposed	0 / 370 (0.00%)	1 / 369 (0.27%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Ear and labyrinth disorders			

Vertigo			
subjects affected / exposed	0 / 370 (0.00%)	1 / 369 (0.27%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Eye disorders			
Anterior chamber inflammation - Study eye			
subjects affected / exposed	1 / 370 (0.27%)	0 / 369 (0.00%)	
occurrences causally related to treatment / all	1 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Blindness - Study eye			
subjects affected / exposed	1 / 370 (0.27%)	0 / 369 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Dry age-related macular degeneration - Study eye			
subjects affected / exposed	0 / 370 (0.00%)	1 / 369 (0.27%)	
occurrences causally related to treatment / all	0 / 0	1 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Retinal artery embolism - Study eye			
subjects affected / exposed	1 / 370 (0.27%)	0 / 369 (0.00%)	
occurrences causally related to treatment / all	1 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Retinal artery occlusion - Study eye			
subjects affected / exposed	0 / 370 (0.00%)	1 / 369 (0.27%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Retinal artery thrombosis - Study eye			
subjects affected / exposed	1 / 370 (0.27%)	0 / 369 (0.00%)	
occurrences causally related to treatment / all	1 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Retinal detachment - Study eye			

subjects affected / exposed	1 / 370 (0.27%)	1 / 369 (0.27%)	
occurrences causally related to treatment / all	1 / 1	0 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	
Retinal pigment epithelial tear - Study eye			
subjects affected / exposed	2 / 370 (0.54%)	0 / 369 (0.00%)	
occurrences causally related to treatment / all	2 / 2	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Retinal tear - Study eye			
subjects affected / exposed	2 / 370 (0.54%)	1 / 369 (0.27%)	
occurrences causally related to treatment / all	1 / 2	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Uveitis - Study eye			
subjects affected / exposed	3 / 370 (0.81%)	0 / 369 (0.00%)	
occurrences causally related to treatment / all	3 / 3	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Visual acuity reduced - Study eye			
subjects affected / exposed	1 / 370 (0.27%)	1 / 369 (0.27%)	
occurrences causally related to treatment / all	1 / 1	1 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	
Gastrointestinal disorders			
Abdominal pain			
subjects affected / exposed	1 / 370 (0.27%)	0 / 369 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Colitis			
subjects affected / exposed	0 / 370 (0.00%)	1 / 369 (0.27%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Duodenitis haemorrhagic			
subjects affected / exposed	0 / 370 (0.00%)	1 / 369 (0.27%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Dyspepsia			

subjects affected / exposed	0 / 370 (0.00%)	1 / 369 (0.27%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Dysphagia			
subjects affected / exposed	0 / 370 (0.00%)	1 / 369 (0.27%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Gastritis haemorrhagic			
subjects affected / exposed	0 / 370 (0.00%)	1 / 369 (0.27%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Gastrointestinal haemorrhage			
subjects affected / exposed	0 / 370 (0.00%)	1 / 369 (0.27%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Gastrointestinal inflammation			
subjects affected / exposed	0 / 370 (0.00%)	1 / 369 (0.27%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Haemorrhoids			
subjects affected / exposed	0 / 370 (0.00%)	1 / 369 (0.27%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Inguinal hernia			
subjects affected / exposed	2 / 370 (0.54%)	0 / 369 (0.00%)	
occurrences causally related to treatment / all	0 / 2	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Intestinal polyp			
subjects affected / exposed	0 / 370 (0.00%)	1 / 369 (0.27%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Large intestine perforation			

subjects affected / exposed	0 / 370 (0.00%)	1 / 369 (0.27%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Lumbar hernia			
subjects affected / exposed	0 / 370 (0.00%)	1 / 369 (0.27%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Pancreatitis			
subjects affected / exposed	1 / 370 (0.27%)	0 / 369 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Rectal haemorrhage			
subjects affected / exposed	2 / 370 (0.54%)	1 / 369 (0.27%)	
occurrences causally related to treatment / all	0 / 2	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Rectal prolapse			
subjects affected / exposed	0 / 370 (0.00%)	1 / 369 (0.27%)	
occurrences causally related to treatment / all	0 / 0	0 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	
Vomiting			
subjects affected / exposed	0 / 370 (0.00%)	1 / 369 (0.27%)	
occurrences causally related to treatment / all	0 / 0	0 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	
Hepatobiliary disorders			
Bile duct stone			
subjects affected / exposed	0 / 370 (0.00%)	1 / 369 (0.27%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Biliary colic			
subjects affected / exposed	1 / 370 (0.27%)	0 / 369 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Cholecystitis acute			

subjects affected / exposed	2 / 370 (0.54%)	0 / 369 (0.00%)	
occurrences causally related to treatment / all	0 / 2	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Cholelithiasis			
subjects affected / exposed	2 / 370 (0.54%)	0 / 369 (0.00%)	
occurrences causally related to treatment / all	0 / 2	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Drug-induced liver injury			
subjects affected / exposed	1 / 370 (0.27%)	0 / 369 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Skin and subcutaneous tissue disorders			
Neuropathic ulcer			
subjects affected / exposed	0 / 370 (0.00%)	1 / 369 (0.27%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Skin necrosis			
subjects affected / exposed	1 / 370 (0.27%)	0 / 369 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Renal and urinary disorders			
Acute prerenal failure			
subjects affected / exposed	0 / 370 (0.00%)	1 / 369 (0.27%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Haematuria			
subjects affected / exposed	0 / 370 (0.00%)	1 / 369 (0.27%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Nephrolithiasis			
subjects affected / exposed	1 / 370 (0.27%)	0 / 369 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Renal failure			

subjects affected / exposed	0 / 370 (0.00%)	1 / 369 (0.27%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 1	
Urinary bladder polyp			
subjects affected / exposed	1 / 370 (0.27%)	0 / 369 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Urinary bladder rupture			
subjects affected / exposed	1 / 370 (0.27%)	0 / 369 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Musculoskeletal and connective tissue disorders			
Arthralgia			
subjects affected / exposed	1 / 370 (0.27%)	1 / 369 (0.27%)	
occurrences causally related to treatment / all	0 / 1	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Intervertebral disc protrusion			
subjects affected / exposed	0 / 370 (0.00%)	1 / 369 (0.27%)	
occurrences causally related to treatment / all	0 / 0	0 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	
Neck pain			
subjects affected / exposed	0 / 370 (0.00%)	1 / 369 (0.27%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Osteoarthritis			
subjects affected / exposed	1 / 370 (0.27%)	2 / 369 (0.54%)	
occurrences causally related to treatment / all	0 / 1	0 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	
Osteoporosis			
subjects affected / exposed	1 / 370 (0.27%)	0 / 369 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Polyarthrititis			

subjects affected / exposed	0 / 370 (0.00%)	1 / 369 (0.27%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Spinal column stenosis			
subjects affected / exposed	0 / 370 (0.00%)	1 / 369 (0.27%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Infections and infestations			
Appendicitis			
subjects affected / exposed	1 / 370 (0.27%)	0 / 369 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Bacterial infection			
subjects affected / exposed	1 / 370 (0.27%)	0 / 369 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Bronchitis			
subjects affected / exposed	1 / 370 (0.27%)	2 / 369 (0.54%)	
occurrences causally related to treatment / all	0 / 1	0 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	
Cytomegalovirus infection			
subjects affected / exposed	0 / 370 (0.00%)	1 / 369 (0.27%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Dacryocystitis - Study eye			
subjects affected / exposed	1 / 370 (0.27%)	0 / 369 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Diverticulitis			
subjects affected / exposed	1 / 370 (0.27%)	0 / 369 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Endophthalmitis - Study eye			

subjects affected / exposed	1 / 370 (0.27%)	1 / 369 (0.27%)	
occurrences causally related to treatment / all	0 / 1	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Gastroenteritis			
subjects affected / exposed	2 / 370 (0.54%)	0 / 369 (0.00%)	
occurrences causally related to treatment / all	0 / 2	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Infective exacerbation of chronic obstructive airways disease			
subjects affected / exposed	1 / 370 (0.27%)	0 / 369 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Intervertebral discitis			
subjects affected / exposed	1 / 370 (0.27%)	0 / 369 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Lower respiratory tract infection			
subjects affected / exposed	0 / 370 (0.00%)	1 / 369 (0.27%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Lung infection			
subjects affected / exposed	0 / 370 (0.00%)	1 / 369 (0.27%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Pharyngitis			
subjects affected / exposed	0 / 370 (0.00%)	1 / 369 (0.27%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Pneumonia			
subjects affected / exposed	2 / 370 (0.54%)	8 / 369 (2.17%)	
occurrences causally related to treatment / all	0 / 2	0 / 8	
deaths causally related to treatment / all	0 / 0	0 / 0	
Respiratory tract infection			

subjects affected / exposed	0 / 370 (0.00%)	1 / 369 (0.27%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Sepsis			
subjects affected / exposed	1 / 370 (0.27%)	1 / 369 (0.27%)	
occurrences causally related to treatment / all	0 / 1	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Skin infection			
subjects affected / exposed	1 / 370 (0.27%)	0 / 369 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Urinary tract infection			
subjects affected / exposed	1 / 370 (0.27%)	1 / 369 (0.27%)	
occurrences causally related to treatment / all	0 / 1	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Urosepsis			
subjects affected / exposed	0 / 370 (0.00%)	1 / 369 (0.27%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Metabolism and nutrition disorders			
Hyperglycaemia			
subjects affected / exposed	0 / 370 (0.00%)	1 / 369 (0.27%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Hyperkalaemia			
subjects affected / exposed	1 / 370 (0.27%)	0 / 369 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Malnutrition			
subjects affected / exposed	1 / 370 (0.27%)	0 / 369 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Vitamin D deficiency			

subjects affected / exposed	1 / 370 (0.27%)	0 / 369 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	

Frequency threshold for reporting non-serious adverse events: 5 %

Non-serious adverse events	RTH258 6mg	Aflibercept 2mg	
Total subjects affected by non-serious adverse events			
subjects affected / exposed	176 / 370 (47.57%)	194 / 369 (52.57%)	
Vascular disorders			
Hypertension			
subjects affected / exposed	28 / 370 (7.57%)	25 / 369 (6.78%)	
occurrences (all)	34	28	
Eye disorders			
Cataract - Fellow eye			
subjects affected / exposed	7 / 370 (1.89%)	22 / 369 (5.96%)	
occurrences (all)	7	22	
Cataract - Study eye			
subjects affected / exposed	11 / 370 (2.97%)	43 / 369 (11.65%)	
occurrences (all)	11	43	
Conjunctival haemorrhage - Study eye			
subjects affected / exposed	17 / 370 (4.59%)	19 / 369 (5.15%)	
occurrences (all)	19	21	
Eye pain - Study eye			
subjects affected / exposed	13 / 370 (3.51%)	19 / 369 (5.15%)	
occurrences (all)	19	26	
Neovascular age-related macular degeneration - Fellow eye			
subjects affected / exposed	31 / 370 (8.38%)	32 / 369 (8.67%)	
occurrences (all)	33	32	
Visual acuity reduced - Study eye			
subjects affected / exposed	31 / 370 (8.38%)	25 / 369 (6.78%)	
occurrences (all)	38	38	
Musculoskeletal and connective tissue disorders			

Back pain subjects affected / exposed occurrences (all)	16 / 370 (4.32%) 20	28 / 369 (7.59%) 33	
Infections and infestations			
Bronchitis subjects affected / exposed occurrences (all)	22 / 370 (5.95%) 31	20 / 369 (5.42%) 23	
Influenza subjects affected / exposed occurrences (all)	24 / 370 (6.49%) 24	27 / 369 (7.32%) 29	
Nasopharyngitis subjects affected / exposed occurrences (all)	43 / 370 (11.62%) 60	31 / 369 (8.40%) 42	

More information

Substantial protocol amendments (globally)

Were there any global substantial amendments to the protocol? Yes

Date	Amendment
16 August 2015	To clarify some inclusion/exclusion criteria and study procedures, and to allow unrestricted access to standard of care therapy for the fellow eye
09 February 2017	To allow ADA analysis of the samples collected from subjects treated with aflibercept 2 mg

Notes:

Interruptions (globally)

Were there any global interruptions to the trial? No

Limitations and caveats

None reported